HRP930931A2 - New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat) - Google Patents
New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat) Download PDFInfo
- Publication number
- HRP930931A2 HRP930931A2 HR07/890,050A HRP930931A HRP930931A2 HR P930931 A2 HRP930931 A2 HR P930931A2 HR P930931 A HRP930931 A HR P930931A HR P930931 A2 HRP930931 A2 HR P930931A2
- Authority
- HR
- Croatia
- Prior art keywords
- urea
- bis
- methylpyridin
- methylthio
- heptyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 6
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 title description 3
- 101710181187 Liver carboxylesterase 1 Proteins 0.000 title description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 73
- 150000001875 compounds Chemical class 0.000 claims description 70
- -1 phenylsulfinyl Chemical group 0.000 claims description 50
- 239000004202 carbamide Substances 0.000 claims description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000003118 aryl group Chemical class 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003435 aroyl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 4
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims description 4
- OIKKEIWYZFBHSN-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-1-[(2,4-dimethylphenyl)methyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=C(C)C=C1C OIKKEIWYZFBHSN-UHFFFAOYSA-N 0.000 claims description 4
- NVFCOHJWDZQMLY-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-1-[(2,5-dimethylphenyl)methyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC(C)=CC=C1C NVFCOHJWDZQMLY-UHFFFAOYSA-N 0.000 claims description 4
- VQTDQERBSPXKKC-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-[(4-propan-2-ylphenyl)methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=C(C(C)C)C=C1 VQTDQERBSPXKKC-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 3
- VYIJJZFOVHXVHH-UHFFFAOYSA-N 1-(2,2-diphenylethyl)-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC1=CC=C2N=CC=CC2=C1NC(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 VYIJJZFOVHXVHH-UHFFFAOYSA-N 0.000 claims description 3
- WBSOTEGFYWJPLP-UHFFFAOYSA-N 1-(2,2-diphenylethyl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 WBSOTEGFYWJPLP-UHFFFAOYSA-N 0.000 claims description 3
- KQYVYFJNGBLOKH-UHFFFAOYSA-N 1-(2,3-dihydro-1H-inden-1-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-[(4-phenylphenyl)methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1C2=CC=CC=C2CC1)CC1=CC=C(C=2C=CC=CC=2)C=C1 KQYVYFJNGBLOKH-UHFFFAOYSA-N 0.000 claims description 3
- MTUQCRGUOVXTJJ-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-1-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-(naphthalen-1-ylmethyl)urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1C2=CC=CC=C2CC1)CC1=CC=CC2=CC=CC=C12 MTUQCRGUOVXTJJ-UHFFFAOYSA-N 0.000 claims description 3
- ZDTGDJSSBURWKU-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-1-[(2,5-dimethylphenyl)methyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC1=CC=C2N=CC=CC2=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC(C)=CC=C1C ZDTGDJSSBURWKU-UHFFFAOYSA-N 0.000 claims description 3
- MQTKDYZIGUCRTE-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-(naphthalen-1-ylmethyl)urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=CC2=CC=CC=C12 MQTKDYZIGUCRTE-UHFFFAOYSA-N 0.000 claims description 3
- SQNONZNLANHLQR-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-(naphthalen-2-ylmethyl)urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=C(C=CC=C2)C2=C1 SQNONZNLANHLQR-UHFFFAOYSA-N 0.000 claims description 3
- AHVGAUMHAWUDPV-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-[(2,4,6-trimethylphenyl)methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=C(C)C=C(C)C=C1C AHVGAUMHAWUDPV-UHFFFAOYSA-N 0.000 claims description 3
- AEMGRJLXUYIKTI-UHFFFAOYSA-N 1-(6-methoxyquinolin-5-yl)-3-(2-naphthalen-1-ylheptyl)urea Chemical compound C1=CC=C2C(C(CNC(=O)NC=3C4=CC=CN=C4C=CC=3OC)CCCCC)=CC=CC2=C1 AEMGRJLXUYIKTI-UHFFFAOYSA-N 0.000 claims description 3
- QEEXZKQADMAGCP-UHFFFAOYSA-N 1-(6-methoxyquinolin-5-yl)-3-[2-(3-methylphenyl)heptyl]urea Chemical compound COC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCC)C1=CC=CC(C)=C1 QEEXZKQADMAGCP-UHFFFAOYSA-N 0.000 claims description 3
- RHROKNPOQRTYFN-UHFFFAOYSA-N 1-(6-methoxyquinolin-5-yl)-3-[2-(3-methylphenyl)octyl]urea Chemical compound COC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCCC)C1=CC=CC(C)=C1 RHROKNPOQRTYFN-UHFFFAOYSA-N 0.000 claims description 3
- RHCRZKBMHUGZKV-UHFFFAOYSA-N 1-(6-methylsulfanylquinolin-5-yl)-3-(2-naphthalen-1-ylheptyl)urea Chemical compound C1=CC=C2C(C(CNC(=O)NC=3C4=CC=CN=C4C=CC=3SC)CCCCC)=CC=CC2=C1 RHCRZKBMHUGZKV-UHFFFAOYSA-N 0.000 claims description 3
- JWCIEKPAOYDDMR-UHFFFAOYSA-N 1-(6-methylsulfanylquinolin-5-yl)-3-(2-naphthalen-1-ylhexyl)urea Chemical compound C1=CC=C2C(C(CNC(=O)NC=3C4=CC=CN=C4C=CC=3SC)CCCC)=CC=CC2=C1 JWCIEKPAOYDDMR-UHFFFAOYSA-N 0.000 claims description 3
- NDPVKBNDZKVFGG-UHFFFAOYSA-N 1-(6-methylsulfanylquinolin-5-yl)-3-[(1-phenylcyclohexyl)methyl]urea Chemical compound CSC1=CC=C2N=CC=CC2=C1NC(=O)NCC1(C=2C=CC=CC=2)CCCCC1 NDPVKBNDZKVFGG-UHFFFAOYSA-N 0.000 claims description 3
- XSQHYTLCWOKFRQ-UHFFFAOYSA-N 1-(6-methylsulfanylquinolin-5-yl)-3-[(1-phenylcyclopentyl)methyl]urea Chemical compound CSC1=CC=C2N=CC=CC2=C1NC(=O)NCC1(C=2C=CC=CC=2)CCCC1 XSQHYTLCWOKFRQ-UHFFFAOYSA-N 0.000 claims description 3
- VNXSLVQZHSKYHH-UHFFFAOYSA-N 1-[(2,3-dichlorophenyl)methyl]-1-(2,3-dihydro-1h-inden-2-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=CC(Cl)=C1Cl VNXSLVQZHSKYHH-UHFFFAOYSA-N 0.000 claims description 3
- WPNHIRAWQRQIBD-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-1-(2,3-dihydro-1h-inden-2-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=CC=C1Cl WPNHIRAWQRQIBD-UHFFFAOYSA-N 0.000 claims description 3
- PDKHDZZAOKBKKZ-UHFFFAOYSA-N 1-[(4-tert-butylphenyl)methyl]-1-(2,3-dihydro-1h-inden-1-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1C2=CC=CC=C2CC1)CC1=CC=C(C(C)(C)C)C=C1 PDKHDZZAOKBKKZ-UHFFFAOYSA-N 0.000 claims description 3
- KHUHFXGZADJAKL-UHFFFAOYSA-N 1-[2,6-di(propan-2-yl)phenyl]-3-(6-methyl-2-naphthalen-1-ylheptyl)urea Chemical compound C=1C=CC2=CC=CC=C2C=1C(CCCC(C)C)CNC(=O)NC1=C(C(C)C)C=CC=C1C(C)C KHUHFXGZADJAKL-UHFFFAOYSA-N 0.000 claims description 3
- SXRDRHWLUUCSGN-UHFFFAOYSA-N 1-[2-(2,3-dimethoxyphenyl)heptyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCC)C1=CC=CC(OC)=C1OC SXRDRHWLUUCSGN-UHFFFAOYSA-N 0.000 claims description 3
- XFRXZTFPSCCKFU-UHFFFAOYSA-N 1-[2-(2,4-dimethylphenyl)heptyl]-3-(6-methoxyquinolin-5-yl)urea Chemical compound COC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCC)C1=CC=C(C)C=C1C XFRXZTFPSCCKFU-UHFFFAOYSA-N 0.000 claims description 3
- XFSHMTSCORPGTD-UHFFFAOYSA-N 1-[2-(2,4-dimethylphenyl)heptyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCC)C1=CC=C(C)C=C1C XFSHMTSCORPGTD-UHFFFAOYSA-N 0.000 claims description 3
- MZQWFXDMJDNKJQ-UHFFFAOYSA-N 1-[2-(2,4-dimethylphenyl)hexyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C=C(C)C=C(C)C=1C(CCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC MZQWFXDMJDNKJQ-UHFFFAOYSA-N 0.000 claims description 3
- NKQCVCDFTYZLCD-UHFFFAOYSA-N 1-[2-(2,5-dimethoxyphenyl)heptyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCC)C1=CC(OC)=CC=C1OC NKQCVCDFTYZLCD-UHFFFAOYSA-N 0.000 claims description 3
- GCFWWPZDPUJZJP-UHFFFAOYSA-N 1-[2-(2,5-dimethoxyphenyl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C(OC)=CC=C(OC)C=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC GCFWWPZDPUJZJP-UHFFFAOYSA-N 0.000 claims description 3
- CWOUCWUPSQXOTF-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)-5-phenylpentyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC(C=1C(=CC=C(C)C=1)C)CCCC1=CC=CC=C1 CWOUCWUPSQXOTF-UHFFFAOYSA-N 0.000 claims description 3
- YEQBFNOFOGAWMP-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C(C)=CC=C(C)C=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC YEQBFNOFOGAWMP-UHFFFAOYSA-N 0.000 claims description 3
- JBGQGSKFVCOURJ-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)hexyl]-3-(6-methoxyquinolin-5-yl)urea Chemical compound COC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCC)C1=CC(C)=CC=C1C JBGQGSKFVCOURJ-UHFFFAOYSA-N 0.000 claims description 3
- NXQGCLLTOVJSPF-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)hexyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCC)C1=CC(C)=CC=C1C NXQGCLLTOVJSPF-UHFFFAOYSA-N 0.000 claims description 3
- ZMEQVYWEVXHHSN-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)hexyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C(C)=CC=C(C)C=1C(CCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC ZMEQVYWEVXHHSN-UHFFFAOYSA-N 0.000 claims description 3
- RZBCKDKNOCQZMY-UHFFFAOYSA-N 1-[2-(3,5-dimethoxyphenyl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C(OC)=CC(OC)=CC=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC RZBCKDKNOCQZMY-UHFFFAOYSA-N 0.000 claims description 3
- GIOIWXNLKJJOBK-UHFFFAOYSA-N 1-[2-(3,5-dimethylphenyl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C(C)=CC(C)=CC=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC GIOIWXNLKJJOBK-UHFFFAOYSA-N 0.000 claims description 3
- BLOGSEMVCKFZRH-UHFFFAOYSA-N 1-[2-(3-methylphenyl)heptyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCC)C1=CC=CC(C)=C1 BLOGSEMVCKFZRH-UHFFFAOYSA-N 0.000 claims description 3
- UEWQJRGKLDUXCG-UHFFFAOYSA-N 1-[2-(3-methylphenyl)octyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCCC)C1=CC=CC(C)=C1 UEWQJRGKLDUXCG-UHFFFAOYSA-N 0.000 claims description 3
- YUYPXRUYSIEHJH-UHFFFAOYSA-N 1-[2-(4-methylphenyl)heptyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCC)C1=CC=C(C)C=C1 YUYPXRUYSIEHJH-UHFFFAOYSA-N 0.000 claims description 3
- MJEDVCHMUCRCTR-UHFFFAOYSA-N 1-[2-methyl-4,6-bis(methylsulfanyl)pyrimidin-5-yl]-3-[[1-(4-methylphenyl)cyclohexyl]methyl]urea Chemical compound CSC1=NC(C)=NC(SC)=C1NC(=O)NCC1(C=2C=CC(C)=CC=2)CCCCC1 MJEDVCHMUCRCTR-UHFFFAOYSA-N 0.000 claims description 3
- DCKKAPNUZCOHIP-UHFFFAOYSA-N 1-[6-(2,3-dimethoxyphenyl)-6-methylheptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound COC1=CC=CC(C(C)(C)CCCCCNC(=O)NC=2C(=NC(C)=CC=2SC)SC)=C1OC DCKKAPNUZCOHIP-UHFFFAOYSA-N 0.000 claims description 3
- LECXVWKGVFHSHN-UHFFFAOYSA-N 1-[6-(2,5-dimethoxyphenyl)-6-methylheptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound COC1=CC=C(OC)C(C(C)(C)CCCCCNC(=O)NC=2C(=NC(C)=CC=2SC)SC)=C1 LECXVWKGVFHSHN-UHFFFAOYSA-N 0.000 claims description 3
- HBDSXWOIXKPADM-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-(2-naphthalen-1-ylheptyl)urea Chemical compound C=1C=CC2=CC=CC=C2C=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC HBDSXWOIXKPADM-UHFFFAOYSA-N 0.000 claims description 3
- LCEYYZBWRHRMBA-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-(2-naphthalen-1-ylhexyl)urea Chemical compound C=1C=CC2=CC=CC=C2C=1C(CCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC LCEYYZBWRHRMBA-UHFFFAOYSA-N 0.000 claims description 3
- ROMWXVNRQRUIQZ-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-(2-naphthalen-2-ylhexyl)urea Chemical compound C=1C=C2C=CC=CC2=CC=1C(CCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC ROMWXVNRQRUIQZ-UHFFFAOYSA-N 0.000 claims description 3
- HOAOUYUPBYJYFM-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-(6-methyl-6-phenylheptyl)urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCCCCCC(C)(C)C1=CC=CC=C1 HOAOUYUPBYJYFM-UHFFFAOYSA-N 0.000 claims description 3
- NZYBBBWOKUODGE-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[(1-phenylcyclopentyl)methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC1(C=2C=CC=CC=2)CCCC1 NZYBBBWOKUODGE-UHFFFAOYSA-N 0.000 claims description 3
- GRTGAXVOHUAJMT-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[2-(2-methylphenyl)hexyl]urea Chemical compound C=1C=CC=C(C)C=1C(CCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC GRTGAXVOHUAJMT-UHFFFAOYSA-N 0.000 claims description 3
- KFHIKGCXEWQRTN-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[2-(3-methylphenyl)heptyl]urea Chemical compound C=1C=CC(C)=CC=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC KFHIKGCXEWQRTN-UHFFFAOYSA-N 0.000 claims description 3
- QVIUYHLORHVQAE-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[2-(3-methylphenyl)octyl]urea Chemical compound C=1C=CC(C)=CC=1C(CCCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC QVIUYHLORHVQAE-UHFFFAOYSA-N 0.000 claims description 3
- GPOXJRVUYSKSQC-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[2-(4-methylphenyl)heptyl]urea Chemical compound C=1C=C(C)C=CC=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC GPOXJRVUYSKSQC-UHFFFAOYSA-N 0.000 claims description 3
- ADDOBHUYSYEMLE-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[5-methyl-2-(3-methylphenyl)hexyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC(CCC(C)C)C1=CC=CC(C)=C1 ADDOBHUYSYEMLE-UHFFFAOYSA-N 0.000 claims description 3
- SYMZRNPAFSCFBN-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[6-methyl-6-(2-methylphenyl)heptyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCCCCCC(C)(C)C1=CC=CC=C1C SYMZRNPAFSCFBN-UHFFFAOYSA-N 0.000 claims description 3
- WNDBGVHSTPTAQB-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[7-methyl-7-(2-methylphenyl)nonyl]urea Chemical compound C=1C=CC=C(C)C=1C(C)(CC)CCCCCCNC(=O)NC1=C(SC)C=C(C)N=C1SC WNDBGVHSTPTAQB-UHFFFAOYSA-N 0.000 claims description 3
- VYVAOLMALHWTBP-UHFFFAOYSA-N 1-[[1-(4-methylphenyl)cyclohexyl]methyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC1=CC=C2N=CC=CC2=C1NC(=O)NCC1(C=2C=CC(C)=CC=2)CCCCC1 VYVAOLMALHWTBP-UHFFFAOYSA-N 0.000 claims description 3
- WVJGWQGVRPVPMW-UHFFFAOYSA-N 1-[[1-(4-methylphenyl)cyclopentyl]methyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC1=CC=C2N=CC=CC2=C1NC(=O)NCC1(C=2C=CC(C)=CC=2)CCCC1 WVJGWQGVRPVPMW-UHFFFAOYSA-N 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- NFGODEMQGQNUKK-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 NFGODEMQGQNUKK-UHFFFAOYSA-M 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000006715 (C1-C5) alkylthio group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- LQGFWBIYTHYCMP-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-1-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-(naphthalen-2-ylmethyl)urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1C2=CC=CC=C2CC1)CC1=CC=C(C=CC=C2)C2=C1 LQGFWBIYTHYCMP-UHFFFAOYSA-N 0.000 claims description 2
- IOLQTHQBWGCTLZ-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-1-[(2,4-dimethylphenyl)methyl]-3-[2-methyl-4,6-bis(methylsulfanyl)pyrimidin-5-yl]urea Chemical compound CSC1=NC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=C(C)C=C1C IOLQTHQBWGCTLZ-UHFFFAOYSA-N 0.000 claims description 2
- LRSKOBLLCBTHAM-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-3-[2-methyl-4,6-bis(methylsulfanyl)pyrimidin-5-yl]-1-[(4-propan-2-ylphenyl)methyl]urea Chemical compound CSC1=NC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=C(C(C)C)C=C1 LRSKOBLLCBTHAM-UHFFFAOYSA-N 0.000 claims description 2
- XOFUIGFZMXFPPS-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-3-[2-methyl-4,6-bis(methylsulfanyl)pyrimidin-5-yl]-1-[[4-(3-methylbutyl)phenyl]methyl]urea Chemical compound CSC1=NC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=C(CCC(C)C)C=C1 XOFUIGFZMXFPPS-UHFFFAOYSA-N 0.000 claims description 2
- RGNFPAXFLNUELS-UHFFFAOYSA-N 1-[2-(2,3-dimethoxyphenyl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C=CC(OC)=C(OC)C=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC RGNFPAXFLNUELS-UHFFFAOYSA-N 0.000 claims description 2
- JLSGTFGGQBTGOA-UHFFFAOYSA-N 1-[2-(2,4-dimethylphenyl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C=C(C)C=C(C)C=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC JLSGTFGGQBTGOA-UHFFFAOYSA-N 0.000 claims description 2
- HOFSHWUEQNSZKY-UHFFFAOYSA-N 1-[2-(2,5-dimethoxyphenyl)octyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C(OC)=CC=C(OC)C=1C(CCCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC HOFSHWUEQNSZKY-UHFFFAOYSA-N 0.000 claims description 2
- MHKJHPXOIFKSOH-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)octyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C(C)=CC=C(C)C=1C(CCCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC MHKJHPXOIFKSOH-UHFFFAOYSA-N 0.000 claims description 2
- QQSKBMMPERYDAG-UHFFFAOYSA-N 1-[2-(4-methoxy-2,5-dimethylphenyl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1C(C)=C(OC)C=C(C)C=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC QQSKBMMPERYDAG-UHFFFAOYSA-N 0.000 claims description 2
- UDEJRIFCSCZDHU-UHFFFAOYSA-N 1-[2-(5-chloro-1-benzothiophen-3-yl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1SC2=CC=C(Cl)C=C2C=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC UDEJRIFCSCZDHU-UHFFFAOYSA-N 0.000 claims description 2
- FOGULEVBDDSGAM-UHFFFAOYSA-N 1-[6-(2,5-dimethylphenyl)-6-methylheptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCCCCCC(C)(C)C1=CC(C)=CC=C1C FOGULEVBDDSGAM-UHFFFAOYSA-N 0.000 claims description 2
- GXKPAMXYRKQAJA-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[(1-phenylcyclohexyl)methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC1(C=2C=CC=CC=2)CCCCC1 GXKPAMXYRKQAJA-UHFFFAOYSA-N 0.000 claims description 2
- JUALTKGOQNUVQW-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[[1-(4-methylphenyl)cyclohexyl]methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC1(C=2C=CC(C)=CC=2)CCCCC1 JUALTKGOQNUVQW-UHFFFAOYSA-N 0.000 claims description 2
- GRQDCQXDSHYZBX-UHFFFAOYSA-N CCCCCC(CNC(=O)NC1=C(C=CC2=C1C=CC=N2)OC)C3=C(C=CC(=C3)OC)OC Chemical compound CCCCCC(CNC(=O)NC1=C(C=CC2=C1C=CC=N2)OC)C3=C(C=CC(=C3)OC)OC GRQDCQXDSHYZBX-UHFFFAOYSA-N 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 claims description 2
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 claims description 2
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 2
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 8
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 4
- 235000010290 biphenyl Nutrition 0.000 claims 4
- 239000004305 biphenyl Substances 0.000 claims 4
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- OYTSENNVTDHLQU-UHFFFAOYSA-N 1-(2,2-diphenylethyl)-3-[2-methyl-4,6-bis(methylsulfanyl)pyrimidin-5-yl]urea Chemical compound CSC1=NC(C)=NC(SC)=C1NC(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 OYTSENNVTDHLQU-UHFFFAOYSA-N 0.000 claims 1
- SGEDUAUMBYKGLF-UHFFFAOYSA-N 1-[2-(3,4,5-trimethoxyphenyl)heptyl]-3-(2,4,6-trimethylpyridin-3-yl)urea Chemical compound C=1C(OC)=C(OC)C(OC)=CC=1C(CCCCC)CNC(=O)NC1=C(C)C=C(C)N=C1C SGEDUAUMBYKGLF-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229910052722 tritium Inorganic materials 0.000 claims 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 311
- 238000005160 1H NMR spectroscopy Methods 0.000 description 156
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 38
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 31
- 239000000243 solution Substances 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 235000012000 cholesterol Nutrition 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 230000031891 intestinal absorption Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- UAGKFAWCAWENHG-UHFFFAOYSA-N 3-isocyanato-6-methyl-2,4-bis(methylsulfanyl)pyridine Chemical compound CSC1=CC(C)=NC(SC)=C1N=C=O UAGKFAWCAWENHG-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical group [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- HUWVZFIXKVKHSB-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-2-yl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-[[4-(3-methylbutyl)phenyl]methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=C(CCC(C)C)C=C1 HUWVZFIXKVKHSB-UHFFFAOYSA-N 0.000 description 3
- LKOLXAMAJJMOPZ-UHFFFAOYSA-N 1-[2-(5-chloro-1-benzothiophen-3-yl)-6,6,6-trifluorohexyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC(CCCC(F)(F)F)C1=CSC2=CC=C(Cl)C=C12 LKOLXAMAJJMOPZ-UHFFFAOYSA-N 0.000 description 3
- JAHGAZXBUVEKHL-UHFFFAOYSA-N 1-[2-(5-methyl-1-benzothiophen-3-yl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound C=1SC2=CC=C(C)C=C2C=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC JAHGAZXBUVEKHL-UHFFFAOYSA-N 0.000 description 3
- GELZJEAWWNHKKM-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-(6-methyl-2-naphthalen-1-ylheptyl)urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC(CCCC(C)C)C1=CC=CC2=CC=CC=C12 GELZJEAWWNHKKM-UHFFFAOYSA-N 0.000 description 3
- DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical class N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 description 3
- 150000005015 5-aminoquinolines Chemical class 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000000802 nitrating effect Effects 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- WMQZKWDHYSGHRW-UHFFFAOYSA-N 1,1-difluoro-5-iodopentane Chemical compound FC(F)CCCCI WMQZKWDHYSGHRW-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PKURDURPHGLCEM-UHFFFAOYSA-N 1-(7,7-difluoro-2-naphthalen-1-ylheptyl)-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC(CCCCC(F)F)C1=CC=CC2=CC=CC=C12 PKURDURPHGLCEM-UHFFFAOYSA-N 0.000 description 2
- UGIWIWOJTYEMHE-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2,5-dimethylphenyl)-5-methylhexyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)NCC(CCC(C)C)C1=CC(C)=CC=C1C UGIWIWOJTYEMHE-UHFFFAOYSA-N 0.000 description 2
- MMBXZYLQLIFBOL-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2,5-dimethylphenyl)-5-phenylpentyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)NCC(C=1C(=CC=C(C)C=1)C)CCCC1=CC=CC=C1 MMBXZYLQLIFBOL-UHFFFAOYSA-N 0.000 description 2
- LZEJRZOACVLBAI-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2,5-dimethylphenyl)-6,6,6-trifluorohexyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)NCC(CCCC(F)(F)F)C1=CC(C)=CC=C1C LZEJRZOACVLBAI-UHFFFAOYSA-N 0.000 description 2
- WDLNZEQVCTTYRW-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2,5-dimethylphenyl)heptyl]urea Chemical compound C=1C(C)=CC=C(C)C=1C(CCCCC)CNC(=O)NC1=C(SCC)C=C(C)N=C1SCC WDLNZEQVCTTYRW-UHFFFAOYSA-N 0.000 description 2
- QCLIRFMWFXCJGY-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2,5-dimethylphenyl)octyl]urea Chemical compound C=1C(C)=CC=C(C)C=1C(CCCCCC)CNC(=O)NC1=C(SCC)C=C(C)N=C1SCC QCLIRFMWFXCJGY-UHFFFAOYSA-N 0.000 description 2
- AXMKFTAOUXZALH-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2-chloro-1-benzothiophen-3-yl)-5-methylhexyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)NCC(CCC(C)C)C1=C(Cl)SC2=CC=CC=C12 AXMKFTAOUXZALH-UHFFFAOYSA-N 0.000 description 2
- BEKRTPQUIYYRRZ-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2-chloro-1-benzothiophen-3-yl)-6-methylheptyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)NCC(CCCC(C)C)C1=C(Cl)SC2=CC=CC=C12 BEKRTPQUIYYRRZ-UHFFFAOYSA-N 0.000 description 2
- FCTHDGZSKYUJJH-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2-chloro-1-benzothiophen-3-yl)heptyl]urea Chemical compound ClC=1SC2=CC=CC=C2C=1C(CCCCC)CNC(=O)NC1=C(SCC)C=C(C)N=C1SCC FCTHDGZSKYUJJH-UHFFFAOYSA-N 0.000 description 2
- IJPRORVCJXNLOA-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(3,5-dimethylphenyl)heptyl]urea Chemical compound C=1C(C)=CC(C)=CC=1C(CCCCC)CNC(=O)NC1=C(SCC)C=C(C)N=C1SCC IJPRORVCJXNLOA-UHFFFAOYSA-N 0.000 description 2
- KKUGTLKSIUEXJO-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(3,5-dimethylphenyl)octyl]urea Chemical compound C=1C(C)=CC(C)=CC=1C(CCCCCC)CNC(=O)NC1=C(SCC)C=C(C)N=C1SCC KKUGTLKSIUEXJO-UHFFFAOYSA-N 0.000 description 2
- XARXVWUBCIVKLT-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(4-methoxy-2,5-dimethylphenyl)heptyl]urea Chemical compound C=1C(C)=C(OC)C=C(C)C=1C(CCCCC)CNC(=O)NC1=C(SCC)C=C(C)N=C1SCC XARXVWUBCIVKLT-UHFFFAOYSA-N 0.000 description 2
- BAXCFYFPEWYRNF-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(5,6,7,8-tetrahydronaphthalen-1-yl)heptyl]urea Chemical compound C=1C=CC=2CCCCC=2C=1C(CCCCC)CNC(=O)NC1=C(SCC)C=C(C)N=C1SCC BAXCFYFPEWYRNF-UHFFFAOYSA-N 0.000 description 2
- FGGTVYLLCYSNQY-UHFFFAOYSA-N 1-[2,6-di(propan-2-yl)phenyl]-3-[5-methyl-2-(5-methyl-1-benzothiophen-3-yl)hexyl]urea Chemical compound C=1SC2=CC=C(C)C=C2C=1C(CCC(C)C)CNC(=O)NC1=C(C(C)C)C=CC=C1C(C)C FGGTVYLLCYSNQY-UHFFFAOYSA-N 0.000 description 2
- LJMQDOZFMQIVSK-UHFFFAOYSA-N 1-[2,6-di(propan-2-yl)phenyl]-3-[6,6,6-trifluoro-2-(5-methyl-1-benzothiophen-3-yl)hexyl]urea Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC(CCCC(F)(F)F)C1=CSC2=CC=C(C)C=C12 LJMQDOZFMQIVSK-UHFFFAOYSA-N 0.000 description 2
- HKKLVSZNMMXWNX-UHFFFAOYSA-N 1-[2-(1-benzothiophen-3-yl)-6-methylheptyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound C=1SC2=CC=CC=C2C=1C(CCCC(C)C)CNC(=O)NC1=C(C(C)C)C=CC=C1C(C)C HKKLVSZNMMXWNX-UHFFFAOYSA-N 0.000 description 2
- AZIUZUXRXNKLOB-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)-4-phenylbutyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC(C=1C(=CC=C(C)C=1)C)CCC1=CC=CC=C1 AZIUZUXRXNKLOB-UHFFFAOYSA-N 0.000 description 2
- KQRIVPRPPLXFJY-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)-6-methylheptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC(CCCC(C)C)C1=CC(C)=CC=C1C KQRIVPRPPLXFJY-UHFFFAOYSA-N 0.000 description 2
- OKFUIBBYANAIET-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)-7,7-difluoroheptyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC(CCCCC(F)F)C1=CC(C)=CC=C1C OKFUIBBYANAIET-UHFFFAOYSA-N 0.000 description 2
- DJIMGHJYIGPQCL-UHFFFAOYSA-N 1-[2-(2,5-dimethylphenyl)heptyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCCC)C1=CC(C)=CC=C1C DJIMGHJYIGPQCL-UHFFFAOYSA-N 0.000 description 2
- PFSVHVHYIQGYIL-UHFFFAOYSA-N 1-[2-(2-chloro-1-benzothiophen-3-yl)-6,6,6-trifluorohexyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC(CCCC(F)(F)F)C1=C(Cl)SC2=CC=CC=C12 PFSVHVHYIQGYIL-UHFFFAOYSA-N 0.000 description 2
- HKPWHLHPDACBTK-UHFFFAOYSA-N 1-[2-(2-chloro-1-benzothiophen-3-yl)-6-methylheptyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound ClC=1SC2=CC=CC=C2C=1C(CCCC(C)C)CNC(=O)NC1=C(C(C)C)C=CC=C1C(C)C HKPWHLHPDACBTK-UHFFFAOYSA-N 0.000 description 2
- JQUKSKVLEQJSQN-UHFFFAOYSA-N 1-[2-(2-chloro-1-benzothiophen-3-yl)-7,7-difluoroheptyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC(CCCCC(F)F)C1=C(Cl)SC2=CC=CC=C12 JQUKSKVLEQJSQN-UHFFFAOYSA-N 0.000 description 2
- AEMPFIKSLXWHRS-UHFFFAOYSA-N 1-[2-(2-chloro-1-benzothiophen-3-yl)heptyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound ClC=1SC2=CC=CC=C2C=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC AEMPFIKSLXWHRS-UHFFFAOYSA-N 0.000 description 2
- PUBMFLBRQSMEGV-UHFFFAOYSA-N 1-[2-(3-methylphenyl)heptyl]-3-(6-pentylsulfanylquinolin-5-yl)urea Chemical compound CCCCCSC1=CC=C2N=CC=CC2=C1NC(=O)NCC(CCCCC)C1=CC=CC(C)=C1 PUBMFLBRQSMEGV-UHFFFAOYSA-N 0.000 description 2
- GQHGECXHWGDQCC-UHFFFAOYSA-N 1-[2-(5-chloro-1-benzothiophen-3-yl)-6-methylheptyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound C=1SC2=CC=C(Cl)C=C2C=1C(CCCC(C)C)CNC(=O)NC1=C(C(C)C)C=CC=C1C(C)C GQHGECXHWGDQCC-UHFFFAOYSA-N 0.000 description 2
- LGEKUZYKZFALCE-UHFFFAOYSA-N 1-[2-(5-chloro-1-benzothiophen-3-yl)heptyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound C=1SC2=CC=C(Cl)C=C2C=1C(CCCCC)CNC(=O)NC1=C(C(C)C)C=CC=C1C(C)C LGEKUZYKZFALCE-UHFFFAOYSA-N 0.000 description 2
- ZJVOXBGPUAPFRS-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[2-(3-methylphenyl)hexyl]urea Chemical compound C=1C=CC(C)=CC=1C(CCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC ZJVOXBGPUAPFRS-UHFFFAOYSA-N 0.000 description 2
- JXRARXAVDGKPAD-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[[1-(4-methylphenyl)cyclopentyl]methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)NCC1(C=2C=CC(C)=CC=2)CCCC1 JXRARXAVDGKPAD-UHFFFAOYSA-N 0.000 description 2
- TVKUNNLOVPLXGH-UHFFFAOYSA-N 1-cycloheptyl-1-(9h-fluoren-2-ylmethyl)-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CCCCCC1)CC1=CC=C2C3=CC=CC=C3CC2=C1 TVKUNNLOVPLXGH-UHFFFAOYSA-N 0.000 description 2
- OLCCFDOEAXBKNY-UHFFFAOYSA-N 1-cycloheptyl-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-(naphthalen-2-ylmethyl)urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CCCCCC1)CC1=CC=C(C=CC=C2)C2=C1 OLCCFDOEAXBKNY-UHFFFAOYSA-N 0.000 description 2
- PWVZPIMZPUQGCV-UHFFFAOYSA-N 1-cycloheptyl-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-[(4-phenylphenyl)methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(C1CCCCCC1)CC1=CC=C(C=2C=CC=CC=2)C=C1 PWVZPIMZPUQGCV-UHFFFAOYSA-N 0.000 description 2
- JSPGJPGKIDGKHX-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-(2,3-dihydro-1h-inden-2-yl)-1-[(2,4,6-trimethylphenyl)methyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=C(C)C=C(C)C=C1C JSPGJPGKIDGKHX-UHFFFAOYSA-N 0.000 description 2
- MUBUEGBMUNXESC-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-(2,3-dihydro-1h-inden-2-yl)-1-[(2,4-dimethylphenyl)methyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=C(C)C=C1C MUBUEGBMUNXESC-UHFFFAOYSA-N 0.000 description 2
- IRKWAOZTNLNBQN-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-(2,3-dihydro-1h-inden-2-yl)-1-[(4-propan-2-ylphenyl)methyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)N(C1CC2=CC=CC=C2C1)CC1=CC=C(C(C)C)C=C1 IRKWAOZTNLNBQN-UHFFFAOYSA-N 0.000 description 2
- MKRGETSRIXQFSF-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-[(4-propan-2-ylphenyl)methyl]-1-(1,2,3,4-tetrahydronaphthalen-2-yl)urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)N(C1CC2=CC=CC=C2CC1)CC1=CC=C(C(C)C)C=C1 MKRGETSRIXQFSF-UHFFFAOYSA-N 0.000 description 2
- SDFRGCMSYCJJPC-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-cycloheptyl-1-(9h-fluoren-2-ylmethyl)urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)N(C1CCCCCC1)CC1=CC=C2C3=CC=CC=C3CC2=C1 SDFRGCMSYCJJPC-UHFFFAOYSA-N 0.000 description 2
- PCYVLJGHRRYCOI-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-cycloheptyl-1-(naphthalen-2-ylmethyl)urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)N(C1CCCCCC1)CC1=CC=C(C=CC=C2)C2=C1 PCYVLJGHRRYCOI-UHFFFAOYSA-N 0.000 description 2
- IGYKNCXVQQRBCI-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-cycloheptyl-1-[(4-phenylphenyl)methyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)N(C1CCCCCC1)CC1=CC=C(C=2C=CC=CC=2)C=C1 IGYKNCXVQQRBCI-UHFFFAOYSA-N 0.000 description 2
- WHSKWSUYGLTZQW-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-heptyl-1-(naphthalen-2-ylmethyl)urea Chemical compound C=1C=C2C=CC=CC2=CC=1CN(CCCCCCC)C(=O)NC1=C(SCC)C=C(C)N=C1SCC WHSKWSUYGLTZQW-UHFFFAOYSA-N 0.000 description 2
- LPFLJERWRYXIJD-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-heptyl-1-[(2,4,6-trimethylphenyl)methyl]urea Chemical compound CCSC=1C=C(C)N=C(SCC)C=1NC(=O)N(CCCCCCC)CC1=C(C)C=C(C)C=C1C LPFLJERWRYXIJD-UHFFFAOYSA-N 0.000 description 2
- FGBNESXSIGGVJA-UHFFFAOYSA-N 3-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-1-heptyl-1-[(3-methyl-1-benzothiophen-2-yl)methyl]urea Chemical compound S1C2=CC=CC=C2C(C)=C1CN(CCCCCCC)C(=O)NC1=C(SCC)C=C(C)N=C1SCC FGBNESXSIGGVJA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- XMIAFAKRAAMSGX-UHFFFAOYSA-N quinolin-5-amine Chemical compound C1=CC=C2C(N)=CC=CC2=N1 XMIAFAKRAAMSGX-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- SJWOFBVBNFLWLP-UHFFFAOYSA-N 1-(1-phenylcyclopentyl)methylamine Chemical compound C=1C=CC=CC=1C1(CN)CCCC1 SJWOFBVBNFLWLP-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- LAIPSYZJRPJCGK-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-(2-naphthalen-1-ylheptyl)urea Chemical compound C=1C=CC2=CC=CC=C2C=1C(CCCCC)CNC(=O)NC1=C(SCC)C=C(C)N=C1SCC LAIPSYZJRPJCGK-UHFFFAOYSA-N 0.000 description 1
- GMUILYBDEWPPJR-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-(6-methyl-2-naphthalen-1-ylheptyl)urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)NCC(CCCC(C)C)C1=CC=CC2=CC=CC=C12 GMUILYBDEWPPJR-UHFFFAOYSA-N 0.000 description 1
- SMXUMTAJNPFIDV-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2,5-dimethylphenyl)-6-methylheptyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)NCC(CCCC(C)C)C1=CC(C)=CC=C1C SMXUMTAJNPFIDV-UHFFFAOYSA-N 0.000 description 1
- ZBZMRTOYSZCAKR-UHFFFAOYSA-N 1-[2,4-bis(ethylsulfanyl)-6-methylpyridin-3-yl]-3-[2-(2,5-dimethylphenyl)-6-phenylhexyl]urea Chemical compound CCSC1=CC(C)=NC(SCC)=C1NC(=O)NCC(C=1C(=CC=C(C)C=1)C)CCCCC1=CC=CC=C1 ZBZMRTOYSZCAKR-UHFFFAOYSA-N 0.000 description 1
- JVYNYNPLDZLJRU-UHFFFAOYSA-N 1-[2,6-di(propan-2-yl)phenyl]-3-(6,6,6-trifluoro-2-naphthalen-2-ylhexyl)urea Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC(CCCC(F)(F)F)C1=CC=C(C=CC=C2)C2=C1 JVYNYNPLDZLJRU-UHFFFAOYSA-N 0.000 description 1
- PGYAFEMEHSUXQE-UHFFFAOYSA-N 1-[2-(1-benzothiophen-3-yl)heptyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound C=1SC2=CC=CC=C2C=1C(CCCCC)CNC(=O)NC1=C(C(C)C)C=CC=C1C(C)C PGYAFEMEHSUXQE-UHFFFAOYSA-N 0.000 description 1
- BFGFXPUWXLGGEZ-UHFFFAOYSA-N 1-[2-(2-chloro-1-benzothiophen-3-yl)-5-methylhexyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound ClC=1SC2=CC=CC=C2C=1C(CCC(C)C)CNC(=O)NC1=C(C(C)C)C=CC=C1C(C)C BFGFXPUWXLGGEZ-UHFFFAOYSA-N 0.000 description 1
- UMVDINRJRYAENB-UHFFFAOYSA-N 1-[2-(2-chloro-1-benzothiophen-3-yl)heptyl]-3-[2,6-di(propan-2-yl)phenyl]urea Chemical compound ClC=1SC2=CC=CC=C2C=1C(CCCCC)CNC(=O)NC1=C(C(C)C)C=CC=C1C(C)C UMVDINRJRYAENB-UHFFFAOYSA-N 0.000 description 1
- NNBGJCVHHBMHDH-UHFFFAOYSA-N 1-[2-(2-methylphenyl)hexyl]-3-(6-methylsulfanylquinolin-5-yl)urea Chemical compound CSC=1C=CC2=NC=CC=C2C=1NC(=O)NCC(CCCC)C1=CC=CC=C1C NNBGJCVHHBMHDH-UHFFFAOYSA-N 0.000 description 1
- CWPTYIRIHXRQDH-UHFFFAOYSA-N 1-[4,6-bis(methylsulfanyl)pyrimidin-5-yl]-3-(2,2-diphenylethyl)urea Chemical compound CSC1=NC=NC(SC)=C1NC(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 CWPTYIRIHXRQDH-UHFFFAOYSA-N 0.000 description 1
- VNVIZZLXQZASPD-UHFFFAOYSA-N 1-[4-[2-(2,5-dimethoxyphenyl)phenyl]butyl]-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]urea Chemical compound COC1=CC=C(OC)C(C=2C(=CC=CC=2)CCCCNC(=O)NC=2C(=NC(C)=CC=2SC)SC)=C1 VNVIZZLXQZASPD-UHFFFAOYSA-N 0.000 description 1
- QCMNHJGNAOYKHM-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[2-(2,4,6-trimethylphenyl)octyl]urea Chemical compound CC=1C=C(C)C=C(C)C=1C(CCCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC QCMNHJGNAOYKHM-UHFFFAOYSA-N 0.000 description 1
- WLWOYQJHPSOUSM-UHFFFAOYSA-N 1-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-3-[2-(3,4,5-trimethoxyphenyl)heptyl]urea Chemical compound C=1C(OC)=C(OC)C(OC)=CC=1C(CCCCC)CNC(=O)NC1=C(SC)C=C(C)N=C1SC WLWOYQJHPSOUSM-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- RXMTUVIKZRXSSM-UHFFFAOYSA-N 2,2-diphenylethanamine Chemical compound C=1C=CC=CC=1C(CN)C1=CC=CC=C1 RXMTUVIKZRXSSM-UHFFFAOYSA-N 0.000 description 1
- LJKLSCLGTUEBNJ-UHFFFAOYSA-N 2,2-diphenylethylurea Chemical class C=1C=CC=CC=1C(CNC(=O)N)C1=CC=CC=C1 LJKLSCLGTUEBNJ-UHFFFAOYSA-N 0.000 description 1
- UBJNMSFVNGJGNO-UHFFFAOYSA-N 2,3-dihydro-1h-inden-2-ylurea Chemical class C1=CC=C2CC(NC(=O)N)CC2=C1 UBJNMSFVNGJGNO-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- ZEZJPIDPVXJEME-UHFFFAOYSA-N 2,4-Dihydroxypyridine Chemical compound OC=1C=CNC(=O)C=1 ZEZJPIDPVXJEME-UHFFFAOYSA-N 0.000 description 1
- RTXYIHGMYDJHEU-UHFFFAOYSA-N 2,4-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=C(Cl)C=CN=C1Cl RTXYIHGMYDJHEU-UHFFFAOYSA-N 0.000 description 1
- INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical class [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- WAECHYLNFVEOEB-UHFFFAOYSA-N 2-(1-benzothiophen-3-yl)-6-methylheptan-1-amine Chemical compound C1=CC=C2C(C(CN)CCCC(C)C)=CSC2=C1 WAECHYLNFVEOEB-UHFFFAOYSA-N 0.000 description 1
- AQCJYBKZEWHVQG-UHFFFAOYSA-N 2-(1-benzothiophen-3-yl)heptan-1-amine Chemical compound C1=CC=C2C(C(CN)CCCCC)=CSC2=C1 AQCJYBKZEWHVQG-UHFFFAOYSA-N 0.000 description 1
- XLRNNSBBICQGFD-UHFFFAOYSA-N 2-(2,5-dimethylphenyl)-6-phenylhexan-1-amine Chemical compound CC1=CC=C(C)C(C(CN)CCCCC=2C=CC=CC=2)=C1 XLRNNSBBICQGFD-UHFFFAOYSA-N 0.000 description 1
- PNPFMEMOXRXBDN-UHFFFAOYSA-N 2-(2,5-dimethylphenyl)-6-phenylhexanenitrile Chemical compound CC1=CC=C(C)C(C(CCCCC=2C=CC=CC=2)C#N)=C1 PNPFMEMOXRXBDN-UHFFFAOYSA-N 0.000 description 1
- NWKMFJMGLMDEFK-UHFFFAOYSA-N 2-(2-chloro-1-benzothiophen-3-yl)-5-methylhexan-1-amine Chemical compound C1=CC=C2C(C(CN)CCC(C)C)=C(Cl)SC2=C1 NWKMFJMGLMDEFK-UHFFFAOYSA-N 0.000 description 1
- HDMKRUBMHLWXFH-UHFFFAOYSA-N 2-(2-chloro-1-benzothiophen-3-yl)-6,6,6-trifluorohexan-1-amine Chemical compound C1=CC=C2C(C(CCCC(F)(F)F)CN)=C(Cl)SC2=C1 HDMKRUBMHLWXFH-UHFFFAOYSA-N 0.000 description 1
- OFPMMYRNQXEKJK-UHFFFAOYSA-N 2-(2-chloro-1-benzothiophen-3-yl)-7,7-difluoroheptanenitrile Chemical compound C1=CC=C2C(C(C#N)CCCCC(F)F)=C(Cl)SC2=C1 OFPMMYRNQXEKJK-UHFFFAOYSA-N 0.000 description 1
- CBWNFQCLFYLDJQ-UHFFFAOYSA-N 2-(2-chloro-1-benzothiophen-3-yl)acetonitrile Chemical compound C1=CC=C2C(CC#N)=C(Cl)SC2=C1 CBWNFQCLFYLDJQ-UHFFFAOYSA-N 0.000 description 1
- YHSQGAWFOVLZLH-UHFFFAOYSA-N 2-(2-methylphenyl)hexan-1-amine Chemical compound CCCCC(CN)C1=CC=CC=C1C YHSQGAWFOVLZLH-UHFFFAOYSA-N 0.000 description 1
- NCRCDSDGQYPIPS-UHFFFAOYSA-N 2-(5-chloro-1-benzothiophen-3-yl)-6,6,6-trifluorohexan-1-amine Chemical compound C1=C(Cl)C=C2C(C(CCCC(F)(F)F)CN)=CSC2=C1 NCRCDSDGQYPIPS-UHFFFAOYSA-N 0.000 description 1
- IESQGZLNUCMTHX-UHFFFAOYSA-N 2-(5-chloro-1-benzothiophen-3-yl)-6-methylheptan-1-amine Chemical compound C1=C(Cl)C=C2C(C(CN)CCCC(C)C)=CSC2=C1 IESQGZLNUCMTHX-UHFFFAOYSA-N 0.000 description 1
- CDWUVDXGHUVYSF-UHFFFAOYSA-N 2-(5-chloro-1-benzothiophen-3-yl)heptan-1-amine Chemical compound C1=C(Cl)C=C2C(C(CN)CCCCC)=CSC2=C1 CDWUVDXGHUVYSF-UHFFFAOYSA-N 0.000 description 1
- BNMSVSPSJSIYPE-UHFFFAOYSA-N 2-(5-methyl-1-benzothiophen-3-yl)heptan-1-amine Chemical compound C1=C(C)C=C2C(C(CN)CCCCC)=CSC2=C1 BNMSVSPSJSIYPE-UHFFFAOYSA-N 0.000 description 1
- NQHLVVJKVNCGHU-UHFFFAOYSA-N 2-ethyl-2-phenylbutan-1-amine Chemical compound CCC(CC)(CN)C1=CC=CC=C1 NQHLVVJKVNCGHU-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- DUFGYCAXVIUXIP-UHFFFAOYSA-N 4,6-dihydroxypyrimidine Chemical class OC1=CC(O)=NC=N1 DUFGYCAXVIUXIP-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- BKYGVGWYPFVKTK-UHFFFAOYSA-N 4-hydroxy-3-nitro-1h-pyridin-2-one Chemical compound OC=1NC=CC(=O)C=1[N+]([O-])=O BKYGVGWYPFVKTK-UHFFFAOYSA-N 0.000 description 1
- QIKWTNPFTOEELW-UHFFFAOYSA-N 4-hydroxy-6-methyl-3-nitro-1h-pyridin-2-one Chemical compound CC1=CC(=O)C([N+]([O-])=O)=C(O)N1 QIKWTNPFTOEELW-UHFFFAOYSA-N 0.000 description 1
- PRJYYKITZGKQDH-UHFFFAOYSA-N 5-bromo-1,1-difluoropentane Chemical compound FC(F)CCCCBr PRJYYKITZGKQDH-UHFFFAOYSA-N 0.000 description 1
- AKSYSVPFFJRLML-UHFFFAOYSA-N 5-methyl-2-(5-methyl-1-benzothiophen-3-yl)hexan-1-amine Chemical compound C1=C(C)C=C2C(C(CN)CCC(C)C)=CSC2=C1 AKSYSVPFFJRLML-UHFFFAOYSA-N 0.000 description 1
- NOYDQGFVFOQSAJ-UHFFFAOYSA-N 5-nitropyrimidine Chemical class [O-][N+](=O)C1=CN=CN=C1 NOYDQGFVFOQSAJ-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- XRVAERXLGKZUEG-UHFFFAOYSA-N 6,6,6-trifluoro-2-(5-methyl-1-benzothiophen-3-yl)hexan-1-amine Chemical compound CC1=CC=C2SC=C(C(CN)CCCC(F)(F)F)C2=C1 XRVAERXLGKZUEG-UHFFFAOYSA-N 0.000 description 1
- WVKBIWSWUWJPNW-UHFFFAOYSA-N 7,7-difluoro-2-naphthalen-1-ylheptan-1-amine Chemical compound C1=CC=C2C(C(CCCCC(F)F)CN)=CC=CC2=C1 WVKBIWSWUWJPNW-UHFFFAOYSA-N 0.000 description 1
- QTSKTLATSHVSKN-UHFFFAOYSA-N 7,7-difluoro-2-naphthalen-1-ylheptanenitrile Chemical compound C1=CC=C2C(C(C#N)CCCCC(F)F)=CC=CC2=C1 QTSKTLATSHVSKN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JZUSVMRKPROXRK-UHFFFAOYSA-N C1=CC=C2C(C(CCCCC(F)F)CN)=C(Cl)SC2=C1 Chemical compound C1=CC=C2C(C(CCCCC(F)F)CN)=C(Cl)SC2=C1 JZUSVMRKPROXRK-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000632319 Homo sapiens Septin-7 Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 102100027981 Septin-7 Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- JEJSMKDMANNLQU-UHFFFAOYSA-N n-[(4-propan-2-ylphenyl)methyl]-2,3-dihydro-1h-inden-2-amine Chemical compound C1=CC(C(C)C)=CC=C1CNC1CC2=CC=CC=C2C1 JEJSMKDMANNLQU-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- MONRWRVYLOHUFA-UHFFFAOYSA-N pentylurea Chemical compound CCCCCNC(N)=O MONRWRVYLOHUFA-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/58—Two sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Pozadina izuma
Ovaj izum odnosi se na nove N-aril i N-heteroarilurea derivate, farmaceutske sastojke koji sadrže takve spojeve, korištenje takvih spojeva za inhibiciju intestinalne apsorpcije kolesterola, smanjivanje serumskog kolesterola i obratno na razvoj ateroskleroze. Spojevi su inhibitori acil koenzima A: kolesterol aciltransferaze (ACAT).
Kolesterol koji se konzumira u hrani (prehrambeni kolesterol) se apsorbira kao slobodni kolesterol od strane mukoznih stanica tankog crijeva. On se zatim esterificira pomoću enzima ACAT, oblikuje u čestice poznate kao hilomikroni, i otpušta u krvnu struju. Hilomikroni su čestice u koje se prehrambeni kolesterol oblikuje i transportira krvnom strujom. Inhibicijom učinka ACAT-a, spojevi ovog izuma sprječavaju intestinalnu apsorpciju prehrambenog kolesterola i tako smanjuju razinu, serumskog kolesterola. Oni su zato korisni u prevenciji ateroskleroze, srčanih napada i udara.
Inhibicijom učinka ACAT-a, spojevi ovog izuma također omogućuju da se odstrani kolesterol sa stijenki krvnih žila. Ovaj učinak čini takve spojeve korisnima u usporavanju i zaustavljanju razvoja ateroskleroze jednako kao i u prevenciji srčanih napada i udara.
Drugi inhibitori ACAT-a se navode u United States Patents 4.994.465, 4.716.175 i 4.743.605 (dio 175 patenta) i u European Patent Applications koji ima brojeve publikacija 0242610, 0245687, 0252524, 0293880, 0297610, 0335374, 0335375, 0386487, 0399422, 0415123, 0421456 i 0439059. Drugi ACAT inhibitori su opisani u PCT publikacijama WO 90/15048 i WO 91/04027. Određeni spojevi uree i tiouree u vidu sredstava protiv ateroskleroze su objavljeni u United States Patent 4.623.662.
Sažetak izuma
Ovaj izum odnosi se na spojeve koji imaju, formulu
[image]
gdje Q je kisik ili sumpor
R17 je -(CH2)n-(CR19R20)2(CH2)r-Ar XXXVIII
gdje
n je 0 ili jedan cijeli broj od 1-3;
z je 0 i 1; i
r je 0 ili jedan cijeli broj od 1 do 4;
R19 i R20 su nezavisno izabrani između vodika, izborno halogeniranog (C1-C12)alkila, izborno supstituiranog aril-(C1-C5)alkila, (C3-C8)cikloalkil-(C1-C5)alkila i Ar; ili R19 i R20 i ugljika na koji su spojeni iz (C4-C7)cikloalkil prstena ili benzen-fuzioniranog (C5-C7)cikloalkil ili -heteroalkil prstena 5 uz uvjet da R19 i R20 ne mogu biti vodik;
Ar je izabran iz skupine koja se sastoji i od
[image]
gdje
U je J, izravan veza -CH=CH- ili –CH2CH2-;
z, n i r su kao što je gore definirano;
x je jedan cijeli broj od 3 do 10 i
w je 0 ili jedan cijeli broj od 1 do x-1
R21, R22 i svaki R23 je nezavisno izabran iz skupinekoja se sastoji od izborno halogsniranog (C1-C6)alkila, izborno nalogeniranog (C1-C6)alkoksi, izborno halogeniranog (C1-C6)alkiltio, fenila i halogena; gdje alkil skupina u navedenim alkil, alkoksi i alkiltio skupinama mogu biti ravni lanci ili razgranati; ili
R21 i R22 zajedno oblikuju skupinu, čija je formula –J(CH2)t-J ili -(CH2)2-
gdje
J je kisik ili sumpor;
t je jedan cijeli broj od 1 do 3; i
q je jedan cijeli broj od 3 do 5;
K je J- ili -CH=CH-;
L je -(CH2)u ili –(CH2)v J-;
gdje
J je kao što je gore definirano;
u je jedan cijeli broj od 3 do 5; i
v je 3 ili 4;
R18je vodik, izborno supstituirani (C1-C8)alkil, izborno supstituirani (C3-C8)cikloalkil, aril ili izborno supstituirani aril-(C1-C4)alkil uz uvjet da R18 je vodik ako bilo koji od n, z ili r u formuli XXXVIII nije 0.
R1je izabran iz skupine koja se sastoji od
[image]
[image]
gdje
m je kao što je definirano gore;
n je 0 ili 1.
Svaki I je nezavisno izabran od 0 do 3;
Svaki R6 i R15 je nezavisno izabran iz skupine koja se sastoji od halogena, (C1-C6)alkila, (C1-C6)haloalkila, izborno halogeniranog (C1-C6)alkoksi, izborno halogeniranog (C1-C6)alkiltio, (C5-C7)cikloalkiltio, fenil(C1-C6)alkiltio, supstituiranog feniltio, heteroariltio, heteroariloksi, (C1-C6)-alkilsulfinila, (C1-C6)alkilsulfonila, (C5-C7)cikloalkilsulfinila, (C5-C7)-cikloalkilsulfonila, fenil(C1-C6)alkilsulfinila, fenil(C1-C6)alkilsulfonila, supstituiranog fenilsulfinila, supstituiranog fenilsulfonila, heteroarilsulfinila, heteroarilsulfonila, i NR10R11, gdje R10 i R11 su isti ili različiti i izabrani iz skupine koja se sastoji od vodika, (C1-C6)alkila, fenila, supstituiranog fenila, (C1-C6)acila, aroila, i supstituiranog aroila, gdje su navedeni supstituirani fenil i supstituirane aroil skupine supstituirane s jednim ili više supstituenata nezavisno izabranih iz skupine koja se sastoji od (C1-C6)alkila, (C1-C6)alkoksi, (C1-C6)alkiltio, halogena i trifluorometila, ili R10 i R11, zajedno s dušikom za koji su vezani oblikuju piperidinski, pirolidinski ili morfolinski prsten; i
B, D, E i G su izabrani iz skupine koja se sastoji od dušika i ugljika, uz uvjet da jedan ili više od B, D i E su dušik, i uz uvjet da kada G je dušik, skupina XVI je spojena na dušik iz formule I na 4 ili 5 mjestu pirimidinskog prstena (označena pomoću a i b) gdje svaki od navedenih dušika može biti oksidiran;
[image]
gdje
R7, R8 i R9 mogu biti isti ili različiti i svaki je nezavisno izabran iz skupine koja se sastoji od izborno halogeniranog (C1-C5)alkoksi, izborno halogeniranog (C1-C5)alkiltio, izborno halogeniranog (C1-C5)alkila i halogena; uz uvjet da R1 je skupina formule XXVII, Ar je skupina formule XXXII, XXXIII ili XXXV i K nije CH=CH osim kada R19 i R20 su nezavisno izabrani iz vodika i halogeniranog (C1-C12)alkila i kada Ar je XXXII R19 ili R20 nije alkil i r u formuli XXXVIII je 0; ili faramceutski prihvatljiva sol navedenog spoja.
Dok se ne označi drugačije pojam "halo", kao što se ovdje koristi, uključuje fluoro, kloro; bromo i jodo.
Dok se ne označi drugačije, pojam "alkil'' kao što se ovdje koristi, može biti ravan, razgranat ili ciklički, i može uključivati ravne ili cikličke polovice jednako kao i razgranate i cikličke polovice.
Dok se ne označi drugačije, pojam "jedan ili više supstituenata", kao što se ovdje koristi, odnosi se na od jedan do najvećeg broja mogućih supstituenata temeljenog na broju raspoloživih mjesta za vezanje.
Pojam "jedan ili više ugljika navedenog ne-aromatskog prstena", kao što se ovdje koristi, odnosi se na od jednog do svih ugljikovih atoma koji su dio ne-aromatskog prstena bilo kojeg od aril-fuzioniranih ili heteroaril-fuzioniranih sistema opisanih ranije, i nisu dio aromatskog prstena navedenog aril-fuzioniranog sistema.
Pojam "jedan ili više ugljika navedenog aromatskog prstena", kao što se ovdje koristi, odnosi se na od jednog do svih ugljikovih atoma koji su dio aromatskog prstena bilo kojeg od aril-fuzioniranih i heteroaril-fuzioniranih sistema opisanih ranije, ili su dio od oba navedena aromatska i ne-aromatska prstena navedenog aril-fuzioniranog i heteroaril-fuzioniranog sistema.
Spojevi formule I mogu imati optička središta i zato se mogu javiti u različitim stereoizomernim konfiguracijama. Ovaj izum uključuje sva stereoizomere takvih spojeva formule I, uključujući njihove mješavine.
Ovaj izum također se odnosi na spojeve formule
[image]
gdje
R21 je (C1-C3)alkil i
R22 je vodik ili (C1-C3)alkil.
Poželjni spojevi formule I su oni gdje R1 je 2,4,6-trifluorofenil, 2,6-diizopropilfenil, 2,4-difluorofenil, 6-metoksikvinolin-5-il, 6-metilkvinolin-5-il, 6-metiltiokvinolin-5-il, 6-metoksiizokvinolin-5-il, 6-metiltioizolkvinolin-5-il, 6-metiltio-8-acetaminokvionlin-5-il, 4,6-bis(metiltio)pirimidin-5-il, 4,6-bis(metiltio)-2-metilpirimidin-5-il, 2,4-bis(metiltio)piridin-3-il, 2,4-bis(metiltio)-6-metilpiridin-3-il, 2,4-bis(etiltio)-6-metilpiridin-3-il, 2,4-bis(metiltio)piridin-3-il i 2,4-bis(izopropiltio)-6-metil priridin-3-il.
Posebno su poželjni spojevi formule I:
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(4-izopropilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2,5-dimetilbenzil)-N'-(indan-2-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2,4-dimetilbenzil)-N'-(indan-2-il)urea;
N-[4,6-bis(metiltio)-2-metilpiridin-5-il]-N'-(indan-2-il)-N'-(4-izopropilbenzil)urea;
N-[4,6-bis(metiltio)-2-metilpiridin-5-il]-N'-(2,4-dimetilbenzil)-N'-(indan-2-il)urea;
N-(2,5-dimetilbenzil)-N-(indan-2-il)-N'-(6-metiltiokvinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2-klorobenzil)-N'-(indan-2-il)-urea;
N-[4,6-bis(metiltio)-2-metilpiridin-5-il]-N'-(2,5-dimetilbenzil)-N'-(indan-2-il)urea;
N-[4,6-bis(metiltio)-2-metilpiridin-5-il]-N'-(indan-2-il)-N'-[4-(3-metilbutil)benzil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-[4-(3-metilbutil)-benzil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(naft-1-ilmetil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(naft-2-ilmetil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(4-t-butilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(4-fenilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(naft-1-ilmetil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(naft-2-ilmetil)urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-cikloheptil-N'-(4-fenilbenzil)urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-cikloheptil-N'-(fluoren-2-ilmetil)urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-cikloheptil-N'-(naft-2-ilmetil)urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-heptil-N'-[naft-2-ilmetil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-heptil-N'-(2,4,6-trimetilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-cikloheptil-N'-(4-fenilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-cikloheptil-N'-(fluoren-2-ilmetil)urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(4-izopropilbenzil)-N'-(1,2,3,4-tetrahidro-naft-2-il)urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-heptil-N'-(3-metilbenzo[b]tiofen-2-ilmetil}urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(1,2,3,4-tetrahidronaft-2-il)-N'-(2,4,6-trimetilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-ciklohepti1-N'-(naft-2-ilmetil)urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(4-izopropilbenzil)urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(2,4-dimetilbenzil)-N'-(indan-2-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(4-izopropilbenzil)-N'-(6,7,8,9-tetrahidro-5H-benzociklohepten-7-il)urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(2,4,6-trimetilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(2,4,6-trimetilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2,3-diklorbenzil)-N'-(indan-2-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N-[2,2-difeniletil]urea;
N-(2,2-difeniletil)-N'-(6-metiltiokvinolin-5-il)urea;
N-[4,6-bis(metiltio)-2-metilpiridin-5-il]-N'-(2,2-difeniletil)urea;
N-[4,6-bis(metiltio)pirimidin-5-il]-N'-(2,2-difeniletil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(1-fenilciklopentil)metil]urea;
N-(6-metiltiokvinolin-5-il)-N'-[(1-fenilciklopentil)metil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[{1-(4-metilfenil)ciklopentil}metil]urea;
N-[{1-(4-metilfenil)ciklopentil}metil]-N'-(6-metiltiokvinolin-5-il)urea;
N-(6-metiltiokvinolin-5-il)-N'-[(1-fenilcikloheksil)metil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(1-fenilcikloheksil)metil]urea;
N-[{1-(4-metilfenil)cikloheksil}metil]-N'-(6-metiltiokvinolin-5-il)urea;
N-[4,6-bis(metiltio)-2-metilpirimidin-5-il]-N'-[{1-(4-metilfenil)cikloheksil}metil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[{1-(4-metilfenil)cikloheksil}metil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-etil-2-fenil)butil]uea;
N-[2,4-bis(izopropiltio)-6-metilpiridin-3-il]-N'-[(2-etil-2-fenil)butil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-etil-2-{2-metilfenil})butil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-fenil-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2-metilfenil}-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2-metilfenil}-2-butil)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2,5-dimetoksifenil}-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2,3-dimetoksifenil}-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2,5-dimetilfenil}-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2-metilfenil)heksil]urea;
N-[2-(2-metilfenil)heksil]-N'-[6-metiltiokvinolin-5-il]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(4-metilfenil)heptil]urea;
N-[2-(4-metilfenil)heptil]-N'-(6-metiltiokvinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3-metilfenil)heptil]urea;
N-[2-(3-metilfenil)heptil]-N'-(6-metiltiokvinolin-5-il)urea;
N-[2-(3-metilfenil)heptil]-N'-(6-metoksikvinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)heksil]urea;
N-[2-(2,5-dimetilfenil)heksil]-N'-(6-metiltiokvinolin-5-il)urea;
N-[2-(2,5-dimetilfenil)heksil]-N' -(6-metoksikvinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,4-dimetilfenil)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3-metilfenil)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-[2,4-dimetilfenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-2-il)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)heksil]urea;
N-(6-metiltiokvinolin-5-il)-N'-[2-(naft-1-il)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,3-dimetoksifenil)heptil]-urea;
N-[2-(2,3-dimetoksifenil)heptil]-N'-(6-metiltiokvinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3-metilfenil)oktil]urea;
N-[2-(3-metilfenil)oktil]-N'-(6-metoksikvinolin-5-il)urea;
N-[2-(3-metilfenil)oktil]-N'-(6-metiltiokvinolin-5-il]urea;
N-[2-(naft-1-il)heptil]-N'-(6-metoksikvinolin-5-il)urea;
N-[2-(naft-1-il)heptil]-N'-(6-metiltiokvinolin-5-il)urea;
N-[2-(2,4-dimetilfenil)heptil]-N'-(6-metiltiokvinolin-5-il)urea;
N-[2-(2,4-dimetilfenil)heptil]-N'-(6-metoksikvinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3,4,5-trimetoksifenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2-(2,5-dimetil-4-metoksifenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetoksifenil)-fenilbutil]urea;
N-[2-(2,5-dimetoksifenil)heptil]-N'-(6-metiltiokvinolin-5-il)urea;
N-[2-(2,5-dimetoksifenil)heptil]-N'-(6-metoksikvinolin-5-il}urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetoksifenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetoksifenil)oktil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-2-[2-(3-metilfenil)-6,6,6-trifluoroheksil]urea;
N-[2-(3-metilfenil)heptil]-N'-(6-pentiltiokvinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-{2-(5-klorobenzo[b]tiofen-3-il)heptil}urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetilfenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)oktil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[5-metil-2-{3-metilfenil}heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-{2,5-dimetilfenil}-4-fenilbutil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-5-fenilpentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)-6-metilheptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)-6-metilheptil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-6-metilheptil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)heptil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-6-fenilheksil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,4,6-trimetilfenil)okstil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-6,6,6-trifluoroheksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(5-metilbenzo[b]tiofen-3lil)heptil]urea:
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2-klorobenzo[b]tiofen-3-il)heptil]urea;
N-[2-(2,5-dimetilfenil)heptil]-N'-[6-metiltiokvinolin-5-il]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-6-metilheptil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-5-fenilpentil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)oktil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-5-metilheksil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2-klorobenzo[b]tiofen-3-il)-6-metilheptil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2-klorobenzo[b]tiofen-3-il)-5-metilheksil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(5,6,7,8-tetrahidronaft-1-il)heptil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetilfenil)heptil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2-klorobenzo[b]tiofen-3-il)heptil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetilfenil)oktil]urea;
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetil-4-metoksifenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(5-metilbenzo[b]tiofen-3-il)heptil]urea;
N-[2-(2-klorobenzo[b]tiofen-3-il)-5-metilheksil]-N'-(2,6-diizopropil)urea;
N-(2,6-diizopropilfenil)-N'-[2-(5-metilbenzo[b]tiofen-3-il)-5-metilheksil]urea;
N-[2-(benzo[b]tiofen-3-il)heptil]-N'-(2,6-diizopropilfenil)urea;
N-[2-(benzo[b]tiofen-3-il)-6-metilheptil]-N'-(2,6-diizopropilfenil)urea;
N-[2-(2-klorobenzo[b]tiofen-3-il)-6-metilheptil]-N'-(2,6-diizopropilfenil)urea;
N-(2,6-diizopropilfenil)-N'-[2-(5-metilbenzo[b]tiofen-3-il)-6,6,6-trifluoroheksil]urea;
N-[2-(2-klorobenzo[b]tiofen-3-il)-6,6,6-trifluoroheksil]-N'-(2,6-diizopropilfenil)urea;
N-(2,6-diizopropilfenil)-N'-[2-(naft-2-il-6,6,6-trifluoroheksil]urea;
N-[7,7-difluoro-2-(naft-1-il)heptil]-N'-(2,6-diizopropilfenil)urea;
N-[7,7-difluoro-2-(2-klorobenzo[b]tiofen-3-il)heptil]-N'-(2,6-diizopropilfenil)urea;
N-[2-(5-klorobenzo[b]tiofen-3-il)heptil]-N'- (2,6-diizopropilfenil)urea;
N-[2-(5-klorobenzo[b]tiofen-3-il)-6,6,6-trifluoroheksil]-N'-(2,6-diizopropilfenil)urea;
N-[2-(2-klorobenzo[b]tiofen-3-il)heptil]-N'-(2,6-diizopropilfenil)urea;
N-[2-(5-klorobenzo[b]tiofen-3-il)-6,6,6-trifluoroheksil]-N'-(2,6-diizopropilfenil)urea;
N-(2,6-(diizopropilfenil)-N'-[2-(5-metilbenzo[b]tiofen-3-il)heptil]urea;
N-[2-(5-klorobenzo[b]tiofen-3-il)-6-metilheptil]-N'-(2,6-diizopropilfenil)urea;
N-(2,6-(diizopropilfenil)-N'-[2-(2,5-dimetilfenil)-6,6,6-trifluoroheksil]urea;
N-[7,7-difluoro-2-(2,5-dimetilfenil)heptil]-N'-(2,6-diizopropilfenil)urea;
N-(2,6-diizopropilfenil)-N'-[2-(naft-1-il)heptil]urea;
N-(2,6-diizopropilfenil)-N'-[6-metil-2-(naft-1-il)heptil]urea.
Ovaj izum također se odnosi na sve radioobilježene oblike spojeva formula I, II i XXVIII. Ovi spojevi su korisni kao istraživačka i dijagnostička sredstva u studijama farmakokinetike metabolizma i testovima vezivanja jednako kod životinja i ljudi.
Ovaj izum također se odnosi na farmaceutske sastojke za inhibiciju ACAT-a, inhibiciju intestinalne apsorpcije kolesterola, zaustavljanje ili usporavanje razvoja ateroskleroze, ili smanjivanja koncentracije kolesterola u serumu kod sisavaca, uključujući čovjeka, obuhvaćajući količinu spoja formule I, ili njegove farmaceutski prihvatljive soli, učinkovite u inhibiranju ACAT-a, inhibiciji crijevne apsorpcije kolesterola, zaustavljanju ili usporavanju razvoja ateroskleroze, ili smanjivanja koncentracije kolesterola u serumu, i farmaceutski prihvatljivog nosača.
Ovaj izum također se odnosi na metodu inhibicije ACAT-a, inhibicije crijevne apsorpcije kolesterola, zaustavljanja ili usporavanja razvoja ateroskleroze, ili smanjivanja koncentracije kolesterola u serumu kod sisavaca, uključujući čovjeka, obuhvaćajući primjenu na sisavcu količine spoja formule I, ili njegove farmaceutski prihvatljive soli, učinkovite u inhibiciji ACAT-a, inhibiciji crijevne apsorpcije kolesterola, zaustavljanju ili usporavanju razvoja ateroskleroze, ili smanjivanju koncentracije kolesterola u serumu.
Primjeri farmaceutski prihvatljivih soli s kiselim dodatkom među spojevima soli formule I su soli od hidroklorne kiseline, p-toluensulfonične kiseline, fumarične kiseline, limunske kiseline, sukcinične kiseline, salicilične kiseline, oksalične kiseline, hidrobromične kiseline, fosforične kiseline, metansulfonične kiseline, tartarične kiseline, di-p-toluoil tartaratne kiseline, i mandelične kiseline.
Podroban opis izuma
Reakcijska shema koja slijedi ilustrira sintezu određenih 5-aminokvinolina i 5-aminoizokvinolina korištenih u izvedbi ovog izuma.
Osim tamo gdje se drugačije izriče, Q, R1, R6, R7, R8, R9, R15, R17, R18, n, m, o, p, A, B, D, E i G su u reakcijskoj shemi i diskusiji koja slijedi definirani kao gore,
[image]
Međuproizvodi aminopirimidina i aminopiridina koji se koriste u ovom izumu su poznati u literaturi i mogu se pripremiti pomoću, metoda poznatih u struci, između proizvoda koji su poznati u literaturi ili komercijalno dostupni. Izviješća za pripremu mnogih međuproizvoda pirimidina i piridma mogu se naći u monografijama "The Pyrimidines", u.r. D.J. Brown (1962) i "Pyridine and its Derivatives", u.r. R.A. Abramovitch (1961), Interscience Publishers, Inc., New York, N.Y., i njihovim dopunama. Pripremanje nekih od ovih međuproizvoda je detaljnije opisano ispod.
2,6-disupstituirani-5-amino-pirimidin derivati mogu se pripremiti pomoću reakcije prikladno supstituiranog 4,6-dihidroksipirimidina sa nitratnim sredstvom kao što je isparavajuća nitratna kiselina u octenoj kiselini na sobnoj temperaturi od oko 15ºC do oko 40ºC u razdoblju od oko 1 do oko 5 sati. 5-nitropirimidini koji nastaju se pretvore u 2,4-dikloro-5-nitropirimidine upotrebom klorinirajućeg sredstva kao što je fosfori1 klorid, sam ili u prisutnosti baze, poželjno dietilanilina, na temperaturi od oko 100 do oko 115ºC u razdoblju od oko 0.5 do oko 2 sata. Postupci za izvođenje ovih pretvorbi su opisani u J. Chem. Soc,. 3832 (1954).
2,6-bis(alkiltio)-5-nitropirimidin derivati mogu se pripremiti pomoću reakcije odgovarajućeg dikloro međuproizvoda sa dva ekvivalenta natrijeva alkiltiolata u otapalu kao što je dimetilformamid ili, poželjno, metanol, kroz oko 4 do oko 16 sati na temperaturi od oko 0º do oko 30ºC, poželjno na sobnoj temperaturi. Monosupstitucija dikloro međuproizvoda se postiže upotrebom jednog ekvivalenta nukleofila, na reakcijskoj temperaturi od oko 0º do oko 100ºC, ovisno o reaktivnosti nukleofila, u inertnom otapalu, kao što je dimetil-formamid ili tetrahidrofuran, u razdoblju od oko 4 do oko 16 sati.
Monokloro derivat koji nastaje zatim reagira sa jednim ekvivalentom različitog nukleofila da se dobije disupstituirani derivat s različitim supstituentima na ugljikovim atomima na položaju 2 i 4, 2,6-disupstituirani-5-nitropirimidin se reducira upotrebom reducirajućeg sredstva kao što je kositreni klorid u koncentriranoj hidroklornoj kiselini ili plinovitom vodiku s odgovarajućim katalizatorom, da se dobije odgovarajući 5-aminopirimidin derivat.
Novi piridini formule XXVIII i drugi 2,4-disupstituirani-3-aminopiridin derivati mogu se pripremiti pomoću reakcije odgovarajućeg 2,4-dihidroksipiridina sa nitratnim sredstvom kao što je koncentrirana dušićna kiselina na 80-100ºC kroz 15-60 minuta. Na primjer, pripremanje 2,4-dihidroksi-6-metil-3-nitropiridina je opisano u J. Heterocyclic Chem., 1970, 7, 389, 2,4-dihidroksi-3-nitro-piridin se postepeno pretvori u 2,4-di k1oro-3-nitropiridin, 2,4-disupstituirani-3-nitro-piridin i 2,4-disupstituirani-3-aminopiridin derivate, upotrebom reakcijskih uvjeta sličnih onima opisanim gore za pirimidinsku seriju.
Priprema nekih 5-aminokvinolina i 5-aminoizokvinolina je ilustrirana u shemi 1. Prema shemi 1, 5-aminokvinolini i izokvinolini formule XV i XVII mogu se pripremiti kao što slijedi. Kvinolin ili izokvinolin formule XIII se nitrira na položaju 5, odnosno reakcijom s nitrirajućim sredstvom kao što je dušična kiselina ili kalijev nitrat sa ili bez kiselog katalizatora kao što je sumporna kiselina, kroz od oko 2 do 16 sati na temperaturi od oko 0-100°C. Tako oblikovan nitro spoj formule XIV se zatim reducira upotrebom reducirajućeg sredstva kao što je kositreni klorid, željezo, cink, ili plinoviti vodik s odgovrajućim katalizatorom, sa ili bez kiselog katalizatora kao što je hidroklorna kiselina, za od oko 2 do 16 sati na sobnoj temperaturi od oko 0-100ºC, da se dobije odgovarajući 5-aminokvinolin ili 5-aminoizokvinolin formule XV.
Spojevi formule XVII, gdje R15 je –SR14 i spojen je za kvinolinski ili izokvinolinski prsten na položaju 6, i gdje R14 je (C1-C6)alkil j, (C5-C7)cikloalkil, fenil (C1-C4) alkil, fenil, supstituirani fenil, heteroaril, ili supstituirani heteroaril, mogu se pripremiti kao što slijedi. Spoj formule XIV, gdje R5 je -Cl i spojen je za kvinolinski ili izokvinolinski prsten na položaju 6, reagira sa spojem formule R14SH, gdje R14 je kao što je gore definirano, i baza kao što je natrijev hidrid, ili takav spoj formule XIV reagira sa spojem formule R14SNa, gdje R14 je kao što je definirano gore, u inertnom otapalu kao što je tetrahidrofuran, kroz oko 4 do 16 sati na temperaturi od oko -10°C do sobne temperature. Poželjna temperatura je -10ºC. Ova reakcija daje spoj formule XVI, koji se zatim pretvori u odgovarajući 5-aminokvinolin ili kvinolin formule XVII pomoću metode opisane gore za redukciju spojeva formule XIV.
Obrada spoja formule R17R18NH sa spojem formule R1N=C=Q daje odgovarajuću ureu (Q=O) ili tioureu (Q=S) formule I. Postupci za pripremanje spojeva formule R1N=C=Q su poznati u literaturi i nekoliko metoda u "Qrganic Functional Group Preparations, Vol 1", Chapter 12, Academic Press, New York (1968), Pripremanje uree ili tiouree pomoću reakcije amina s izocijanatima i izotiocijanatima nalzi se u Qrganic Functional Group Preparations, Vol. 2, Chapter 6., Academic Press, New York (1971).
Spojevi formule R1N=C=O se mogu dobiti pomoću reakcije spoja formule R1NH2 sa 1 do 6 ekvivalenata odgovarajućeg reagensa kao što je fosgen, triklorometil kloroformat ili bis(triklorometil)}karbonat. Reakcija se uopćeno izvodi u inertnom eteru, aromatskom ugljikohidratnom ili kloriniranom ugljikohidratnom otapalu kao što je dioksan, diizopropil eter, benzen, toluen, diklorometan ili kloroform. Može se izovditi u prisutnosti baze kao što je tercijarni amin (npr. piridin, trietilamin ili kvinolin). Reakcijske temperature mogu biti u rasponu od oko 0ºC do oko 120°C, i poželjno od oko 20ºC do oko 100°C. Poželjno je da heterociklički amin formule R1NH2 reagira s 1 do 2 ekvivalenta triklorometil kloroformata u refluksnom diklorometanu kroz oko 18 sati.
Reakcija spojeva formule R1N=C=Q sa spojevima formule R17R18NH da se dobiju spojevi formule I se izvodi u inertnom anhidridnom otapalu kao što je kloroform, benzen, dimetilformamid, dioksan ili tetrahidrofuran, na temperaturi od oko 20ºC do 100°C, kroz oko 3 do 30 sati, poželjno u dimetilformamidu na oko 80ºC kroz oko 16 sati.
Amini formule NHR17R18 mogu se pripremiti pomoću različitih metoda dobro poznatih u struci (vidi npr. Vogel's Textbook of Practical Orqanic Chemistry, Longman, Inc., New York, str. 769-782 i str. 717-718 (5th ed. 1989), Organic Functional Group Preparations. Vol 2. Academic Press, New York, str. 401-405 (2nd ed. 1983). Drugi primjeri metoda za pripremu amina formule NHR17R18 su opisani u EP 0399 422 A1, EP 0415 123 A2 i EP 0439 059 A2.
Na primijer, spojevi formule R17R18NH gdje R19 je vodik i R20 je izborno supstituiran aril-(C1-C6)alkil ili izborno halogeniran (C1-C12)alkil mogu se pripremiti obradom spoja formule Ar-CH2-CN s alklanim metalnim aminom nakon čega slijedi dodavanje spoja formule R20 i da se dobije spoj formule [image] koji se postepeno reducira do amina formule [image] standardnim sredstvima.
Alkalno metalne polovice amida mogu se dokazati pomoću litija, natrija i kalija, poželjno litija. Najpoželjniji amid je litij diizopropilamid.
Readukcija nitrila može se postići uporabom borana, npr. u obliku njihova kompleksa s tetrahidrofuranom, ili pomoću hidrogenacije u prisutnosti Raney-eva nikla.
Osim tamo gdje se drugačije označi, tlak nije presudan niti u jednoj od gornjih reakcija. Poželjne temperature za gornje reakcije su kao što je poznato. Uopćeno, poželjna temperatura za svaku reakciju je najniža temperatura na kojoj se proizvod oblikuje. Poželjna temperatura za pojedinu reakciju može biti određena praćenjem reakcije upotrebom tankoslojne kromatografije.
Priprema nekih novih međuproizvoda korisnih u pripremanju spojeva ovog izuma je opisana u primjerima za pripremu, od A do R.
Novi spojevi formule I i njihove farmaceutski prihvatljive soli su korisni inhibitori acil koenzima A: kolesterol aciltransferaze (ACAT). Kao takvi oni inhibiraju crijevnu apsorpciju kolesterola kod sisavaca i korisni su u liječenju visokog serumskog kolesterola u sisavaca, uključujući ljude. Kao što se ovdje koristi, liječenje podrazumijeva prevenciju i smanjenje visokog kolesterola u serumu. Osobi kojoj je liječenje potrebno, spoj se može primjeniti različitim uobičajenim putevima, uključujući oralni, parenteralni i topijski. Uopćeno, ovi spojevi će se upotrijebiti oralno ili parenteralno u dnevnim dozama između oko 0.08 i oko 30 mg/kg tjelesne težine osobe koja se liječi, poželjno od oko 0.08 do 5 mg/kg. Za odraslu osobu približno 70 kg tjelesne težine, uobičajena doza će stoga biti oko 5.6 do oko 2100 mg na dan. Međutim, neizbježno će se pojaviti neke vrijacije u dozi zavisno o stanju osobe koja se liječi i učinkovitosti spoja koji se koristi. Osoba odgovorna za primjenu će u svakom slučaju odrediti prikladnu dozu za svaku osobu individualno.
Spoj formule I ili njegova farmaceutski prihvatljiva sol mogu se primijeniti samostalno ili u kombinaciji s farmaceutski prihvatljivim nosačem, u jednoj ili više doza. Prikladni faramceutski nosač uključuje inertno kruto otapalo, sterilnu vodenu otopinu i različita organska otapala. Farmaceutski sastojci koji nastaju se zatim jednostavno primjenjuju u različitim oblicima kao što su tablete, puderi, sirupi, otopine za injekcije i slično. Ovi farmaceutski sastojci mogu, ako se želi, sadržavati dodatne sastojke kao što su arome, tvari za vezanje, ekscipijenti i slično. Tako, za svrhu oralne primjene, tablete koje sadrže različite ekscipijente kao što su natrij citrat, kalcij karbonat i kalcij fofsfat mogu se upotrebljavati zajedno s različitim dezintegrantima kao što su škrob, alginična kiselina i neki kompleksni silikati, zajedno s tvarima za vezanje kao što su polivinilpirolidin, sukroza, želatina i akacija. Osim toga, lubrikantne tvari kao što su magnezijev stearat, natrijev lauril sulfat i talk su često korisne za spravljanje tableta, čvrsti sastojci sličnog tipa mogu se također koristiti kao punjenja u mekim i tvrdim želatinskim kapsulama. Poželjni materijali za ovo uključuju laktozu ili mliječni šećer i polietilen glikole visoke molekularne težine. Kada se za oralnu primjenu žele vodene suspenzije ili eliksiri, tada osnovni aktivni spoj može biti kombiniran s različitim sredstvima za zaslađivanje i poboljšanje okusa, tvarima koje daju boju ili bojama, i ako se želi, emulgirajućim ili suspendirajućim sredstvima, zajedno s diluensima kao što je voda, etanol, propilen glikol, glicerin i njihove kombinacije.
Za parenteralnu primjenu, mogu se koristiti otopine spoja formule I ili njegove faramceutski prihvatljive soli u sezamovom ulju ili ulju od kikirikija, vodenom propilen glikolu., ili u sterilnoj vodenoj otopini. Takve vodene otopine trebaju imati prikladan pufer ako je neophodno i izotonični tekući diluens s dovoljno soli ili glukoze. Takve otopine su posebno prikladne za intravensku, intramuskularnu, subkutanu i intraperitonealnu primjenu. S tim u vezi, sterilni vodeni mediji koji se koriste su svi lako dostupni pomoću standardnih tehnika poznatih poznavateljima struke.
Aktivnost spojeva ovog izuma kao ACAT inhibitora može se odrediti pomoću nekoliko standardnih bioloških ili farmakoloških testova. Na primjer, slijedeći postupak je korišten da se odredi ACAT inhibirajuća aktivnost spojeva formule I. ACAT je testiran u mikrosomima izoliranim iz Sprague-Dawley štakora prema Bilheimer, J.T., Meth. Enzymol., 111 str. 286-293 (1985), s manjim modifikacijama. Mikrosomi iz jetre štakora se pripreme pomoću diferencijalnog centrifugiranja i isperu sa puferom prije upotrebe. Smjesa, za test sadrži 25 μl BSA (40 mg/ml), 30 μl otopine mikrosoma jetre štakora (100 µg mikrosomalnog proteina), 20 µl pufera (0.1 M K2PO4, 1.0 mM reduciranog glutationa, pH 7.4), 20 µg kolesterola u 100 μl 0,67. Triton WR-1339 otopini pufera, i 5 µl spoja koji se testira u 100% DMSO (ukupni volumen = 180 µl). Smjesa se inkubira kroz 30 min. na 37°C. Reakcija se započinje dodavanjem 20 µl 14C-Oleoyl-CoA otopine (1000 µM, 2,000 dpm/nmol) i traje 15 min na 37°C. Reakcija se zaustavi pomoću dodatka 1 ml EtOH. Lipidi se ekstrahiraju u 4 ml heksana. Količina od 3 ml se osuši pod N2, i resuspendira u 100 µl kloroforma. 50 µl kloroforma se nakapa na toplinom aktiviranu TLC ploču i razvijenu u heksan: dietil eter:octena kiselina (85:15:1, v:v:v). Ugrađivanje radioaktinosti u kolesteril estere se odredi na Berthold LB2842 Linear TLC Analyzer-u. ACAT inhibicija se izračuna relativno prema DNSO kontrolnom testu.
Aktivnost spojeva formule I u inhibiranju crijevne apsorpcije kolesterola može se odrediti pomoću postupka prema Melchoir i Harwell, J. Lipid. Res., 26, 306-315 (1985).
Ovaj izum je ilustriran pomoću slijedećih primjera. Razumljivo je, međutim, da ovaj izum nije ograničen na specifične detalje ovih primjera. Točke taljenja nisu korigirane. Spektar protonske nuklearne magnetske rezonance (1H NMR) i 13C spektar nuklearne magnetske rezonance (13C NMR) su mjereni za otopine u deuterokloroformu (CDCl3) i položaji vrhova su izraženi u parts per million (ppm) niže od tetrametilsilana (TMS). Oblici vrhova su označeni kao što slijedi: s, jednostruki; d, dvostruki; t, trostruki; q, četverostruki; q, peterostruki; hx, šesterostruki; h, sedmerostruki; m, mnogostruki; br, široki; vb, vrlo široki; c, složeni.
PRIPREMANJE MEĐUPROIZVODA
PRIPRAVNI PRIMJER A
5-jodo-1,1-difluoropentan
Otopina 5-bromo-1,1-difluoropentana (2.65 g, 14.2 mmol) i natrijeva jodida (10.63 g, 70.8 mmol) u acetonu (150 ml) se drži na refluksu pod dušikom preko noći. Reakcijska smjesa se zatim filtrira i filtrat se koncentrira na atmosferskom tlaku. Ostatak se otopi u diklorometanu (50 ml) i otopina se ispere sa vodom (2×30 ml) i slanom vodom (30 ml), osuši (natrij sulfat) i koncentrira pod smanjenim tlakom na sobnoj temperaturi. Sirovi proizvod se destilira pod smanjenim tlakom da se dobije naslovni spoj u obliku žućkaste tekućine (2.24 g, 93%), bp 73-75° C, 10 mm Hg. 1H NMR (300 MHz, CDCl3) δ 1.59 (m, 2H), 1.84 (c, 4H), 3.2 (t, 2H), 5.63, 5.82, 6.01 (3t, ukupno 1H).
PRIPRAVNI PRIMJER B
2-(2-klorobenzo[b]tiofen-3-il)-7,7-difluoroheptannitril
Otopina litij diizopropilamida u cikloheksanu (5.13 mmol, 3.42 ml 1.5 M otopine) se kapajući doda otopini (2-klorobenzo[b]tiofen-3-il)acetonitrila (1.06 g, 5.13 mmol) u tetrahidrofuranu (10 ml) ohlađenom na -70ºC pod dušikom. Otopina koja nastaje se miješa na -70ºC kroz 20 minuta, zatim se polako dodaje otopina 5-jodo-1,1-difluoropentana (1.2 g, 5.13 mmol) u tetrahidrofuranu (5 ml) na -70°C. Reakcijska smjesa se miješa na -70ºC kroz 1 sat, zatim se ostavi polako zagrijati do sobne temperature i ostavi stajati na toj temperaturi preko noći. (60 ml) vode se doda reakcijskoj otopini i smjesa koja nastaje se ekstrahira sa etil acetatom (3×70 ml). Spojeni etil acetat ekstrakti se isperu sa slanom vodom (80 ml), osuše (natrij sulfat) i koncentriraju in vacuo. Sirovi proizvod (2.1 g) se pročisti pomoću kromatografije na stupcu na silika gelu (200 g), elucijom sa 4:1 heksan/diklorometan nakon čega slijedi 7:3 heksan/diklorometan da se dobije naslovni spoj u obliku ulja (950 mg, 597,). 1H NMR (300 MHz, CDCl3) δ 1.4-1.7 (c, 4H), 1.7-2.05 (c, 3H), 2.2 (c, 1H), 4.3 (t, 1H), 5.6, 5.78, 5,93 (3t, ukupno 1H), 7.42 (m, 2H), 7.75 (d, 1H), 7.95 (d, 1H).
Na sličan način sintetiziraju se slijedeći nitrili:
PRIPRAVNI PRIMJER C
2-(naft-1-il)-7,7-d fluoroheptannitril
dobitak 757.
1H NMR (300 MHz, CDCl3) δ 1.44-1.72 (c, 4H), 1.72-1.94 (c, 2H), 2.07 (m, 2H), 4.57 (t, 1H), 5.6, 5.8, 5.99 (3t, ukupno 1H), 7.44-7.64 (m, 3H), 7.69 (d, 1H), 7.9 (m, 3H).
PREPARATIVNI PRIMJER D
2-(2,5-dimetilfenil)-6-fenilheksannitril
dobitak 867.
1H NMR (300 MHz, CDCl3) δ 1.48-2.0 (c, 6H), 2.28 (s, 3H), 2.34 (s, 3H), 2.63 (t, 2H), 3.89 (q, 1H), 7.06 (m, 2H), 7.12-7.32 (m, 6H).
PRIPRAVNI PRIMJER E
2-(2-klorobenzo[b]tiofen-3-il)-7,7-difluoroheptanamin
Otopina boran-tetrahidrofuran kompleksa u tetrahidrofuranu (6.07 mmol, 6.07 ml 1.0 M otopine) se kapajući doda otopini (2-klorobenzo[b]tiofen-3-il)-7,7-difluoroheptannitrila (950 mg, 3.03 mmol) u tetrahidrofuranu (15 ml) na sobnoj temperaturi pod dušikom i reakcija se ostavi stajati na sobnoj temperaturi preko noći. Zatim se doda vodena hidroklorna kiselina (5 ml 3N otopine) i reakcijska smjesa se drži na refluksu kroz 30 minuta nakon čega slijedi odstranjivanje tetrahidrofurana in vacuo. Vodena faza koja nastane se razrijedi s vodom (10 ml) i ekstrahira sa etil acetatom (3×30 ml). Spojeni ekstrakti etil acetata se isperu slanom vodom (40 ml), osuše (natrij sulfat) i koncentriraju in vacuo. Ostatak (930 mg) se pročisti pomoću kromatografije na stupcu silika gela (100 g) elucijom s 9:1 etil acetat/metanol da se dobije naslovni spoj u obliku ulja (632 mg, 66% dobiti).
Na sličan način sintetiziraju se slijedeći amini:
PRIPRAVNI PRIMJER F
2-(2-klorobenzo[b]tiofen-3-il)-5-metilheksanamin
dobitak 67%
1H NMR (300 MHz, CDCl3) δ 0.79, 0.80, 0.81, 0.83 (2d, 6H), 0.92-1.08 (m, 1H), 1.1-1.28 (m, 1H), 1.5 (h, 1H), 1.66 (b, 2H), 1.78 (m, 1H), 1.94 (c, 1H), 3.09 (m, 1H), 3.18-3.37 (c, 2H), 7.32 (c, 2H), 7.71 (c, 1H), 7.79 (c, 1H).
PRIPRAVNI PRIMJER G
5-metil-2-(5-metilbenzo[b]tiofen-3-il)heksanamin
dobitak 53%
1H NMR (300 MHz, CDCl3) δ 0.84 (d, 6H), 1.18 (c5 2H), 1.52 (h, 1H), 1.75 (bq, 2H), 2.02 (b, 2H), 2.49 (s, 3H), 3.0 (d, 2H), 3.12 (p, 1H), 7.1 (s, 1H), 7.17 (d, 1H), 7.59 (s, 1H), 7.73 (d, 1H).
PRIPRAVNI PRIMJER H
2-(benzo-[b]tiofen-3-il)heptanamin
dobitak 65%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.25 (c, 6H), 1.76 (c, 2H), 2.05 (b, 2H), 3.03 (c, 2H), 3.19 (p, 1H), 7.14 (s, 1H), 7.36 (t, 2H), 7.81 (m, 1H), 7.87 (m, 1H).
PRIPRAVNI PRIMJER I
2-(benzo[b]tiofen-3-il)-6-metilheptanamin
dobitak 66%
1H NMR (300 MHz, CDCl3) δ 0.78, 0.80, 0.81, 0.82 (2d, 6H), 1.1-1.44 (c, 4H), 1.47 (h, 1H), 1.74 (q, 2H), 2.06 (b, 2H), 3.04 (c, 2H), 3.19 (p, 1H), 7.14 (s, 1H), 7.36 (c, 2H), 7.84 (m, 2H).
PRIPRAVNI PRIMJER J
2-(5-metilbenzo[b]tiofen-3-il)-6,6,6-trifluoroheksanamin
dobitak 51%
1H NMR (300 MHz, CDCl3) δ 1.54 (m, 2H), 1.69 (b, 2H), 1.86 (c, 2H), 2.06 (m, 2H), 2.49 (s, 3H), 3.03 (d, 2H), 3.16 (p, 1H), 7.12 (s, 1H), 7.19 (d, 1H), 7.57 (s, 1H), 7.75 (d, 1H).
PRIPRAVNI PRIMJER K
2-(2-klorobenzo[b]tiofen-3-il)-6,6,6-trifluoroheksanamin
dobitak 60%
1H NMR (300 MHz, CDCl3) δ 1.35-1.7 (c, 4H), 1.89 (c, 1H), 2.05 (c, 3H), 3.09 (q, 1H), 3.2-3.4 (c, m, 2H), 7.34 (m, 2H), 7.75 (m, 2H).
PRIPRAVNI PRIMJER L
2-(2-klorobenzo[b]tiofen-5-il)heptanamin
dobitak 68%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 1.2 (c, 6H), 1.65 (b, 2H), 1.78 (c, 1H), 1.95 (c, 1H), 3.07 (q, 1H), 3.16-3.38 (c, m, 2H), 7.32 (c, 2H), 7.72 (m, 1H), 7.8 (m, 1H).
PRIPRAVNI PRIMJER M
2-(5-klorobenzo[b]tiofen3-il)-heptanamin
dobitak 60%
1H NMR (300 MHz, CDCl3) δ 0.84 (t, 3H), 1.26 (c, 6H), 1.65-1.9 (c, 4H), 3.0 (d, 2H), 3.1 (p, 1H), 7.19 (s, 1H), 7.29, 7.30, 7.32, 7.33 (q, 1H)5 7.77 (m, 2H).
PRIPRAVNI PRIMJER N
2-(5-metilbenzo[b]tiofen-3-il)heptanamin
dobitak 63%
1H NMR (300 MHz, CDCl3) δ 0.84 (t, 3H), 1.26 (c, 6H), 1,76 (c, 2H), 1.84 (b, 2H), 2.49 (s, 3H), 3.0 (d, 2H), 3.13 (p, 1H), 7.1 (s, 1H), 7.18 (d, 1H), 7.6 (s, 1H), 7.74 (d, 1H).
PRIPRAVNI PRIMJER O
2-(5-klorobenzo[b]tiofen-3-il)-6,6,6-trifluoroheksanamin
dobitak 33%
1H NMR (300 MHz, CDCl3) δ 1.43-2.0 (c, 6H), 2.08 (m, 2H), 3.02 (c, 2H), 3.12 (m, 1H), 7.22 (s, 1H), 7.31, 7.32, 7.34, 7.35 (q, 1H), 7.75, 7.76, 7.77, 7.8 (q, 2H).
PRIPRAVNI PRIMJER P
2-(5-klorobenzo[b]tiofen-3-il)-6-metilheptanamin
dobitak 69%
1H NMR (300 MHz, CDCl3) δ 0.79, 0.81, 0.82, 0.83 (2d, 6H), 1.1-1.33 (c, 4H), 1.47 (h, 1H), 1.62-1.93 (c, 4H), 3.01 (d, 2H), 3.11 (p, 1H), 7.2 (s, 1H), 7.2 (s, 1H), 7.29, 7.30, 7.32, 7.33 (q, 1H), 7.76, 7.77, 7.78, 7.784 (q, 2H).
PRIPRAVNI PRIMJER Q
2-(naft-1-il)-7,7-difluoroheptanamin
Mješavina 2-(naft-1-il)-7,7-difluoroheptannitrila (413 mg, 1.51 mmol), Raney-eva nikla (413 mg) i amonijaka (0.9 g) u metanolu (20 ml) se hidrogenizira pod 340 kPa (50 psi) vbodika preko noći na sobnoj temperaturi. Mješavina se filtrira i filtrat koncentrira in vacuo. Ostatak se razdijeli između etil acetata (50 ml) i vode (40 ml) i ikstrakt etil acetata se ispere sa slanom vodom (30 ml), osuši (natrij sulfat) i koncentrira in vacuo. Ostatak (400 mg) se pročisti pomoću kromatografije na stupcu silika gela (100 g), elucijom sa 85:15 etil acetat/metanol da se dobije naslovni spoj u obliku ulja (321 mg, 77% dobiti). 1H NMR (300 MHz, CDCl3) δ 1.35 (c, 6H), 1.78 (c, 4H), 3.08 (c, 2H), 3.61 (c, 1H), 5.52, 5,71, 5.9 (3t, ukupno 1H), 7.37 (d, 1H), 7.5 (m, 3H), 7.75 (d, 1H), 7.88 (d, 1H), 8.16 (d, 1H).
Slijedeći spojevi se sintetiziraju na sličan način:
PRIPRAVNI PRIMJER R
2-(2,5-dimetilfenil)-6-fenilheksanamin
dobitak 74%
1H NMR (300 MHz, CDCl3) δ 1.15-1.44 (cs 4H), 1.5-1.75 (c, 4H), 2,29 (s, 3H),2.32 (s, 3H), 2.55 (m, 2H)5 2.9 (c, 3H), 6.91, 6.94, 6.95 (t, 2H), 7.05 (d, 1H), 7,14 (m, 3H), 7.29 (t, 2H).
PRIMJER 1
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(4-izopropilbenzil)urea
Otopina 2-(4-izopropilbenzilamino)indana (159 mg, 0.6 mmol) i 2,4-bis(metiltio)-6-metilpiridin-3-il izocijanata (136 mg, 0.6 mmol) u 3 ml dimetilformamida se zagrijava na 80°C pod dušikom preko noći. Reakcijska smjesa se ohladi do sobne temperature, razrijedi sa 50 ml etil acetata i ispere sa 3×50 ml vode, zatim 50 ml slane vode, osuši (natrijev sulfat), filtrira i koncentrira in vacuo. Kruti ostatak (265 mg) se pročisti pomoću kromatograf ije na stupcu, silika gela (150 g), elucijom sa 7:3 heksan/etil acetat da se dobije naslovni spoj u obliku bijele krutine (195 mg, 66%).
1H NMR (300 MHz, CDCl3) δ 1.25 (d, 6H), 2.36 (s, 3H), 2.45 (s, 3H), 2.47 (s, 3H), 2.91 (h, 1H), 3.06 (dd, 2H), 3.31 (dd, 2H), 4.57 (s, 2H), 5.39 (p, 1H), 5.57 (s, 1H), 6.59 (s, 1H), 7.15 (c, 4H), 7.22-7.35 (m, 4H).
1- i indan-2-il urea derivati iz primjera 2-18 su sintetizirani na sličan način.
PRIMJER 2
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2,5-dimetilbenzil)-N'-(indan-2-il)urea
dobitak 66%
1H NMR (300 MHz, CDCl3) δ 2.15 (s, 3H), 2,37 (s, 3H), 2,39 (s, 3H), 2.45 (s, 3H), 2.47 (s, 3H), 2.99 (dd, 2H), 3,29 (dd, 2H), 4.47 (s, 2H), 5.48 (s) i 5.50 (m) (ukupno 2H), 6,58 (s, 1H), 7.04 (m, 2H), 7.15 (c, 5H), 7.43 (s, 1H).
PRIMJER 3
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2,4-dimetilbenzil)-N'-(indan-2-il)urea
dobitak 66%
1H NMR (300 MHz, CDCl3) δ 2.17 (s, 3H), 2.33 (s, 3H), 2.37 (s, 3H), 2.45 (s, 3H), 2.48 (s, 3H), 2.99 (dd, 2H), 3.26 (dd, 2H), 4.48 (s, 2H), 5.44 (m) i 5.49 (s) (ukupno 2H), 6.58 (s, 1H), 6.99 (s, 1H), 7.14 (c, 5H), 7.47 (d, 1H).
PRIMJER 4
N-[4,6-bis (metiltio)-2-metilpirimidin-5-il]-N'-(indan-2-il)-N'-(4-izopropilbenzil)urea
dobitak 62%
1H NMR (300 MHz, CDCl3) δ 1.25 (d, 6H), 2,46 (s, 6H), 2.56 (s, 3H), 2.92 (h, 1H), 3.04 (dd, 2H), 3.31 (dd, 2H), 4.55 (s, 2H), 5.41 (m) i 5.46 (s) (ukupno 2H), 7.16 (c, 4H), 7.23 -7.34 (m, 4H).
PRIMJER 5
N-[4,6-bis(metiltio)-2-metilpirimidin-5-il]-N'-(2,4-dimetilbenzil)-N'-(indan-2-il)urea
dobitak 70%
1H NMR (300 MHz, CDCl3) δ 2.17 (s, 3H), 2.33 (s, 3H), 2.47 (s, 6H), 2.56 (s, 3H), 2.99 (dd, 2H), 3.28 (dd, 2H), 4.46 (s, 2H), 5.41 (s) i 5.44 (m) (ukupno 2 H), 6.99 (m, 1H), 7.14 (c, 5H), 7.44 (d, 1H).
PRIMJER 6
N-(2,5-dimetilbenzil)-N-(indan-2-il)-N'-(6-metiltiokvinolin-5-il)urea
dobitak 19%
1H NMR (300 MHz, CDCl3) δ 2.20 (s, 3H), 2.45 (s, 6H), 3.06 (dd, 2H), 3.34 (dd, 2H), 4.60 (s, 2H), 5.54 (p, 1H), 6.20 (s, 1H), 7.07 (m, 2H), 7.16 (c, 4H), 7.38 (q, 1H), 7.46 (s, 1H), 7.60 (d, 1H), 7.96 (d, 1H), 8.07 (d, 1H), 8.82 (m, 1H).
PRIMJER 7
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2-klorobenzil)-N'-(indan-2-il)urea
dobitak 17%
1H NMR (300 MHz, CDCl3) δ 2.38 (s, 3H), 2.45 (s, 3H), 2.48 (s, 3H), 3.02 (dd, 2H), 3.26 (dd, 2H), 4.67 (s, 2H), 5.37 (p, 1H), 5.51 (s, 1H), 6.59 (s, 1H), 7.14 (c, 4H), 7.25 (c, 1H), 7.38 (c, 2H), 7.64 (d, 1H).
PRIMJER 8
N-[4,6-bis(metiltio)-2-metilpiriroidin-5-il]-N'-(2,5-dimetilbenzil)-N'-(indan-2-il)urea
dobitak 69%
1H NMR (300 MHz, CDCl3) δ 2.15 (s, 3H), 2.39 (s, 3H), 2.47 (s, 6H), 2.57 (s, 3H), 2.98 (dd, 2H), 3.29 (dd, 2H), 4.45 (s, 2H), 5.40 (s, 1H), 5.50 (p, 1H), 7.06 (m, 2H), 7.14 (m, 4H), 7.38 (s, 1H).
PRIMJER 9
N-[4,6-bis(metiltio)-2-metilpirimidin-5-il]-N'-(indan-2-il)-N'-[4-(3-metilbutil)benzil]urea
dobitak 71%
1H NMR (300 MHz, CDCl3) δ 0.93 (d, 6H), 1.45-1.69 (c, 3H), 2.47 (s, 6H), 2.57 (s) i 2.61 (m) (ukupno 5H), 3.03 (dd, 2H), 3.31 (dd, 2H), 4.55 (s, 2H), 5.40 (m) i 5.46 (m) (ukupno 2H), 7.10-7.33 (c, 8H).
PRIMJER 10
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-[4-(3-metilbutil)benzil]urea
dobitak 58%
1H NMR (300 MHz, CDCl3) δ 0.92 (d, 6H), 1.44-1.68 (c, 3H), 2.36 (s, 3H), 2.44 (s, 3H), 2.46 (s, 3H), 2.60 (m, 2H), 3.04 (dd, 2H), 3.30 (dd, 2H); 4.56 (s, 2H), 5.39 (p, 1H), 5.54 (s, 1H), 6.58 (s, 1H), 7.10-7.34 (c, 8H).
PRIMJER 11
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(naft-1-ilmetil)urea
dobitak 25 %
1H NMR (300 MHz, DCDl3) δ 2.1 (c, 1H); 2.32-2.54 [ukupno 10 H, uključujući 2.4 (s, 3H), 2.46 (s, 3H), 2.51 (s, 3H)], 2.33 (c, 2H), 4.69 (d, 1H), 5.26 (d, 1H), 5.5 (b, 1H), 6.06 (vb, 1H), 6.6 (s, 1H), 7.15-7.39 (c, 4H), 7.5 (c, 3H), 7.72-8.0 (c, 4H).
PRIMJER 12
N-[2,4-bis(metiltio)-6-nietilpiridin-3-il]-N'-(indan-1-il)-N'-(naft-2-ilmetil)urea
dobitak 32%
1H NMR (300 MHz, CDCl3) δ 2.1 (c, 1H), 2.33-2.55 [ukupno 10 H, uključujući 2.37 (s, 3H), 2.47 (s, 3H), 2.49 (s, 3H)], 2.88 (c, 2H), 4.5 (d, 1H), 4.8 (d, 1H), 5.6 (b, 1H), 6.08 (vb, 1H), 6.6 (s, 1H), 7.22 (c, 3H), 7.47-7.54 (c5 4H), 7.83 (c, 3H), 7.93 (s, 1H).
PRIMJER 13
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(4-t-butilbenzil)urea
dobitak 23%
1H NMR (300 MHz, CDCl3) δ 1.32 (s, 9H), 2.1 (c, 1H), 2,36-2.55 [ukupno 10 H, uključujući 2.38 (s, 3H), 2.46 (s, 3H), 2.48 (s, 3H)], 2.9 (c, 2H), 4.29 (d, 1H), 4.6 (d, 1H), 5.52 (b, 1H), 6.05 (vb, 1H), 6.6 (s, 1H), 7.22 (c, 4H), 7.32 (d, 2H), 7.39 (d, 2H).
PRIMJER 14
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(4-fenilbenzil)urea
dobitak 28%
1H NMR (300 MHz, CDCl3) δ 2.1 (c, 1H), 2.38-2.58 [ukupno 10 H, uključujući 2.39 (s, 3H), 2.47 (s, 3H), 2,5 (s, 3H)], 2.9 (c, 2H), 4.4 (d, 1H), 4.7 (d, 1H), 5.54 (b, 1H), 6.02 (vb, 1H), 6.61 (s, 1H), 7.24 (c, 4H), 7.31-7.52 (c, 5H), 7,6 (c, 4H).
PRIMJER 15
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(naft-1-ilmetil)urea
dobitak 20%
1H NMR (300 MHz, CDCl3) δ 2.4 (s, 3H), 2.48 (s, 3H), 2.53 (s, 3H), 3.07 (dd, 2H), 3.33 (dd, 2H), 5.1 (s, 2H), 5.5 (m) i 5.57 (s) (ukupno 2H), 6.6 (s, 1H), 7.12 (c, 4H), 7.48-7.64 (c, 3H), 7.76-7.97 (c, 4H).
PRIMJER 16
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(naft-2-ilmetil)urea
dobitak 20%
1H NMR (300 MHz, CDCl3) δ 2.37 (s, 3H), 2.48 (s, 6H), 3.1 (dd, 2H), 3.34 (dd, 2H), 4.78 (s, 2H), 5,47 (p, 1H), 5.68 (s, 1H), 6.6 (s, 1H), 7.15 (c, 4H), 7.38-7.58 (c, 3H), 7.87 (c, 3H), 7.95 (s, 1H).
PRIMJER 17
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(2,4,6-trimetilbenzil)urea
dobitak 13%
1H NMR (300 MHz, CDCl3) δ 2.27 (s, 3H), 2.38 (s, 3H), 2.4 (s, 6H), 2.46 (s, 3H), 2.5 (s, 3H), 3.07 (dd, 2H), 3,55 (dd, 2H), 4.16 (m, 1H), 4.77.(s, 2H), 5.41 (s, 1H), 6.6 (s, 1H), 6.88 (s, 2H), 7.12 (c, 4H).
PRIMJER 18
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2,3-diklorobenzil)-N'-(indan-2-il)urea
dobitak 27%
1H NMR (300 MHz, CDCl3) δ 2.41 (s, 3H), 2.49 (s, 3H), 2.52 (s, 3H), 3-0 (dd, 2H), 3.28 (dd, 2H), 4.68 (s, 2H), 5.32 (q, 1H), 5.54 (s, 1H), 6.63 (s, 1H), 7.16 (c, 4H), 7.34 (t, 1H), 7.45 (d, 1H), 7.55 (d, 1H).
PRIMJER 19
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-cikloheptil-N'-(4-fenilbenzil)urea
dobitak 33%
1H NMR (300 MHz, CDCl3) δ 1.28, 1.32 (2t, 6H), 1.4-1.8 (C, 10H), 2.02 (c, 2H), 2.42 (s, 3H), 2.86 (q, 2H), 3.09 (q, 2H), 4.37 (c, 1H), 4.62 (s, 2H), 5.54 (s, 1H), 6.62 (s, 1H), 7.34 (t, 1H), 7.44 (t, 2H), 7.51 (d, 2H), 7.6 (m, 4H).
PRIMJER 20
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-cikloheptil-N'-(f1uoren-2-ilmetil)urea
dobitak 40%
1H NMR (300 MHz, CDCl3) δ 1.22, 1.24, 1.26, 1.27, 1.3 (2t, 6H), 1.4-1.8 (c, 10H), 2,02 (c, 2H), 2.41 (s, 3H), 2.84 (q, 2H), 3.06 (q, 2H), 3.91 (s, 2H), 4.42 (c, 1H), 4.65 (s, 2H), 5.55 (s, 1H), 6.6 (s, 1H), 7.25-7.44 (m, 3H), 7.54 (d, 1H), 7.68 (s, 1H), 7.78 (d, 2H).
PRIMJER 21
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-cikloheptil-N'-(naft-2-ilmetil)urea
dobitak 31%
1H NMR (300 MHz, CDCl3) δ 1.2, 1.22, 1.25, 1.27, 1.3 (2t, 6H), 1.4-1.8 (c, 10H), 2.04 (c, 2H), 2.4 (s, 3H), 2.82 (q, 2H), 3.04 (q, 2H), 4.47 (c, 1H), 4.73 (s, 2H), 5.6 (s, 1H), 6.59 (s, 1H), 7.48 (c, 3H), 7.85 (m, 3H), 7.99 (s, 1H).
PRIMJER 22
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-heptil-N'-[naft-2-ilmetil]urea
dobitak 33%
1H NMR (300 MHz, CDCl3) δ 0.86 (t, 3H), 1.2-1.42 (c, 14H), 1.72 (c, 2H), 2.43 (s, 3H), 2.88 (q, 2H), 3.11 (q, 2H), 3.44 (t, 2H), 4.79 (s, 2H), 5.73 (s, 1H), 6.65 (s, 1H), 7.48 (m, 3H), 7.85 (m, 4H).
PRIMJER 23
N-[2,4-bis(etiitio)-6-metilpiridin-3-il]-N'-heptil-N'-(2,4,6-trimetilbenzil)urea
dobitak 34%
1H NMR (300 MHz, CDCl3) δ 0.86 (t, 3H), 1,23 (c, 8H)5 1.3, 1.32, 1.33, 1.35, 1.36, 1.38 (2t, 6H), 1.65 (c, 2H), 2.27 (s, 3H), 2.36 (s, 6H), 2.46 (s, 3H), 2.91 (q, 2H), 3.05 (t, 2H), 3.15 (q, 2H), 4.71 (s, 2H), 5.7 (s, 1H), 6.68 (s, 1H), 6.87 (s, 2H).
PRIMJER 24
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N’-cikloheptil-N'-(4-fenilbenzil)urea
dobitak 17%
1H NMR (300 MHz, CDCl3) δ 1.4-1.77 (c, 10H), 2.02 (c, 2H), 2.36 (s, 3H), 2.45 (s, 3H), 2.46 (s, 3H), 4.38 (c, 1H), 4.62 (s, 2H), 5.51 (s, 1H), 6.58 (s, 1H), 7.34 (t, 1H), 7.4-7.54 (m, 4H), 7.61 (t, 4H).
PRIMJER 25
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-cik1oheptil-N'-(fluoren-2-ilmetil)urea
dobitak 9%
1H NMR (300 MHz, CDCl3) δ 1.4-1.8 (c, 10H), 2.02 (c, 2H), 2.35 (s, 3H), 2.43 (s, 3H), 2.44 (s, 3H), 3.91 (s, 2H), 4.42 (c, 1H), 4.66 (s, 1H), 5.52 (s, 1H), 6.57 (s, 1H), 7.24-7.45 (m, 3H), 7.55 (d, 1H), 7.67 (s, 1H), 7.79 (d, 2H).
PRIMJER 26
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(4-izopropilbenzil)-N'-(1,2,3,4-tetrahidronaft-2-il)urea
dobitak 13%
1H NMR (300 MHz, CDCl3) δ 1.25, 1.26, 1.27, 1.29, 1.31, 1.34, 1.36 (2t i d, 12H), 1.88 (m, 1H), 2.13 (c, 1H), 2.42 (s, 3H), 2.8-3,02 (m i q, 6H), 3.02-3.18 (c i q, 3H), 4.61 (s, 2H), 4.78 (c, 1H), 5.62 (s, 1H), 6.63 (s, 1H), 7.08 (s, 4H), 7.26 (d, 2H), 7.4 (d, 2H).
PRIMJER 27
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-heptil-N'-(3-metilbenzo[b]tiofen-2-ilmetil)urea
dobitak 35%
1H NMR (300 MHz, CDCl3) δ 0.87 (t, 3H), 1.29-1.9 [c uključujući 2t (1.26, 1.28, 1.29, 1.31, 1.32), ukupno 14 H], 1.75 (c, 2H), 2.42 (s, 3H), 2.45 (s, 3H), 2.88 (q, 2H), 3.11 (q, 2H), 3.36 (t, 2H), 4.86 (s, 2H), 5.77 (s, 1H), 6.67 (s, 1H), 7.28-7.4 (m, 2H), 7.66 (d, 1H), 7.79 (d, 1H).
PRIMJER 28
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(1,2,3,4-tetrahidronaft-2-il)-N'-(2,4,6-trimetilbenzil)urea
dobitak 26%
1H NMR (300 MHz, CDCl3) δ 1.32, 1.36 (2t, 6H), 2.06 (c, 1H), 2.15-2.35 [c i s (2.25), ukupno 4H], 2.42 (s, 6H), 2.44 (s, 3H), 2.6-2.96 (c, 5H), 3.14 (q, 2H), 3.42 (m, 1H), 3.73 (c, 1H), 4.74 (s, 2H), 5.75 (s, 1H), 6,66 (s, 1H), 6.84 (s, 2H), 7.06 (c, 4H).
PRIMJER 29
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-cikloheptil-N'-(naft-2-ilmetil)urea
dobitak 18%
1H NMR (300 MHz, CDCl3) δ 1.49-1.74 (c, 10H), 2.04 (c, 2H), 2.33 (s, 3H), 2.43 (s, 6H), 4.45 (c, 1H), 4.74 (s, 2H), 5.57 (s, 1H), 6.56 (s, 1H), 7.48 (c? 3H), 7.85 (c, 3H), 7.97 (s, 1H).
PRIMJER 30
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(4-izopropilbenzil)urea
dobitak 17%
1H NMR (300 MHz„ CDCl3) δ 1.26 (d) i 1.29, 1.34 (2t) (ukupno 12H), 2.42 (s, 3H), 2.82-2.98 (m, 3H), 3.0-3.14 (m, 4H), 3.31 (dd, 2H), 4.57 (s, 2H), 5.41 (p, 1H), 5.58 (s, 1H), 6.63 (s, 1H), 7.15 (c, 4H), 7.25 (d, 2H), 7.33 (d, 2H).
PRIMJER 31
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(2,4-dimetilbenzil)-N'-(indan-2-il)urea
dobitak 43%
1H NMR (300 MHz, CDCl3,) δ 1.31, 1.35 (2t, 6H), 2.18 (s, 3H), 2.33 (s, 3H), 2.43 (s, 3H), 2.89 (q, 2H), 3.0 (dd, 2H), 3.11 (q, 2H), 3.29 (dd, 2H), 4.49 (s, 2H), 5.44 (p, 1H), 5.52 (s, 1H), 6.63 (s, 1H), 6.99 (s, 1H), 7.1-7.2 (c, 5H), 7.49 (d, 1H).
PRIMJER 32
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(4-izopropilbenzil)-N'-(6,7,8,9-tetrahidro-5H-benzociklohepten-7-il]urea
dobitak 39%
1H NMR (300 MHz, CDCl3) δ 1-24 (d, 6H), 1.45 -1.6 (m, 2H), 2.22 (c, 2H), 2.36 (s, 3H), 2.46 (s, 3H), 2.7-2.96 (m, 6H), 4.45 (s, 2H), 4.72 (c, 1H), 5.52 (s, 1H), 6.59 (s, 1H), 7.1 (m, 4H), 7.23 (d, 2H), 7.31 (d, 2H).
PRIMJER 33
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(2,4,6-trimetilbenzil)urea
dobitak 27%
1H NMR (300 MHz, CDCl3) δ 1.3, 1.34 (2t, 6H), 2.27 (s, 3H); 2.4 (s, 6H), 2.41 (s, 3H), 2.88 (q, 2H), 2.98-3.18 (m, 4H), 3.57 (dd, 2H), 4.16 (p, 1H), 4.77 (s, 2H), 5.43 (s, 1H), 6.62 (s, 1H), 6.87 (s, 2H), 7.11 (c, 4H).
PRIMJER 34
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2,2-difeniletil]urea
Otopina 2,2-difeniletilamina (148 mg, 0.75 mmol) i 2,4-bis(metiltio)-6-metilpiridin-3-il izocijanata (170 mg, 0.75 mmol) u 15 ml diklorometana se drži na refluksu pod dušikom preko noći. Reakcijska smjesa se zatim ohladi do sobne temperature i koncentrira in vacuo. Krutina koja ostaje se pročisti pomoću kromatografije na stupcu silika gela (200 g), elucijom sa 8:2 diklorometan/etil acetat da se dobije naslovni spoj u obliku, bijele krutine (111 mg, 35% dobiti).
1H NMR (300 MHz, CDCl3) δ 2.29 (s, 3H), 2.46 (s, 3H), 2.50 (s, 3H), 3.82 (q, 2H), 4.18 (t, 1H), 6.53 (s, 1H), 7.12-7.28 (c, 12H).
Derivati (2,2-difeniletil)uree iz primjera 35-37 se pripremaju u. skladu sa metodom iz primjera 34.
PRIMJER 35
N-(2,2-difeniletil)-N'-(6-metiltiokvinolin-5-il]urea
dobitak 63%
1H NMR (300 MHz, CDCl3) δ 2.27 (s, 3H), 3.62 (bd, 2H) 5 3.98 (t, 1H), 6.39 (b, 1H), 6.88-7.08 (c, 10 H), 7.54 (q, 1H), 7.62 (d, 1H), 7.95 (s, 1H), 8.27 (d, 1H), 8.39 (d, 1H), 8.64 (m, 1H).
PRIMJER 36
N-[4,6-bis(metiltio)-2-metilpirimidin-3-il]-N'-(2,2-difeniletil)urea
dobitak 80%
1H NMR (CDCl3)) δ 2.42 (s, 6H), 2.60 (s5 3H), 3.82 (bm, 2H), 4.19 (t, 1H), 4.50 (b, 1H), 5.07 (b, 1H), 7.09-7.27 (c, 10H).
PRIMJER 37
N-[4,6-bis(metiltio)pirimidin-3-il]-N'-(2.2-difeniletil)urea
dobitak 49%
1H NMR (300 MHz, CDCl3) δ 2.43 (s, 3H), 3.84 (q, 2H), 4.20 (t, 1H), 4.43 (c, 1H), 5.46 (s, 1H), 7.12-7.31 (c, 10H), 8.59 (s, 1H).
PRIMJER 38
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(1-fenilciklopentil)metil]urea
Otopina (1-fenilciklopentil)metilamina (140 mg, 0.8 mmol) i 2,4-bis(metiltio)-6-metilpiridin-3-il izocijanata (180 mg, 0.8 mmol) u 3 ml dimetilformamida se zagrijava na 80°C pod dušikom preko noći. Reakcijska smjesa se ohladi do sobne temperature i razrijedi sa 70 ml etil acetata. Otopina koja nastaje se ispere sa 3 × 60 ml vode i 60 ml slane vode, osuši (natrijev sulfat), filtrira i koncentrira in vacuo. Ostatak se kromatografira na silika gelu (200 g), elucijom sa 1:1 etil acetat/heksan da se dobije naslovni spoj u obliku bijele krutine (90 mg, 287. dobiti).
1H NMR (300 MHz, CDCl3) δ 1.6-1.9 (c, 6H), 2.03 (c, 2H), 2.35 (s, 3H), 2.49 (s, 3H), 2.51 (s, 3H), 3.27 (d, 2H), 4.07 (b, 1H), 5.38 (b, 1H), 6.55 (s, 1H), 7.12 (c, 5H).
Derivati uree iz primjera 39-46 se pripremaju u skladu sa metodom iz primjera 38.
PRIMJER 39
N-(6-metiltiokvinolin-5-il)-N'-[(1-fenilciklopentil)metil]urea
dobitak 31%
1H NMR (300 MHz, CDCl3) δ 1.59-1.96 (c, 8H), 2.50 (s, 3H)5 3.25 (d, 2H), 3.91 (b, 1H), 5.96 (bs, 1H), 6.81 (c, 2H), 6.95 (c, 3H), 7.41 (q, 1H), 7.57 (d, 1H), 8.05 (d, 1H), 8.22 (d, 1H), 8.86 (m, 1H).
PRIMJER 40
N-[2,4-bis (metiltio)-6-metilpiridin-3-il]-N'-[{1-(4-metilfenil)ciklopentil}metil]urea
dobitak 24%
1H NMR (300 MHz, CDCl3) δ 1.6-1.9 (c, 6H), 2,0 (c, 2H), 2.27 (s, 3H), 2.35 (s, 3H), 2.49 (s, 3H), 2.51 (s, 3H), 3.24 (d, 2H), 4.06 (b, 1H), 5.36 (b, 1H), 6.51 (s, 1H), 6.93 (q, 4H).
PRIMJER 41
N-[[1-(4-metilfenil)ciklopentil]metil]-N'-(6-metiltiokvinolin-5-il)urea
dobitak 28%
1H NMR (300 MHz, CDCl3) δ 1.6-1.98 (c, 8H), 2.19 (s, 3H), 2.52 (s, 3H), 3.25 (d, 2H), 3.98 (b, 1H), 5.95 (b, 1H), 6,74 (q, 4H), 7.43 (q, 1H), 7.60 (d, 1H), 8.11 (d, 1H), 8.24 (d, 1H), 8.87 (m, 1H).
PRIMJER 42
N-(6-metiltiokvinolin-5-il)-N'-[(1-fenilcikloheksil)metil]urea
dobitak 37%
1H NMR (300 MHz, CDCl3) δ 1.18-1.62 (c, 8H), 1.96 (c, 2H), 2.51 (s, 3H), 3.25 (d, 2H), 3.86 (b, 1H), 5.99 (b, 1H), 6.97 (c, 5H), 7.43 (q, 1H), 7.58 (d, 1H), 8.09 (d, 1H), 8.23 (d, 1H), 8.85 (m, 1H).
PRIMJER 43
N-[2,4-bis(metiltio)-6-metilpiridin-5-il]-N'-[(1-fenlicikloheksil)metil]urea
dobitak 42%
1H NMR (300 MHz, CDCl3) δ 1.22-1,72 (c, 8H), 2,08 (c, 2H), 2.35 (s, 3H), 2.50 (s, 3H), 2.51 (s, 3H), 3,25 (d, 2H), 3,95 (b, 1H), 5.38 (b, 1H), 6.51 (s, 1H), 7.05-7.25 (c, 5H).
PRIMJER 44
N-[{1-(4-metilfenil)cikloheksil}metil]-N'-(6-metiltiokvinolin-5-il)urea
dobitak 42%
1H NMR (300 MHz, CDCl3) δ 1.15-1.6 (c, 8H), 1.93 (c, 2H), 2.18 (s, 3H), 2.51 (s, 3H), 3.22 (d, 2H), 3.81 (b, 1H), 5.94 (b, 1H), 6.77 (b, 4H), 7.41 (q, 1H), 7.59 (d, 1H), 8.07 (d, 1H), 8,21 (d, 1H), 8.86 (m, 1H).
PRIMJER 45
N-[4,6-bis(metiltio)-2-metilpirimidin-5-il]-N'-[{1-(4-metilfenil)cikloheksil}metil]urea
dobitak 42%
1H NMR (300 MHz, CDCl3) δ 1.23-1.68 (c, 8H), 2.06 (c, 2H), 2.30 (s, 3H), 2.47 (s, 6H), 2.62 (s, 3H), 3.23 (d, 2H), 3.89 (b, 1H), 5.27 (b, 1H), 7.04 (q, 4H).
PRIMJER 46
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[{1-(4-metiltenil)cikloheksil}metil]urea
dobitak 24%
1H NMR (300 MHz, CDCl3) δ 1-2-1.7 (c, 8H), 2.06 (c, 2H), 2.28 (s, 3H), 2.35 (s, 3H), 2.50 (s, 3H), 2.52 (s, 3H), 3.22 (d, 2H), 3.95 (b, 1H), 5.38 (b, 1H), 6.56 (s, 1H), 7.03 (q, 4H).
PRIMJER 47
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-etil-2-fenil)butil]urea
Otopina 2-etil-2-fenilbutilamina (106 mg, 0.6 mmol) i 2,4-bis(metiltio)-6--etilpiridin-3-il izocijanata (136 mg, 0.6 mmol) u 3 ml dimetilformamida se zagrijava na 80ºC pod dušikom preko noći. Reakcijska mješavina se ohladi do sobne temperature i razrijedi sa 50 ml etil acetata. Otopina koja nastaje se ispere redom sa 3 × 25 ml vode i 25 ml salne vode, osuši (natrij sulfat), filtrira i koncentrira in vacuo. Ostatak se kromatografira na silika gelu (125 g), elucijom sa 65:35 heksan/etil acetat da se dobije naslovni spoj u obliku bijele krutine (67 mg, 28% dobiti).
1H NMR (300 MHz, CDCl3) δ 0.74 (t, 6H), 1.57-1.8 (c, 4H), 2.33 (s, 3H), 2.47 (s, 3H), 2.48 (s, 3H), 3.41 (d, 2H), 3.95 (b, 1H), 5.36 (b, 1H), 6.52 (s, 1H), 7.05-7.27 (c, 5H).
Derivati uree iz primjera 48-55 se pripremaju u skladu sa metodom iz primjera 47.
PRIMJER 48
N-[2,4-bis(izopropiltio)-6-metilpiridin-3-il]-N'-[(2-etil-2-fenil)butil]urea
dobitak 35%
1H NMR (300 MHz, CDCl3) δ 0.72 (t, 6H), 1.29 (d, 6H), 1.33 (d, 6H), 1.57-1.8 (c, 4H), 2.45 (s, 3H)5 3.39 (d i m, 3H), 3.93 (m i b, 2H), 5.28 (b, 1H), 6.58 (s, 1H), 7,04-7.2 (c, 5H).
PRIMJER 49
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-etil-2-{2-metilfenil})butil]urea
dobitak 33%
1H NMR (300 MHz, CDCl3) δ 0.74 (t, 6H), 1.67 (m, 4H), 2.28 (s, 3H), 2.33 (s, 3H), 2.47 (s, 3H), 2.49 (s, 3H), 3.4 (d, 2H), 3.97 (b, 1H), 5.35 (b, 1H), 6.53 (s, 1H), 6.94 (t, 1H), 6.98 (s, 2H), 7.08 (t, 1H).
PRIMJER 50
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-fenil-2-propil)pentil]urea
dobitak 88%
1H NMR (300 MHz, CDCl3) δ 0.85 (t, 6H), 0.88-1.3 (c, 4H), 1.59 (c, 4H), 2.32 (s, 3H), 2.47 (s, 3H), 2.49 (s, 3H), 3.4 (d, 2H), 3.96 (b, 1H), 5.33 (b, 1H), 6.52 (s, 1H), 7.05-7.24 (c, 5H).
PRIMJER 51
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2-metilfenil}-2-propil)pentil]urea
dobitak 43%
1H NMR (300 MHz, CDCl3) δ 0.84 (t, 6H), 0.96-1.3 (c, 4H), 1.58 (c, 4H), 2.27 (s, 3H), 2.32 (s, 3H), 2.46 (s, 3H), 2.47 (s, 3H), 3.39 (d, 2H), 3.96 (b, 1H), 5.3 (s, 1H), 6.52 (s, 1H), 6.93 (t, 1H), 6.97 (s, 2H), 7.06 (t, 1H).
PRIMJER 52
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2-metilfenil}-2-butil)heksil]urea
dobitak 57%
1H NMR (300 NHz, CDCl3) δ 0.84 (t, 6H), 0.94-1.33 (c, 8H), 1.59 (c, 4H), 2.27 (s, 3H), 2.32 (s, 3H), 2.46 (s, 3H), 2.48 (s, 3H), 3.4 (d, 2H), 3.96 (b, 1H), 5.29 (s, 1H), 6.53 (s, 1H), 6.93 (c, 3H), 7.07 (t, 1H).
PRIMJER 53
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2,5-dimetoksifenil}-2-propil)pentil]urea
dobitak 30%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 6H), 0.94-1.3 (c, 4H), 1.5-1.8 (c, 4H), 2.33 (s, 3H), 2.45 (s, 3H), 2.48 (s, 3H), 3.6 (d, 2H), 3.68 (s, 3H), 3.74 (s, 3H), 4.11 (b, 1H), 5.38 (b, 1H), 6.5 (s, 1H), 6.64 (s i m, ukupno 3H).
PRIMJER 54
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2,3-dimetoksifenil}-2-propil)pentil]urea
dobitak 45%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 6H), 0.98-1.25 (c, 4H), 1.67 (c, 4H), 2.32 (s, 3H), 2.44 (s, 3H), 2.47 (s, 3H), 3.59 (d, 2H), 3.78 (s, 3H), 3.82 (s, 3H), 4.08 (b, 1H), 5.33 (b, 1H), 6.51 (s, 1H), 6.66 (d, 1H), 6.77 (d, 1H), 6.84 (t, 1H).
PRIMJER 55
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2-2,5-dimetilfenil-2-propil)pentil urea
dobitak 30%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 6H), 1.08 (m, 4H), 1.65 (c, 4H), 2.22 (s, 3H), 2.32 (s, 3H), 2.38 (s, 3H), 2.45 (s, 3H), 2.46 (s, 3H), 3.57 (d, 2H), 4.04 (b, 1H), 5.37 (b, 1H), 6.49 (s, 1H), 6.85 (c, 3H).
PRIMJER 56
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2-metilfenil)heksil]urea
Otopina 2-(2-metilfenil)heksilamina (153 mg, 0.8 mmol) i 2,4-bis(metiltio)-6-metilpiridin-3-il izocijanata (180 mg, 0.8 mmol) u 3 ml dimetilformamida se zagrijava na 80ºC pod dušikom preko noći. Reakcijska mješavina se ohladi do sobne temperature i razrijedi sa 60 ml etil acetata. Otopina koja nastaje se ispere redom sa 3 × 50 ml vode i 50 ml slane vode, osuši (natrij sulfat), filtrira i koncnetrira in vacuo. Ostatak se kromatografira na silika gelu (200 g) elucijom sa 7:3 heksan/etil acetat da se dobije naslovni spoj u obliku bijele krutine (110 mg, 33% dobiti).
1H NMR (300 MHz, CDCl3) δ 0.80 (t, 3H), 1.06-1.32 (c, 4H), 1.46-1.74 (c, 2H), 2.23 (s, 3H), 2.30 (s, 3H), 2.43 (s, 3H), 2.48 (s, 3H), 3.03-3.26 (c, 2H), 3.51 (p, 1H), 4.21 (b, 1H), 5.33 (b, 1H), 6.52 (s, 1H), 7.01-7.11 (c, 4H).
Derivati u.ree iz primjera 57-82 se pripremaju u skladu s metodom iz primjera 56.
PRIMJER 57
N-[2-(2-metilfenil)heksil]-N'-[1-metiltiokvinolin-5-il]urea
dobitak 28%
1H NMR (300 MHz, CDCl3) δ 0.80 (t, 3H), 0.98-1.28 (c, 4H), 1.4-1.65 (c, 2H), 2.08 (s, 3H), 2.48 (s, 3H), 2.96-3.27 (c, 2H), 3.51 (p, 1H), 4.10 (b, 1H), 5.94 (b, 1H), 6.87-7.02 (c, 4H)5 7.36 (q, 1H), 7.57 (d, 1H), 8.06 (d, 1H), 8.14 (d, 1H), 8.82 (m, 1H).
PRIMJER 58
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(4-metilfenil)heptil]urea
dobitak 24%
1H NMR (300 MHz, CDCl3) δ 0.80 (t, 3H), 1.07-1.28 (c, 6H), 1.45-1.7 (c, 2H), 2.28 (s, 3H), 2.32 (s, 3H), 2.45 (s, 3H), 2.48 (s, 3H), 2.65 (c, 1H), 3.10 (c, 1H), 3.56 (p, 1H), 4.21 (b, 1H), 5.35 (b, 1H), 6.54 (s, 1H), 6.98 (q, 4H).
PRIMJER 59
N-[2-(4-metilfenil)heptil]-N'-(6-metiltiokvinolin-5-il)urea
dobitak 30%
1H NMR (300 MHz, CDCl3) δ 0.79 (t, 3H), 1.02-1.26 (c, 6H), 1.46-1.62 (c, 2H), 2.23 (s, 3H), 2.48 (s, 3H), 2.57 (c, 1H), 3.10 (c, 1H), 3.56 (p, 1H), 4.11 (b, 1H), 5.96 (s, 1H), 6.81 (q, 4H), 7.34 (q, 1H), 7.57 (d, 1H), 8.04 (d, 1H), 8.13 (d, 1H), 8.82 (m, 1H).
PRIMJER 60
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3-metilfenil)heptil]urea
dobitak 26%
1H NMR (300 MHz, CDCl3) δ 0.82 (p, 3H), 1.06-1.32 (c, 6H), 1,45-1.72 (c, 2H), 2.28 (s, 3H), 2.34 (s, 3H), 2.48 (s, 3H), 2.50 (s, 3H), 2.67 (c, 1H), 3.14 (m, 1H), 3.57 (p, 1H), 4.31 (b, 1H), 5.47 (b, 1H), 6.56 (s, 1H), 6.87 (d, 1H), 6.89 (s, 1H), 6.96 (d, 1H), 7.09 (t, 1H).
PRIMJER 61
N-[2-(3-metilfenil)heptil]-N'-(6-metiltiokvinolin-5-il)urea
dobitak 24%
1H NMR (300 MHz, CDCl3) δ 0.8 (t, 3H), 1.0-1.3 (c, 6H), 1.37-1.64 (c, 2H), 2.19 (s, 3H), 2.48 (s, 3H), 2.59 (c, 1H), 3.14 (m, 1H), 3.57 (p, 1H), 4.23 (b, 1H), 6.11 (b, 1H), 6.7 (d, 1H), 6.72 (s, 1H), 6.88 (d, 1H), 6.97 (t, 1H), 7.35 (q, 1H), 7.56 (d, 1H), 8.04 (d, 1H), 8.14 (d, 1H), 8.81 (m, 1H).
PRIMJER 62
N-[2-(3-metilfenil)heptil]-N'-(6-metoksikvinolin-5-il)urea
dobitak 53%
1H NMR (300 MHz, CDCl3) δ 0.8 (t, 3H), 1.04-1.28 (c, 6H), 1.38-1,63 (c, 2H), 2.21 (s, 3H), 2.6 (m, 1H), 3.13 (m, 1H), 3.59 (m, 1H), 3.9 (s, 3H), 4.22 (b, 1H), 5.98 (b, 1H9, 6.71 (d, 1H), 6.73 (s, 1H), 6.91 (d, 1H), 7.01 (t, 1H), 7.31 (q, 1H), 7.46 (d, 1H), 8.07 (d, 1H), 8.18 (d, 1H), 8.77 (m, 1H).
PRIMJER 63
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)heksil]urea
dobitak 32%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.04-1.32 (c, 4H), 1.45-1.74 (c, 2H), 2.18 (s5 3H), 2.23 (s, 3H)5 2.31 (s, 3H), 2.45 (s,.3H), 2.49 (s, 3H), 3.04 (m, 1H), 3.2 (m, 1H), 3.53 (t, 1H), 4-2 (b, 1H), 5.34 (b, 1H), 6.53 (s, 1H), 6.84 (d, 1H), 6.93 (d, 1H).
PRIMJER 64
N-[2-(2,5-dimetilfenil)heksil]-N'-(6-metiltiokvinolin-5-il)urea
dobitak 33%
1H NMR (300 MHz, CDC3 + DMSO-d6) δ 0.76 (t, 3H), 1.0-1.26 (c, 4H), 1.35-1.65 (c, 2H), 2.1 (s, 3H), 2.17 (s, 3H), 2.44 (s, 3H), 3.0 (c, 1H), 3.15 (rn, 1H), 3.56 (p, 1H), 4.96 (b, 1H), 6.74-6.92 [ukupno 4H, uključujući 6.78 (d, 1H), 6.81 (s, 1H), 6.87 (d, 1H i b)], 7.34 (q, 1H), 7.56 (d, 1H), 8.02 (d, 1H), 8.16 (d, 1H), 8.76 (m, 1H).
PRIMJER 65
N-[2-(2,5-dimetilfenil)heksil]-N'-(6-metoksikvinolin-5-il]urea.
dobitak 37%
1H NHR (300 MHz, CDCl3 + DMSO-d6) δ 0.76 (t, 3H), 1.0-1.28 (c, 4H), 1.35-1.64 (c, 2H), 2.07 (s, 3H), 2.17 (s, 3H), 3.0 (c, 1H), 3.11 (m, 1H), 3.57 (p, 1H), 3.86 (s, 3H), 4.71 (b, 1H), 6.46 (b, 1H), 6.77 (s, 1H), 6.78 (d, 1H), 6.86 (d, 1H), 7,28 (q, 1H), 7,42 (d, 1H), 8.0 (d, 1H), 8.16 (d, 1H), 8.71 (m, 1H).
PRIMJER 66
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)heptil]urea
dobitak 28%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.08-1.3 (c, 6H), 1.43-1.74 (c, 2H), 2.19 (s, 3H), 2.23 (s, 3H), 2.33 (s, 3H), 2.48 (s, 3H), 2.53 (s, 3H), 3.04 (c, 1H), 3.21 (m, 1H), 3.51 (p, 1H), 4.35 (b, 1H), 5.0 (b, 1H), 6.56 (s, 1H), 6.84 (d, 1H), 6.86 (d, 1H), 6.93 (d, 1H).
PRIMJER 67
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,4-dimetilfenil)heksil]urea
dobitak 68%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 1.05-1.31 (c, 4H), 1.42-1.75 (c, 2H), 2.2 (s, 3H), 2.26 (s, 3H), 2.32 (s, 3H), 2.46 (s, 3H), 2.52 (s, 3H), 3.04 (c, 1H), 3.18 (m, 1H), 3.49 (p, 1H), 4.3 (b, 1H), 5.46 (b, 1H), 6.55 (s, 1H), 6.86 (s, 1H), 6.89 (d, 1H), 6.95 (d, 1H).
PRIMJER 68
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3-metilfenil)heksil]urea
dobitak 60%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 1.05-1.33 (c, 4H), 1.45-1.75 (c, 2H), 2.28 (s, 3H), 2.34 (s, 3H), 2.49 (s, 3H), 2.51 (s, 3H), 2.67 (m, 1H), 3.15 (m, 1H), 3.57 (p, 1H), 4.34 (b, 1H), 5.48 (b, 1H), 6.57 (s, 1H), 6.88 (d, 1H), 6.89 (s, 1H), 6.96 (d, 1H), 7.1 (t, 1H).
PRIMJER 69
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,4-dimetilfenil)heptil]urea
dobitak 59%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 1.08-1.28 (c, 6H), 1.42-1.72 (c, 2H), 2.19 (s, 3H), 2.26 (s, 3H), 2.32 (s, 3H), 2.45 (s, 3H), 2.51 (s, 3H), 3.04 (c, 1H), 3.18 (m, 1H), 3.49 (p, 1H), 4.24 (b, 1H), 5.38 (b, 1H), 6.55 (s, 1H), 6.86 (s, 1H), 6.89 (d, 1H), 6.95 (d, 1H).
PRIMJER 70
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)heptil]urea
dobitak 50%
1H NMR (300 MHz, CDCl3) δ 0.79 (t, 3H), 1.14-1.34 (c, 6H), 1.56-1.92 (c, 2H), 2.14 (s, 3H), 2.38 (s, 3H), 2.44 (s, 3H), 3.48 (m, 1H), 3.6 (p, 1H), 3.73 (c, 1H), 4.26 (b, 1H), 5.37 (b, 1H), 6.39 (s, 1H), 7.28 (d, 1H), 7.36 (t, 1H), 7.47 (c, 2H), 7.67 (d, 1H), 7.82 (c, 1H), 8.13 (c, 1H).
PRIMJER 71
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-2-il)heksil]urea
dobitak 36%
1H NMR (300, MHz, CDCl3) δ 0.8 8t, 3H), 1.06-1.35 (c, 4H), 1.55-1.81 (c, 2H), 2.07 (s, 3H), 2.37 (s, 3H), 2.4 (s, 3H), 2.9 (c, 1H), 3.24 (m, 1H), 3.66 (p„ IH), 4.25 (b, 1H), 5.39 (b, 1H), 6.34 (s, 1H), 7.25 (m, 1H), 7.4-7.51 (c, 3H), 7.68-7.87 (c, 3H).
PRIMJER 72
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2-(naft-1-il)heksil]urea
dobitak 36%
1H NMR (300 MHz, CDCl3) δ 0.79 (t, 3H), 1.1-1.34 (c, 4H), 1.56-1.92 (c, 2H), 2.13 (s, 3H), 2.37 (s, 3H), 2.44 (s, 3H), 3.47 (m, 1H), 3.6 (p, 1H), 3.73 (c, 1H), 4.28 (b, 1H), 5.36 (b, 1H), 6.4 (s, 1H), 7.28 (d, 1H), 7.35 (t, 1H), 7.46 (c, 2H), 7.66 (d, 1H), 7.82 (c, 1H), 8.12 (c, 1H).
PRIMJER 73
N-(6-metiltiokvinolin-5-il)-N'-[2-(naft-1-il)heksil]urea
dobitak 34%
1H NMR (300 MHz, CDCl3) δ 0.78 (t, 3H), 1.1-1.3 (c, 4H), 1.56-1.82 (c, 2H), 2.35 (s, 3H), 3.44 (c, 1H), 3.7 (c, 2H), 4.21 (b, 1H), 5.98 (s, 1H), 7.08 (c, 2H), 7.22 (t, 1H), 7.42 (c, 3H), 7.6 (d, 1H), 7.8 (d, 1H), 7.9 (d, 1H), 7.94 (d, 1H), 8.03 (d, 1H), 8.7 (m, 1H).
PRIMJER 74
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetoksifenil)heptil]-urea
dobitak 26%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 1.1-1.3 (c, 6H), 1.45-1.77 (c, 2H), 2.33 (s, 3H), 2.48 (s, 3H), 2.53 (s, 3H), 3.12-3.35 (c, 2H), 3.45 (p, 1H), 3.69 (s, 3H), 3.84 (s, 3H), 4.54 (b, 1H), 5.52 (b, 1H), 6.59 (s, 1H), 6.7 (d, 1H), 6.73 (d, 1H), 6.95 (t, 1H).
PRIMJER 75
N-[2-(2,3-dimetoksifenil)heptil]-N'-(6-metiltiokvinolin-5-il)urea
dobitak 31%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 1.05-1.3 (c, 6H), 1.42-1.65 (c, 2H9, 2.49 (s, 3H), 3,12 (c, 1H), 3.27 (c, 1H), 3.46 (m, 1H), 3.53 (s, 3H), 3.8 (s, 3H), 4.44 (b, 1H), 6.04 (b, 1H), 6.56 (d, 1H), 6.66 (d, 1H), 6,85 (t, 1H), 7.37 (q, 1H), 7.61 (d, 1H), 8.08 (d, 1H), 8.17 (d, 1H), 8.82 (m, 1H).
PRIMJER 76
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3-metilfenil)oktil]urea
dobitak 47%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.19 (b, 8H), 1.46-1.72 (c, 2H), 2.27 (s, 3H), 2.33 (s, 3H), 2.46 (s, 3H), 2.48 (s, 3H), 2-66 (c, 1H), 3.13 (c, 1H), 3.58 (p, 1H), 4.23 (b, 1H), 5.35 (s, 1H), 6.55 (s, 1H), 6.87 (d) i 6.88 (ukupno 2H), 6.96 (d, 1H), 7.09 (t, 1H).
PRIMJER 77
N-[2-(3-metilfenil)oktil]-N'-(6-metoksikvinolin-5-il)urea
dobitak 54%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.18 (b, 8H), 1.53 (c, 2H), 2.22 (s, 3H), 2.61 (m, 1H), 3.14 (m, 1H), 3.6 (p, 1H), 3.91 (s, 3H), 4.24 (b, 1H), 5.99 (s, 1H), 6.72 (d) i 6.73 (s) (ukupno 2H), 6.92 (d, 1H), 7.01 (t, 1H), 7.33 (q, 1H), 7.47 (d, 1H), 8.09 (d, 1H), 8.19 (d, 1H), 8.77 (q, 1H).
PRIMJER 78
N-[2-(3-metilfenil)oktil]-N'-(6-metiltiokvinolin-5-il)urea
dobitak 25%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.17 (b, 8H), 1.52 (c, 2H), 2.2 (s, 3H), 2.49 (s, 3H), 2.6 (m, 1H), 3.15 (m, 1H), 3.58 (p, 1H), 4.21 (b, 1H), 6.05 (s, 1H), 6.71 (d) (6.73 (s) (ukupno 2H), 6.89 (d, 1H), 6.99 (t, 1H), 7.37 (q, 1H), 7.58 (d, 1H), 8.07 (d, 1H), 8.17 (d, 1H), 8.82 (t, 1H).
PRIMJER 79
N-[2-(naft-1-il)heptil]-N'-(6-metoksikvinolin-5-il)urea
dobitak 58%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 1.19 (b, 6H), 1.7 (b, 2H)5 3.41 (c, 1H), 3.72 (c) i 3.75 (s) (ukupno 5H), 4.21 (b, 1H), 5.88 (s, 1H), 7.02 (q, 1H), 7.13 (d, 1H), 7.25 (t, 1H), 7.33 (d, 1H), 7.45 (m, 2H), 7.63 (d, 1H), 7.83 (d, 1H), 7.92 (d, 1H), 7.98 (d, 1H), 8.04 (d, 1H), 8.65 (m, 1H).
PRIMJER 80
N-[2-(naft-1-il)heptil]-N'-(6-metiltiokvinolin-5-il)urea
dobitak 47%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 1.17 (b, 6H), 1.7 (b, 2H), 2.35 (s, 3H), 3.44 (c, 1H), 3.6-3.78 (c, 2H), 4.22 (b, 1H), 5.97 (s, 1H), 7.06 (q, 1H), 7.12 (d, 1H), 7.23 (t, 1H), 7.43 (m, 3H), 7.6 (d, 1H), 7.81 (d, 1H), 7.9 (d, 1H), 7.96 (d, 1H), 8.03 (d, 1H), 8.69 (m, 1H).
PRIMJER 81
N-[2-(2,4-dimetilfenil)heptil]-N'-(6-metiltiokvinolin-5-il)urea
dobitak 41%
1H NMR (300, MHz, CDCl3) δ 0.79 (t, 3H), 1.14 (b, 6H), 1.48 (c, 2H), 2.0 (s, 3H), 2.2 (s, 3H), 2.47 (s, 3H), 2.95 (c, 1H), 3.15 (m, 1H), 3.5 (p, 1H), 4.06 (b, 1H), 5.91 (s, 1H), 6.71 (s, 1H), 6.75 (s, 2H), 7.32 (q, 1H), 7.55 (d, 1H), 8.03 (d, 1H), 8.03 (d, 1H), 8.11 (d, 1H), 8.82 (q, 1H).
PRIMJER 82
N-[2-(2,4-dimetilfenil)-heptil]-N'-(6-metoksikvinolin-5-il)urea
dobitak 57%
1H NMR (300 MHz, CDCl3) δ 0.8 (t, 3H), 1.16 (b, 6H), 1.49 (c, 2H), 2.02 (s, 3H), 2.23 (s, 3H), 2.97 (c, 1H), 3.13 (m, 1H), 3.55 (p, 1H), 3.9 (s, 3H), 4.14 (b, 1H), 5.89 (s, 1H), 6.75 (s, 1H), 6.78 (s, 2H), 7.28 (q, 1H), 7.44 (d, 1H), 8.04 (d, 1H), 8.14 (d, 1H), 8.77 (q, 1H).
PRIMJER 83
N-[2,4-bis(metil)-6-metil]piridin-5-il]-N'-[2-(3,4,5-trimetoksifenil)heptil]urea
dobitak 45%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.23 (b, 6H), i.4-1.7 (c, 2H), 2.3 (s, 3H), 2.45 (s, 3H), 2.48 (s, 3H), 2.64 (c, 1H), 3.12 (m, 1H), 3.57 (q, 1H), 3.79 (s, 6H), 3.82 (s, 3H)5 4.23 (b, 1H), 5.39 (b, 1H), 6.27 (s, 2H), 6.54 (s, 1H).
PRIMJER 84
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetil-4-metoksifenil)heptil]urea
dobitak 35%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.19 (b, 6H), 1.5 (c, 1H), 1.63 (c, 1H), 2.11 (s, 3H), 2.2 (s, 3H), 2.34 (s, 3H), 2.49 (s, 3H), 2.54 (s, 3H), 2,98 (c, 1H), 3.18 (cn, 1H), 3.49 (p, 1H), 3.79 (s, 3H), 4.2 (b, 1H), 5.35 (b, 1H), 6.5 (s, 1H), 6.58 (s, 1H), 6.79 (s, 1H).
PRIMJER 85
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetoksifenil)heptil]urea
dobitak 40%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.2 (b, 6H), 1.63 (b, 2H), 2.34 (s, 3H), 2.46 (s, 3H), 2.51 (s, 3H), 3.15 (c, 1H), 3.26-3.5 (c, 2H), 3.62 (s, 3H), 3.73 (s, 3H), 4.48 (b, 1H), 5.54 (b, 1H), 6.58 (s, 1H), 6.61-6.71 (c, 3H).
PRIMJER 86
N-2-(2,5-dimetoksifenil)heptil-N'-(6-metiltiokvinolin-5-il)urea
dobitak 30%
1H NMR (300 MHz,CDCl3) δ 0.81 (t, 3H), 1.17 (b, 6H), 1.54 (b, 2H), 2.49 (s, 3H)5 3.08 (c, 1H), 3.24-3.4 (m uključujući s na 3.38, ukupno 4H), 3.45 (p, 1H), 3.72 (s, 3H), 4.42 (b, 1H), 6.05 (b, 1H), 6.49 (d, 1H), 6.52-6.61 (c, 2H), 7.35 (q, 1H), 7.61 (d, 1H), 8.09 (d, 1H), 8.14 (d, 1H), 8.81 (m, 1H).
PRIMJER 87
N-[2-(2,5-dimetoksifenil)heptil-N'-(6-metoksikvinolin-5-il)urea
dobitak 39%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 1.18 (b, 6H), 1.55 (b, 2H), 3.09(c, 1H), 3.27 (m, 1H), 3.37 (s, 3H), 3.49 (p, 1H), 3.72 (s, 3H), 3.9 (s, 3H), 4.45 (b, 1H), 5.98 (b, 1H), 6.51 (d, 1H), 6.55-6.63 (c, 2H), 7.31 (q, 1H), 7.48 (d, 1H), 8.09 (d, 1H), 8.17 (d, 1H), 8.77 (q, 1H).
PRIMJER 88
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetoksifenil)heptil]urea
dobitak 45%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.2 (b, 8H), 1.64 (b, 2H), 2.33 (2, 3H), 2.45 (s, 3H), 2.5 (s, 3H), 3.15 (c, 1H), 3.27-3.5 (c, 2H), 3.61 (s, 3H), 3.73 (s, 3H), 4.43 (b, 1H), 5.47 (b, 1H), 6.57 (s, 1H), 6.6-6.71 (c, 3H).
PRIMJER 89
N-[2,4-bis(metiltio)-6-metilpiridin-5-il]-N'-[2-(2,5-dimetoksifenil)oktil]urea
dobitak 50%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.2 (b, 8H), 1.64 (b, 2H), 2.33 (s, 3H), 2.45 (s, 3H), 2.5 (s, 3H), 3.15 (c, 1H), 3.27-3.5 (c, 2H), 3.61 (s, 3H), 3.73 (s, 3H), 4.43 (b, 1H), 5.47 (b, 1H), 6.57 (s, 1H), 6.6-6.71 (c, 3H).
PRIMJER 90
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-2-[2-(5-metilfenil)-6,6,6-trifluoroheksil]urea
dobitak 34%
1H NMR (300 MHz, CDCl3) δ 1.41 (c, 2H), 1.55-1.82 (c, 2H), 2.0 (c, 2H), 2.28 (s, 3H), 2.34 (s, 3H), 2.47 (s, 3H), 2.48 (s, 3H), 2.68 (c, 1H), 3.17 (m, 1H), 3.56 (p, 1H), 4.28 (b, 1H), 5.39 (s, 1H), 6.56 (s, 1H), 6.88 (d) i 6.89 (s) (ukupno 2H), 6.98 (d, 1H), 7.12 (t, 1H).
PRIMJER 91
N-[2-(3-metilfenil)heptil]-N'-(6-pentiltiokvinolin-5-il)urea
dobitak 53%
1H NMR (300 MHz, CDCl3) δ 0.81 (t, 3H), 0.9 (t, 3H), 1.04-1.7 (c, 14H), 2.2 (s, 3H), 2.59 (c, 1H), 2.93 (t, 2H), 3.14 (m, 1H), 3.59 (p, 1H), 4.15 (b, 1H), 6.11 (s, 1H), 6.69 (d) i 6.71 (s) (ukupno 2H), 6.89 (d, 1H), 6.99 (p, 1H), 7.33 (q, 1H), 7.62 (d, 1H), 7.98 (d, 1H), 8.13 (d, 1H), 8.82 (q, 1H).
PRIMJER 92
N-[2,4-bis(metiltio)-6-metilpirdin-3-il]-N'-[2-(5-klorobenzo[b]tiofen-3-il)heptil]urea
dobitak 36%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.22 (b, 6H), 1.63 (b, 2H), 2.23 (s, 3H), 2.4 (s, 3H), 2.46 (s, 3H), 3.21 (m, 1H), 3.51 (c, 2H), 4.32 (b, 1H), 5.44 (b, 1H), 6.48 (s, 1H), 7.13 (s, 1H), 7.29 (c, 1H), 7.72 (d, 1H), 7.41 (s, 1H).
PRIMJER 93
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetilfenil)heptil]urea
dobitak 34%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.21 (b, 6H), 1.57 (b, 2H), 2.23 (s, 6H), 2.33 (s, 3H), 2.46 (s, 3H9, 2.48 (s, 3H), 2.61 (c, 1H), 3.13 (m, 1H), 3.56 (p, 1H), 4.21 (b, 1H), 5.33 (s, 1H), 6.55 (s, 1H), 6.67 (s, 2H), 6.78 (s, 1H).
PRIMJER 94
N-[2,4-bis(metiltio)-6-metilpirdin-3-il]-N'-[2-(2,5-dimetilfenil)oktil]urea
dobitak 35%
1H NMR (300 MHz, CDCl3) δ 0.84 (t, 3H), 1.19 (b, 8H), 1.6 (b, 2H), 2.18 (s, 3H), 2.23 (s, 3H), 2.31 (s, 3H), 2.45 (s, 3H), 2.49 (s, 3H), 3.04 (c, 1H), 3.2 (m, 1H), 3.52 (p, 1H), 4.22 (b, 1H), 5.37 (b, 1H), 6.54 (s, 1H), 6.84 (d) i 6.85 (s), (ukupno 2H), 6.92 (d, 1H).
PRIMJER 95
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[5-metil-2-{3-metilfenil}heksil]urea
dobitak 44%
1H NMR (300 MHz, CDCl3) δ 0.79, 0.8, 0.81, 0.82 (2d, 6H), 0.92-1.18 (c, 2H), 1.38-1,74 (c, 3H), 2.28 (s, 3H), 2.33 (s, 3H), 2.46 (s, 3H), 2.48 (s, 3H), 2.63 (c, 1H), 3.14 (m, 1H), 3.58 (p, 1H), 4.22 (b, 1H), 5.36 (s, 1H), 6.55 (s, 1H), 6.87 (d) i 6.88 (s) (ukupno 2H), 6.96 (d, 1H), 7.09 (t, 1H).
PRIMJER 96
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-{2,5-dimetilfenil}-4-fenilbutil]urea
dobitak 33%
1H NMR (300 MHz, CDCl3) δ 1.8-1.96 (m, 1H), 1.99-2.14 (m) i 2.11 (s) (ukupno 4H), 2.24 (s, 3H), 2.3 (s, 3H), 2.4-2.54 (m, 8H), uključujući 2.44 (s, 3H), i 2.49 (s, 3H), 3.08 (c, 1H), 3.3 (m, 1H), 3.49 (p, 1H), 4.25 (b, 1H), 5.37 (s, 1H), 6.54 (s, 1H), 6.87 (d) i 6.9 (s) (ukupno 2H), 6.95 (d, 1H), 7.08 (d) i 7.09 (s) (ukupno 2H), 7.14 (m, 1H), 7.23 (m, 2H).
PRIMJER 97
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetifenil)-5-fenilpentil]urea
dobitak 19%
1H NMR (300 MHz, CDCl3) δ 1.4-1.8 (c, 4H), 2.17 (s, 3H), 2.22 (s, 3H), 2.3 (s, 3H), 2.43 (s, 3H), 2=48 (s, 3H), 2.53 (c, 2H), 3.08 (c, 1H), 3.2 (m, 1H), 3.52 (p, 1H), 4.22 (b, 1H), 5.36 (s, 1H), 6.52 (s, 1H), 6.81 (s) i 6.83 (d) (ukupno 2H), 6.91 (d, 1H), 7.08 (d, 2H), 7.13 (m, 1H), 7.23 (m, 2H).
PRIMJER 98
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)-6-metilheptil]urea
dobitak 59%
1H NMR (300 MHz, CDCl3) δ 0.76 (t, 6H), 1.06-1.34 (c, m, 4H), 1.43 (h, 1H), 1.75 (c, 2H), 2.13 (s, 3H), 2.37 (s, 3H), 2.43 (s, 3H), 3.48 (m, 1H), 3.56-3.82 (c, 2H), 4.21 (c, 1H), 5.28 (s, 1H), 6.37 (s, 1H), 7.28 (m, 1H), 7.36 (t, 1H), 7.46 (m, 2H), 7.67 (d, 1H), 7.83 (m, 1H), 8.13 (m, 1H).
PRIMJER 99
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)-6-metilheptil]urea
dobitak 31%
1H NMR (300 MHz, CDCl3) δ 0.74, 0.76, 0.79 (2d, 6H), 1.06-1.32 (m, c, 10H), 1.42 (h, 1H), 1.78 (c, 2H), 2.42 (s, 3H), 2.68 (q, 2H), 3.02 (q, 2H), 3.53 (m, 2H), 3.72 (c, 1H), 4.20 (c, 1H), 5.27 (s, 1H), 6.42 (s, 1H), 7.28 (m, 1H), 7.34 (t, 1H), 7.46 (m, 2H), 7.67 (d, 1H), 7.81 (m, 1H), 8.12 (m, 1H).
PRIMJER 100
N-[2,4-bis(etiltio)-6-metilpiridin-5-il]-N-[2-(2,5-dimetilfenil)-6-metilheptil]urea
dobitak 38%
1H NMR (300 MHz, CDCl3) δ 0.77, 0.79, 0.81 (sd, 6H), 1.04-1.72 [c, m uključujući 2t (1.29, 1.31, 6H) ukupno 13 H], 2.18 (s, 3H), 2.22 (s, 3H), 2.46 (s, 3H), 2.81 (q, 2H), 2.98-3.25 [m ukljućujudi q (3.08, 2H) ukupno 4H] 3.53 (p, 1H), 4.2 (c, 1H), 5.32 (s, 1H), 6.56 (s, 1H), 6.84 (d, 1H), 6.92 (d, 1H), 7.26 (s, 1H).
PRIMJER 101
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-iljheptil]urea
dobitak 15%
1H NMR (300 MHz, CDCl3) δ 0.79 (t, 3H), 1.23 (m, c, 12 H), 1.65-1.94 (c, 2H), 2.42 (s, 3H), 2.68 (q, 2H), 3.02 (q, 2H), 3.54 (c, 2H), 3.72 (c, 1H), 4.22 (c, 1H), 5.28 (s, 1H), 6.42 (s, 1H), 7.32 (m, 2H), 7.45 (m, 2H), 7.67 (d, 1H), 7.82 (m, 1H), 8.11 (m, 1H).
PRIMJER 102
N-[2,4-bis(etiltio)-6-metilpirdin-3-il]-N'-[2-(2,5-dimetilfenil)-6-fenilheksil)urea
dobitak 57%
1H NMR (300 MHz, CDCl3,) δ 1.14-1.36 [c ukljućujući 2t, (1.28, 1.3, 6H), ukupno 10H] 1.48-1.8 (m, c, 4H), 2.17 (s, 3H), 2.23 (s, 3H), 2.46 (s, 3H), 2.52 (t, 2H), 2.81 (q, 2H), 2.29-3.13 [c i q (3.07, 2H) ukupno 3H],3.2 (m, 1H), 3.52 (p, 1H), 4.21 (c, 1H), 5.33 (s, 1H), 6.56 (s, 1H), 6.85 (d, 1H), 6.93 (d, 1H), 7.13 (m, 3H), 7.24 (m, 3H).
PRIMJER 103
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)heptil]urea
dobitak 48%
1H NMR (300 HHz, CDCl3) δ 0.82 (t, 3H), 1.2 (c, 6H), 1.29, 1.31 (2t, 6H), 1.47-1.72 (c, 2H), 2.17 (s, 3H), 2.23 (s, 3H), 2.46 (s, 3H), 2.82 (q, 2H), 2.98-3.13 [c uključujući q (3.08) ukupno 3H] (3.19 (m, 1H), 3.53 (p, 1H), 4,13 (b, 1H), 5,29 (s, 1H), 6.56 (s, 1H), 6.84 (d) i 6.85 (s) ukupno 2H), 6.92 (d, 1H).
PRIMJER 104
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,4,6-trimetilfenil)oktil]urea
dobitak 27%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.2 (c, 8H), 1.7 (c, 2H), 2.16 (s, 3H), 2.22 (s, 3H), 2,28 (s, 3H), 2.3 (s, 3H), 2.42 (s, 3H), 2.48 (s, 3H), 3.28 (c, 2H), 3.68 (m, 1H), 4.14 (b, 1H), 5.29 (s, 1H), 6.48 (s, 1H), 6.66 (s, 1H), 6.69 (s, 1H).
PRIMJER 105
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-6,6,6-trifluoroheksil]urea
dobitak 20%
1H NMR (300 MHz, CDCl3) δ 1.29, 1.32 (2t, 6H), 1.43 (c, 2H), 1.63 (c, 1H), 1.78 (c, 1H), 2.0 (c, 2H), 2.2 (s, 3H), 2.24 (s, 3H), 2.46 (s, 3H), 2.84 (q, 2H), 3.0-3.15 [c uključujući t (3.09) ukupno 3H], 3.22 (m, 1H), 3.49 (p, 1H), 4.25 (b, 1H), 5.34 (s, 1H), 6.58 (s, 1H), 6.86 (d, 2H), 6.95 (d, 1H).
PRIMJER 106
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(5-metilbenzo[b]tiofen-3-il)heptil]urea
dobitak 10%
1H NMR (300 MHz, CDCl3) δ 0.82 (c, 3H), 1.24 (c, 6H), 1.74 (c, 2H), 2.2 (s, 3H), 2.4 (s, 3H), 2.46 (s, 6H), 3.25 (m, 1H), 3.5 (t, 2H), 4.28 (b, 1H), 5.37 (s, 1H), 6.45 (s, 1H), 6.99 (s, 1H), 7.15 (d, 1H), 7.55 (s, 1H), 7.71 (d, 1H).
PRIMJER 107
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2-klorobenzo[b]tiofen-3-il)heptil]urea
dobitak 32%
1H NMR (300 MHz, CDCl3) δ 0.79 (c, 3H), 1.2 (c, 6H), 1.79 (c, 1H), 1.91 (c, 1H), 2.23 (s, 3H), 2.37 (s, 3H), 2.46 (s, 3H), 3.4-3.59 (c, 2H), 3.79 (c, 1H), 4.27 (b, 1H), 5.36 (s, 1H), 6.47 (s, 1H), 7.3 (m, 2H), 7.67 (m, 1H), 7.76 (c, 1H).
PRIMJER 108
N-[2-(2,5-dimetilfenil)heptil]-N'-[6-metiltiokvinolin-5-il]urea
dobitak 33%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.16 (c, 6H), 1.5 (c, 2H), 2.0 (s, 3H), 2.13 (s, 3H), 2.47 (s, 3H), 2.96 (m, 1H), 3.16 (m, 1H), 3.55 (p, 1H), 4.09 (b, 1H), 5.97 (s, 1H), 6.7 (s, 1H), 6.77 (q, 2H), 7.34 (q, 1H), 7.56 (d, 1H), 8.03 (d, 1H), 8.2 (d, 1H), 8.82 (q, 1H).
PRIMJER 109
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-6-metilheptil]urea
dobitak 35%
1H NMR (300 MHz, CDCl3) δ 0.77, 0.79, 0.81 (2d, 6H), 1.04-1.7 (c, 7H), 2.18 (s, 3H), 2.23 (s, 3H), 2.31 (s, 3H), 2.44 (s, 3H), 2.48 (s, 3H), 3.04 (c, 1H), 3.19 (m, 1H), 3.53 (p, 1H), 4.2 (b, 1H), 5.33 (s, 1H), 6.53 (s, 1H), 6.84 (d i s 2H), 6.92 (d, 1H).
PRIMJER 110
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-5-fenilpentil]urea
dobitak 37%
1H NMR (300 NHz, CDCl3) δ 1-26, 1.29, 1.31, 1.33 (2t, 6H), 1.41-1.82 (c, 4H), 2.17 (s, 3H), 2.22 (s, 3H), 2.46 (s, 3H), 2.54 (c, 2H), 2,81 (q, 2H), 3.0-3.24 [c i uključujući q (3.08), ukupno 4l], 3.52 (p, 1H), 4.2 (b, 1H), 5.31 (s, 1H), 6.56 (s, 1H), 6.82, 6.85 (s i d 2H), 6.91 (d, 1H), 7.08 (d, 2H), 7.15 (d, 1H), 7.23 (t, 2H).
PRIMJER 111
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)oktil]urea
dobitak 26%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.19 (c, 8H), 1.27, 1.29, 1.32, 1.34 (2t, 6H), 1.54 (c, 1H), 1.67 (c, 1H), 2.18 (s, 3H), 2.23 (s, 3H), 2.46 (s, 3H), 2,82 (q, 2H), 2.98-3,14 [c uključujući t (3.08) ukupno 3H], 3.19 (m, 1H), 3.53 (p, 1H9, 4.2 (b, 1H), 5.31 (s, 1H), 6.56 (s, 1H), 6.83, 6.85 (s i d, 2H), 6.92 (d, 1H),
PRIMJER 112
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-5-metilheksil]urea
dobitak 39%
1H NMR (300 MHz, CDCl3) δ 0,79, 0.80, 0.81, 0.82 (2d, 6H), 0.92-1.18 (c, 2H), 1.27, 1.29, 1.31, 1.34 (2t, 6H), 1.4-1.75 (c, 3H), 2.17 (s, 3H), 2.23 (s, 3H), 2.46 (s, 3H), 2.82 (q, 2H), 2.93-3.13 [c uključujući t (3.08), ukupno 3H], 3.2 (m, 1H), 3.53 (p, 1H), 4.2 (b, 1H), 5.3 (s, 1H), 6.56 (s, 1H), 6.83, 6.85 (d i s , 2H), 6.92 (d, 1H).
PRIMJER 113
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2-klorobenzo[b]tiofen-3-il)-6-metilheptil]urea
dobitak 19%
1H NMR (300 MHz, CDCl3) δ 0.73, 0.75, 0.76, 0.78 (2d, 6H), 1.01-1.42 [5 i 2t (1.22, 1.23, 1.24, 1.25, 1.27, 1.28), ukupno 10H], 1.41 (h, 1H), 1.79 (c, 1H), 1.92 (c, 1H), 2.44 (s, 3H), 2.74 (c, 2H), 3.02 (q, 2H), 3.48 (c, 2H), 3.8 (c, 1H), 4.26 (b, 1H), 5.3 (s, 1H), 6.5 (s, 1H), 7.29 (m, 2H), 7.66 (m, 1H), 7.77 (c, 1H).
PRIMJER 114
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2-klorobenzo[b]tiofen-3-il)-5-metilheksil]urea
dobitak 35%
1H NMR (300 MHz, CDCl3) δ 0.75-1.3 [c uključujući 2d (0.77, 0.78, 0.79, 0.80, 6H), i 2t (1.22, 1.23, 1.24, 1.25, 1.27, 1.28, 6H), ukupno 14H], 1.47 (h, 1H), 1.75-1.2 (c, 2H), 2.44 (s, 3H), 2.75 (c, 2H), 3.02 (q, 2H), 3.46 (c, 2H), 3.8 (c, 1H), 4.27 (b, 1H), 5.3 (s, 1H), 6.5 (s, 1H), 7.3 (nv, 2H), 7.66 (m, 1H), 7.77 (c, 1H).
PRIMJER 115
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(5,6,7,8-tetrahidronaft-1-il)heptil]urea
dobitak 36%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.2 (c, 6H), 1.29, 1.31, 1.34 (2t, 6H), 1.45-1.82 (c, 6H), 2.46 (s, 3H), 2.7 (c, 4H), 2.83 (q, 2H), 3.03-3.28 (c uključujući q (3.08), ukupno 4H), 3.46 (p, 1H), 4.23 (b, 1H), 5.3 (s, 1H), 6.58 (s, 1H), 6.85, 6.88, 6.91 (2d, 2H), 6.98 (t, 1H).
PRIMJER 116
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetilfenil)heptil]urea
dobitak 20%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.21 (c, 6H), 1.28, 1.30, 1.32, 1.35 (2t, 6H), 1.6 (c, 2H), 2.33 (s, 6H), 2.45 (s, 3H), 2.61 (c, 1H), 2.84 (q, 2H), 3.05-3.2 [c i q (3.1), ukupno 3H], 3.56 (p, 1H), 4.2 (b, 1H), 5.3 (s, 1H), 6.59 (s, 1H), 6.67 (s, 2H), 6.78 (s, 1H).
PRIMJER 117
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2-klorobenzo[b]tiofen-3-il)heptil]urea
dobitak 51%
1H NMR (300 MHz, CDCl3) δ 0.79 (t, 3H), 1.04-1.32 [c uključujući 2t (1.22, 1.23, 1.24, 1.25, 1.27, 1.28), ukupno 12H], 1.81 (c, 1H), 1.94 (c, 1H), 2.44 (s, 3H), 2.76 (c, 2H), 3.02 (q, 2H), 3.48 (c, 2H), 3.8 (c, 1H), 4.27 (b, 1H), 5.3 (s, 1H), 6.5 (s, 1H), 7.3 (m, 2H), 7.66 (m, 1H), 7.78 (c, 1H).
PRIMJER 118
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetilfenil)oktil]urea
dobitak 19%
1H NMR (300 MHz, CDCl3) δ 0.83 (t, 3H), 1.2 (c, 8H), 1.27, 1.30, 1.32, 1.35 (2t, 6H), 1.45-1.72 (c, 2H), 2.22 (s, 6H), 2.45 (s, 3H), 2.6 (c, 1H), 2.84 (q, 2H), 3.05-3.2 [c i q (3.1), ukupno 3H], 3.56 (h, 1H), 4.23 (b, 1H), 5.35 (s, 1H), 6.58 (s, 1H), 6.67 (s, 2H), 6.77 (s, 1H).
PRIMJER 119
N-[2,4-bis(etiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetil-4-metoksifenil)heptil]urea
dobitak 50%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.2 (c, 6H), 1.26, 1.29, 1.31, 1.34 (2t, 6H), 1.44-1.72 (c, 2H), 2.09 (s. 3H), 2.18 (s, 3H), 2.46 (s, 3H), 2.82 (q, 2H), 2.96 (c, 1H), 3.01-3.2 [c uključujući q (3.07), ukupno 3H], 3.48 (p, 1H), 3.78 (s, 3H), 4.18 (b, 1H), 5.29 (s, 1H), 6.48 (s, 1H), 6.56 (s, 1H), 6.77 (s, 1H).
PRIMJER 120
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(5-metilbenzo[b]tiofen-3-il)heptil]urea
dobitak 10%
1H NMR (300 MHz, CDCl3) δ 0.82 (t, 3H), 1.23 (c, 6H), 1.73 (c, 2H), 2.2 (s, 3H), 2.41 (s, 3H), 2.46 (s, 6H), 3.25 (p, 1H), 3.5 (t, 2H), 4.28 (b, 1H), 5.35 (s, 1H), 6.45 (s, 1H), 6.99 (s, 1H), 7.15 (d, 1H), 7.55 (s, 1H), 7.7 (d, 1H).
PRIMJER 121
N-[2-(2-klorobenzo[b]tiofen-3-il)-5-metilheksil]-N'-(2,6-diizopropilfenil)urea
dobitak 43%
1H NMR (300 MHz, CDCl3) δ 0.72-1.31 (c, 20H), 1.46 (h, 1H), 1.78 (c, 1H), 1.82 (c, 1H), 3.06 (c, 2H), 3.44 (c, 2H), 3.76 (c, 1H), 4.01 (b, 1H), 5.52 (s, 1H), 7.06 (c, 2H), 7.26 (c, 3H), 7.64 (c, 1H), 7.71 (c, 1H).
PRIMJER 122
N-(2,6-diizopropilfenil)-N'-[2-(5-metilbenzo[b]tiofen-3-il)-5-metilheksil]urea
dobitak 44%
1H NMR (300 MHz, CDCl3) δ 0.76-1.3 [m, c uključujući d (0.79, 0.81) ukupno 21H], 1.46 (h, 1H), 1.68 (c, 2H), 2.45 (s, 3H), 3.08 (c) i 3.17 (m), (ukupno 2H), 3.47 (c, 2H), 4.08 (b, 1H), 5.57 (s, 1H), 6.86 (s, 1H), 7.05 (s, 1H), 7.07 (s, 1H), 7.14 (d, 1H), 7.22 (d, 1H), 7.51 (s, 1H), 7.67 (d, 1H).
PRIMJER 123
N-[2(benzo[b]tiofen-5-il)heptil]-N'-(2,6-diizopropilfenil)urea
dobitak 41%
1H NMR (300 NHz, CDCl3) δ 0.76-1.31 (c, 20H), 1.68 (c, 2H), 1.95 (c, 1H), 3.05 (c, 2H), 3.25 (p, 1H), 3.49 (c, 2H), 4.1 (b, 1H), 5.72 (s, 1H), 6.92 (s, 1H), 7.06 (s, 1H), 7.08 (s, 1H), 7.21-7.38 (c, 3H), 7.74 (m, 1H), 7.8 (m, 1H).
PRIMJER 124
N-[2-(benzo[b]tiofen-3-il)-6-metilheptil]-N'-(2,6-diizopropilfenil)urea
dobitak 58%
1H NMR (300 MHz, CDCl3) δ 0.74-1.48 [m, c uključujući 2d (0.76, 0.77, 0.78, 0.80) ukupno 22H], 1.67 (m, 2H), 1.8 (c, 1H), 3.07 (c, 2H), 3.25 (p, 1H), 3.48 (c, 2H), 4.1 (b, 1H), 5.68 (s, 1H), 6.92 (s, 1H), 7.06 (s, 1H), 7.08 (s, 1H), 7.2-7.4 (c, 3H), 7.74 (m, 1H), 7.8 (m, 1H).
PRIMJER 125
N-[2-(2-klorobenzo[b]tiofen-3-il)-6-metilheptil]-N'-(2,6-diizopropilfenil)urea
dobitak 70%
1H NMR (300 MHz, CDCl3) δ 0.7,1.3 [c i 2d (0.73, 0.75, 0.76, 0.78), ukupno 22H], 1.4 (h, 1H), 1.73 (c, 1H), 1.91 (c, 1H), 3.06 (c, 2H), 3.44 (c, 2H), 3.76 (c, 1H), 4.02 (b, 1H), 5.54 (s, 1H), 7.06 (c, 2H), 7.2-7.32 (c, 3H), 7,64 (m, 1H), 7.71 (c, 1H).
PRIMJER 126
N-(2,6-diizopropilfenil)-N'-[2-(5-metilbenzo[b]tiofen-3-il)-6,6,6-trifluoroheksil]urea
dobitak 70%
1H NMR (300 MHz, CDCl3) δ 0.8-1.3 (c, 12H), 1.51 (m, 2H), 1.78 (m, 2H), 2.0 (m, 2H), 2.46 (s, 3H), 3.07 (c, 2H), 3.25 (p, 1H), 3.48 (m, 2H), 4.11 (b, 1H), 5.6 (s, 1H), 6.92 (s, 1H), 7.07 (d, 2H), 7.16 (d, 1H), 7.24 (d, 1H), 7.52 (s, 1H), 7.69 (d, 1H).
PRIMJER 127
N-[2-(2-klorobenzo[b]tiofen-3-il)-6,6,6-trifluoroheksil]-N'-(2,6-diizopropilfenil)urea
dobitak 46%
1H NMR (300 MHz, CDCl3) δ 0.78-1.27 (c, 12H), 1.42 (c, 2H), 1.85 (c, 1H), 2.02 (c, 3H), 3.08 (c, 2H), 3.47 (c, 2H), 3.79 (c, 1H), 4.08 (b, 1H), 5.58 (s, 1H), 7.07 (d, 2H), 7.2-7.35 (c, 3H), 7.7 (c, 2H).
PRIMJER 128
N-(2,6-diizopropilfenil)-N'-[2-(naft-2-il)-6,6,6-trifluoroheksil]urea
dobitak 67%
1H NMR (300 MHz, CDCl3) δ 0.63-1.14 (c, 12H), 1.45 (m, 2H), 1.68-2.08 (c, 4H), 2.9 (c, 1H), 3.09 (c, 1H), 3.4 (c, 1H), 3.6 (c, 1H), 3.79 (c, 1H), 4.07 (b, 1H), 5.67 (s, 1H), 7.02 (d, 2H), 7.2 (m, 2H), 7.34 (t, 1H), 7.47 (m, 2H), 7.68 (d, 1H), 7.82(m, 1H), 8.06 (c, 1H).
PRIMJER 129
N-[7,7-difluoro-2-(naft-1-il)heptil]-N'-(2,6-diizopropilfenil)urea
dobitak 58%
1H NMR (300 MHz, CDCl3) δ 0.63-1.46 (c, 16H), 1.57-1.9 (c, 4H), 2.92 (c, 1H), 3.08 (c, 1H), 3.39 (m, 1H), 3.59 (c, 1H), 3.75 (c, 1H), 4.03 (b, 1H), 5.57 (s, 1H), 5.48, 5.67, 5.86 (3t, ukupno 1H), 7.0 (d, 1H), 7.18 (t, 2H), 7.32 (t, 1H), 7.44 (m, 2H), 7.65 (d, 1H), 7.8 (m, 1H), 8.05 (m, 1H).
PRIMJER 130
N-[7,7-difluoro-2-(2-klorobenzo[b]tiofen-3-il)heptil]-N'-(2,6-diizopropilfenil)urea
dobitak 73%
1H NMR (300 MHz, CDCl3) δ 0.73-1.5 (c, 16H), 1.56-1.85 (c, 3H), 1.96 (c, 1H), 3.07 (c, 2H), 3.47 (c, 2H), 3.77 (c, 1H), 4.05 (b, 1H), 5.59 (s, 1H), 5.50, 5.69, 5.88 (3t, ukupno 1H), 7.06 (d, 2H), 7.2-7.35 (c, 3H), 7.62-7.77 (c, 2H).
PRIMJER 131
N-[2-(5-klorobenzo[b]tiofen-3-il)heptil]-N'-(2,6-diizopropilfenil)urea
dobitak 59%
1H NMR (300 MHz, CDCl3) δ 0.77-1.46 (c, 21H), 1.65 (m, 2H), 3.01-3.24 (m, 3H), 3.46 (m, 2H), 4.04 (b, 1H), 5.6 (s, 1H), 7.02 (s, 1H), 7.08 (c, 2H), 7.26 (m, 2H), 7.71 (m, 2H).
PRIMJER 132
N-[2-(2-klorobezo[b]tiofen-3-il)heptil]-N'-(2,6-diizopropilfenil)urea
dobitak 60%
1H NMR (300 MHz, CDCl3) δ 0.74-1.42 (c, 21H), 1.75 (c, 1H), 1.92 (c, 1H), 3.07 (c, 2H), 3.45 (c, 2H), 3.76 (c, 1H), 4.02 (b, 1H), 5.74 (s, 1H), 7.06 (c, 2H), 7.2-7.34 (m, 3H), 7.65 (m, 1H), 7.7 (c, 1H).
PRIMJER 133
N-[2-(5-klorobenzo[b]tiofen-3-il)-6,6,6-trifluoroheksil]-N'-(2,6-diizopropilfenil)urea
dobitak 72%
1H NMR (300 MHz, CDCl3) δ 0.82-1.32 (c, 12H), 1.5-(m, 2H), 1.76 (c, 2H), 2.0 (c, 2H), 3.07 (c, 2H), 3.23 (p, 1H), 3.48 (c,2H), 4.11 (b, 1H), 5.68 (s, 1H), 7.07, 7.09 (d i s 3H), 7.21-7.34 (m, 2H), 7.72, 7.75 (d i s 2H).
PRIMJER 134
N-(2,6-(diizoprppilfenil)-N'-[2-(5-metilbenzo[b]tiofen-3-il)heptil]urea
dobitak 50%
1H NMR (300 MHz, CDCl3) δ 0.76-1.32 (c, 21H), 1.67 (c, 2H), 2.45 (s, 3H), 3.08 (c, 2H), 3.2 (p, 1H), 3.47 (t, 2H), 4.06 (b, 1H), 5.6 (s, 1H), 6.86 (s, 1H), 7.07 (d, 2H), 7.14 (d, 1H), 7.22 (d, 1H), 7.52 (s, 1H), 7.67 (d, 1H).
PRIMJER 135
N-[2-(5-kIorobenzo[b]tiofen-3-il)-6-metilheptil]-N'-(2,6-diizopropilfenil)urea
dobitak 49%
1H NMR (300 MHz, CDCl3) δ 0.75-1.8 [c ukljudujući 2d (0.76, 0.78, 0.79, 0.80) ukupno 23H], 2,26 (m, 2H), 3.07 (p, 2H), 3.18 (p, 1H), 3.47 (c, 2H), 4.06 (b, 1H), 5.65 (s, 1H), 7.03 (s, 1H), 7.08 (c, 2H), 7.2-7.3 (m, 2H), 7.71 (m, 2H).
PRIMJER 136
N-(2,6-(diizoprofiilfenil)-N'-[2-(2,5-dimetilfenil)-6,6,6-trifluoroheksil]urea
dobitak 37%
1H NMR (300 MHz, CDCl3) δ 0.9-1.76 (c, 16H), 1.98 (m, 2H), 2.08 (s, 3H), 2.19 (s, 3H), 2.95-3.21 (c, 4H), 3.52 (p, 1H), 3.97 (b, 1H), 5.6 (b, 1H), 6.74 (s, 1H), 6.83 (d, 1H), 6.9 (d, 1H), 7.11 (d, 2H), 7.28 (t, 1H).
PRIMJER 137
N-[7,7-difluoro-2-(2,5-dimetilfenil)heptil]-N'-(2,6-diizopropilfenil)urea
dobitak 65%
1H NMR (300 MHz, CDCl3) δ 0.92-1.82 (c, 20H), 2.06 (s, 3H), 2.18 (s, 3H), 2.98 (c, 1H), 3.12 (c, 3H), 3.51 (p, 1H), 3.95 (b, 1H), 5.61 (s, 1H), 5.52, 5.71, 5.9 (3t, ukupno 1H), 6.74 (s, 1H), 6.81 (d, 1H), 6.89 (d, 1H), 7.1 (d, 2H), 7.27 (t, 1H).
PRIMJER 138
N-(2,6-diizopropilfenil)-N'-[2-(naft-1-il)heptil]urea
dobitak 61%
1H NMR (300 MHz, CDCl3) δ 0.78 (t, 3H), 0.9-1.3 (m i c, 18H), 1.72 (c, 2H), 2.85-3.16 (c, 2H)„ 3.41 (m, 1H), 3.58 (c, 1H), 3.72 (c, 1H), 4.02 (b, 1H), 5.49 (s, 1H), 7.01 (d, 2H), 7.18 (m, 2H), 7.31 (t, 1H), 7.44 (m, 2H), 7.65 (d, 1H), 7.8 (m, 1H), 8.07 (m, 1H).
PRIMJER 139
N-(2,6-diizopropilfenil)-N'-[6-metil-2-(naft-1-il)heptil]urea
dobitak 59%
1H NMR (300 MHz, CDCl3) δ 0.74 (t, 6H), 0.91-1.29 (m i c, 18H), 1.4 (h, 1H), 1.7 (c, 2H), 2.84-3.16 (c, 2H), 3.41 (m, 1H), 3.51-3.8 (c, 2H), 4.02 (c, 1H), 5.51 (s, 1H), 7.0 (d, 2H), 7.19 (m, 2H), 7.31 (t, 1H), 7.44 (m, 2H), 7.66 (d, 1H), 8.07 (m, 1H).
Claims (10)
1. Spoj formule
[image]
naznačen time da
gdje Q je kisik ili sumpor
R17 je -(CH2)n-(CR19R20)2(CH2)r-Ar XXXVIII
gdje
n je 0 ili jedan cijeli broj od 1 do 3;
z je 0 ili 1; i
r je 0 ili cijeli broj od 1 do 4;
R19 i R20 su nezavisno izabrani između vodika, izborno halogeniranog (C1-C12)alkila, izborno supstituiranog aril-(C1-C5)alkila, (C3-C8)cikloalkil-(C1-C5)alkila i Ar; ili R19 i R20 i ugljik na koji su vezani oblikuju (C4-C7)cikloalkilski prsten ili benzen-fuzionirani (C5-C7)cikloalkilski ili -heteroalkilski prsten; uz uvjet da R19 i R20 ne mogu obojica biti vodik;
Ar je izabran iz skupine koja se sastoji od
[image]
[image]
[image]
gdje
U je J, izravna veza –CH=CH- ili –CH2Hx-;
Z, n i r su kao što je opisano gore, x je cijeli broj od 3 do 10 i w je 0 ili cijeli broj od 1 do x-1,
R21, R22 i svaki R23 su nezavisno izabrani unutar skupine koja se sastoji od izborno halogeniranog (C1-C6)alkila., izborno halogeniranog (C1-C6)alkoksi, izborno halogenirani (C1-C6)alkiltio, fenil i halogen; gdje alkil skupine u navedenim alkil, alkoksi i alkiltio skupinama mogu biti ravni lanac ili razgranat; ili R21 i R22 zajedno oblikuju skupinu čija je formula
-J(CH2)t-J- ili -(CH2)q
gdje
J je kisik ili sumpor;
t je cijeli broj od 1 do 3; i
q je cijeli broj od 3 do 5;
K je J- ili -CH=CH-;
L je -(CH2)u ili -(CH2)v-;
gdje
J je kao što je gore definirano;
u je cijeli broj od 3 do 5; i
v je 2, 3 ili 4;
R18je vodik, izborno sufostituiran (C1-C8)alkil, izborno supstituiran (C3-C8)cikloalkil, ili izborno supstituiran aril(C1-C4)alkil; uz uvjet da R18 je vodik ili bilo koji od n, z ili r u formuli XXXVIII nije 0;
R1 je izabran iz skupine koja se sastoji od
[image]
gdje
m je 0 ili cijeli broj od 1 do 4;
y je 0 ili 1,
Svaki I je nezavisno izabran od 0 do 3,
Svaki R6 i R15 je nezavisno izabran iz skupine koja se sastoji od halogena, izborno halogeniranog (C1-C6)alkil, izborno halogenirani (C1-C6)alkoksi, izborno halogenirani (C1-C6)alkiltio, (C5-C7)cikloalkiltio, fenil(C1-C6)alkiltio, supstituirani feniltio, heteroariltio, heteroariloksi, (C1-C6)alkilsulfinil, (C1-C6)alkilsulfonil, (C5-C7)cikloalkilsulfinil, (C5-C7)cikloalkilsulfonil, fenil(C1-C6)alkilsulfinil, fenil(C1-C6)alkilsulfonil, supstituirani fenilsulfinil, supstituirani fenilsulfonil, heteroarilsulfinil, heteroarilsulfonil, i NR10R11, gdje R10 i R11 su isti ili različiti i izabrani iz skupine koja se sastoji od vodika, (C1-C6)alkil, fenil, supstituirani fenil, (C1-C6)acil, aroil, i supstituirani aroil, gdje navedeni supstituirani fenil i supstituirane aroil skupine su supstituirane s jednim ili više supstituenata nezavisne izabranih iz skupine koja se sastoji od (C1-C6)alkil, (C1-C6)alkoksi, (C1-C6)alkiltio, halogen i trifluorometil s ili R10 i R11 zajedno s dušikom za koji su spojeni, oblikuju piperidinski, pirolidinski ili morfolinski prsten; i
B, D, E, i S su izabrani iz skupine koja se sastoji od dušika i ugljika, uz uvjet da jedan ili više od B, D, i E je dušik, i uz uvjet da kada G je dušik, skupina XVI je spojena za dušik iz formule I na 4 ili 5 položaju piridimdinskog prstena (označeno pomoću a i b) gdje bilo koji od navedenih dušika može biti oksidiran;
[image]
gdje
R7, R8 i R9 mogu biti isti ili različiti i svaki je nezavisno izabran iz skupine koja se sastoji od izborno halogeniranog i (C1-C5)al koksi, izborno halogeniranog (C1-C5)alkiltio, izborno halogenirnog (C1-C5)alkila i halogena; uz uvjet da kada R1 je skupina formule XXVII, Ar je skupina formule XXXII, XXXIII, ili XXXV i K nije CH=CH osim kada R19 i R20 su nezavisno izabrani između vodika i halogeniranog (C1-C12)alkila i kada Ar je XXXII R19 ili R20 nije alkil i r u formuli XXXVIII je 0; ili farmaceutski prihvatljiva sol navedenog spoja.
2. Spoj prema zahtjevu 1 naznačen time da R1 je skupina formule XXIV gdje E je ugljik i B ili D je dušik.
3. Spoj prema zahtjevu 1 naznačen time da R1 je skupina formule XXVI gdje G je ugljik.
4. Spoj prema zahtjevu 1 naznačen time da R1 je skupina formule XXVI gdje G je dušik.
5. Spoj prema zahtjevu 2 naznačen time da R1je
[image]
i R15 je izabran iz skupine koja se sastoji od izborno supstituiranog (C1-C8)alkila i izborno supstituiranog (C1-C8)alkoksi, izborno supstituiranog (C1-C8)alkiltio, poželjno alkiltio; R17 je izabran iz skupine koja se sastoji od benzen fuzioniranog (C5-C8)cikloalkila, i izborno supstituiranog (C1-C8)alkila gdje su navedeni supstituenti izabrani iz skupine koja se sastoji od fenila, benzo[b]tiofenila, bifenila, fluorenila, naftila, halogena, i (C3-C12)cikloalkila, gdje su navedene fenil, naftil, cikloalkil, bifenil, fluorenil, i benzo[b]tiofenil skupine supstituirane sa supstituentima izabranim iz skupine koja se sastoji od izborno halogeniranog (C1-C6)alkila, izborno halogeniranog (C1-C6)alkoksi, izborno halogeniranog (C1-C6)alkiltio, i halogena i R18 je izabran između vodika, izborno halogeniranog (C1-C8)alkila, (C3-C12)cikloalkila, izborno supstituiranog aril-(C1-C6)aikila gdje navedene arilske skupine su izborno supstituirane sa supstituentima izabranih iz skupine koja se sastoji od izborno halogeniranog (C1-C6)alkila, izborno halogeniranog (C1-C6)alkoksi , izborno halogeniranog (C1-C6)alkiltio i halogena.
6. Spoj prema zahtjevu 3 ili 4 naznačen time da R1 je
[image]
i svaki R6 je nezavisno izabran iz skupine koja se sastoji od (C1-C8)alkila, i (C1-C8)alkiltio, R17 je izabran iz skupine koja se sastoji od benzen fuzioniranog (C5-C7)cikloalkila i izborno supstituiranog (C1-C8)alkila gdje su navedeni supstituenti izabrani iz skupine koja se sastoji od fenila, bifenila, fluorenila, benzo[b]tiofenila, naftila, halogena i (C3-C12)cikloalkila gdje navedene fenil, naftil, cikloalkil, bifenil, fluorenil i benzo[b]tiofenil skupine su izborno supstituirane sa supstituentima izabranim iz skupine koja se sastoj i od izborno halogeniranog (C1-C6)alkoksi izborno supstituiranog (C1-C6)alkila, izborno halogeniranog (C1-C6)alkiltio i halogena i R18 je izabran između vodika, izborno halogeniranog (C1-C8)alkila, (C3-C12)cikloalkila ili izborno supstituiranog aril-(C1-C6)alkila gdje navedene arilske skupine su izborno supstituirane sa supstituentima izabranim iz skupine koja se sastoji od izborno halogeniranog (C1-C6)alkila, izborno halogeniranog (C1-C6)alkoksi, izborno halogeniranog (C1-C6)alkiltio, i halogena uz uvjet da R1 je formule XXVIA; R6 na 6-položaju je poželjno vodik ili aklil i svaki R6 na 4-položaju i 2-položaju je poželjno alkiltio i ako je R1 formule XXVIB; R6 na 2-položaju je poželjno vodik ili alkil i svaki R6 na 4- i 6-položaju je poželjno alkiltio.
7. Spoj prema zahtjevu 1 naznačen time da je izabran iz skupine koja se sastoji od:
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(4-izopropilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2,5-dimetilbenzil)-N'-(indan-2-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2,4-dimetilbenzil)-N'-(indan-2-il)urea;
N-[4,6-bis(metiltio)-2-metilpirimidin-5-il]-N'-(indan-2-il)-N'-(4-izopropilbenzil)urea;
N-[4,6-bis(metiltio)-2-metilpirimidin-5-il]-N'-(2,4-dimetilbenzil)-N'-(indan-2-il)urea;
N-(2,5-dimetilbenzil)-N-(indan-2-il)-N'-(6-metiltiokvinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2-klorobenzil)-N'-(indan-2-il)urea;
N-[2,4-bis(metiltio)-2-metilpiridin-5-il]-N'-(2,5-dimetilbenzil)-N'-(indan-2-il)urea;
N-[4,6-bis(metiltio)-2-metilpirimidin-5-il]-N'-(indan-2-il)-N'-[4-(3-metilbutil)benzil]urea;
N-[2,4-bis(metiltio)-2-metilpiridin-5-il]-N'-(indan-2-il)-N'-[4-(3-metilbutil)benzil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(naft-1-ilmetil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(naft-2-ilmetil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(4-t-butilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-1-il)-N'-(4-fenilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(naft-1-ilmetil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(naft-2-ilmetil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(indan-2-il)-N'-(2,4,6-trimetilbenzil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2,3-diklorobenzil)-N'-(indan-2-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2,2-difeniletil]urea;
N-(2,2-difeniletil)-N'-(6-metiltiokvinolin-5-il)urea;
N-[4,6-bis(metiltio)-2-metilpirimidin-5-il]-N'-(2,2-difeniletil)urea;
N-[4,6-bis(metiltio)piridimidin-5-il]-N'-(2,2-difeniletil)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(1-fenilciklopentil)metil]urea;
N-(6-metiltiokvinolin-5-il)-N'-[(1-fenilciklopentil)metil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[{1-(4-metilfenil)ciklopenti}metil]urea;
N-[{1-(4-metilfenil)ciklopentil}metil]-N'-(6-metiltiokvinolin-5-il)urea;
N-(6-metiltiokvinolin-5-il)-N'-[(1-fenilcikloheksil)metil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(1-fenilcikloheksil)metil]urea;
N-[{1-(4-metilfenil)cikloheksil}metil]-N'-(6-metiltiokvinolin-5-il)urea;
N-[4,6-bis(metiltio)-2-metilpirimidin-5-il]-N'-[{1-(4-metilfenil)cikloheksil}metil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[{1-(4-metilfenil)cikloheksil}metil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-etil-2-fenil)butil]urea;
N-[2,4-bis(izopropiltio)-6-metilpiridin-3-il-N'-[(2-etil-2-fenil)butil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[{2-etil-2-(2-metilfenil)}butil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-fenil-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2-metilfenil}-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2-metilfenil}-2-butil)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2,5-dimetoksifenil}-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2,3-dimetoksifenil}-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2,5-dimetilfenil}-2-propil)pentil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2-metilfenil)heksil]urea;
N-[2-(2-etilfenil}heksil]-N'-[6-metiltiokinolin-5-il]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'- [2-(4-metilfenil)heptil]urea;
N-[2-(4-metilfenil)heptil]-N'-(6-metiltiokinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3-metilfenil)heptil]urea ;
N-[2-(3-metilfenil)heptil]-N'-(6-metiltiokinolin-5-il)urea;
N-[2-(3-metilfenil)heptil]-N'-(6-metoksikinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)heksil]urea,
N-[2-(2,5-dimetilfenil)heksil]-N'-(6-metiltiokinolin-5-il)urea;
N-[2-(2,5-dimetilfenil)heksil]-N'-(6-metoksikinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,4-dimetilfenil)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-(2-(3-metilfenil)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,4-dimetilfenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-2-il)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(naft-1-il)heksil]urea;
N-(6-metiltiokinolin-5-il)-N'-[2-(naft-1-il)heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,3-dimetoksifenil)heptil]urea;
N-[2-(2,3-dimetoksifenil)heptil]-N'-(6-metiltiokinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3-metilfenil)oktil]urea;
N-[2-(3-metilfenil)oktil]-N'-(6-metoksikinolin-5-il)urea;
N-[2-(3-metilfenil)oktil]-N'-(6-metiltiokinolin-5-il)urea;
N-[2-(naft-1-il)heptil]-N'-(6-metoksikinolin-5-il)urea;
N-[2-(naft-1-il)heptil]-N'-(6-metiltiokinolin-5-il)urea;
N-[2-(2,4-dimetilfenil)heptil]-N'-(6-metiltiokinolin-5-il)urea;
N-[2-(2,4-dimetilfenil)heptil]-N'-(6-metiloksikinolin-5-il)urea;
N-[2,4-bis(metil)-6-metilpiridin-3-il]-N'-[2-(3,4,5-trimetoksifenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetil-4-metoksifenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetoksifenil)heptil]urea;
N-[2-(2,5-dimetoksifenil)heptil]-N'-(6-metiltiokinolin-5-il)urea;
N-[2-(2,5-dimetoksifenil)heptil]-N'-(6-metoksikinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetoksifenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetoksifenil)oktil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3-metilfenil)-6,6,6-trifluoroheksil]urea;
N-[2-(3-metilfenil)heptil-N'-(6-pentiltiokinolin-5-il)urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(5-klorobenzo[b]tiofen-3-il)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(3,5-dimetilfenil)heptil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)oktil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[5-metil-2-{3-metilfenil}heksil]urea;
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[(2-{2,5-dimetilfenil}-4-fenilbu til]urea; i
N-[2,4-bis(metiltio)-6-metilpiridin-3-il]-N'-[2-(2,5-dimetilfenil)-5-fenilpentil]urea;
N-(2,6-diizopropilfenil)-N'-[2-(naft-1-il)heptil]urea;
N-(2,6-diizopropilfenil)-N'-[6-metil-2-(naft-1-il)heptil]urea.
8. Spoj prema zahtjevu 1 naznačen time da obuhvaća najmanje jednu radioaktivnu oznaku izabranu iz skupine koja se sastoji od tricija i ugljika-14.
9. Farmaceutski pripravak naznačen time da se sastoji od efikasne količine spoja prema zahtjevu 1 za inhibiciju ACAT i farmaceutski prihvatljivog razrjeđivača ili nosača.
10. Metoda inhibicije ACAT kod čovjeka ili životinje naznačena time da se sastoji od davanja tom čovjeku ili životinji efikasne količine spoja prema zahtjevu 1 za inhibiciju ACAT.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89005092A | 1992-05-28 | 1992-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP930931A2 true HRP930931A2 (en) | 1997-06-30 |
Family
ID=25396173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR07/890,050A HRP930931A2 (en) | 1992-05-28 | 1993-05-26 | New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat) |
Country Status (23)
Country | Link |
---|---|
US (1) | US6001860A (hr) |
EP (1) | EP0642498A1 (hr) |
JP (1) | JPH07503737A (hr) |
KR (1) | KR950701621A (hr) |
CN (1) | CN1080919A (hr) |
AU (1) | AU4028393A (hr) |
BG (1) | BG99188A (hr) |
BR (1) | BR9306421A (hr) |
CA (1) | CA2134359C (hr) |
FI (1) | FI932423A (hr) |
HR (1) | HRP930931A2 (hr) |
HU (1) | HUT64303A (hr) |
IL (1) | IL105756A0 (hr) |
IS (1) | IS4023A (hr) |
MA (1) | MA22896A1 (hr) |
MX (1) | MX9303100A (hr) |
OA (1) | OA10114A (hr) |
PL (1) | PL299082A1 (hr) |
RU (1) | RU94046149A (hr) |
SK (1) | SK142694A3 (hr) |
UY (1) | UY23589A1 (hr) |
WO (1) | WO1993024458A1 (hr) |
YU (1) | YU37193A (hr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950701621A (ko) * | 1992-05-28 | 1995-04-28 | 알렌 제이. 스피겔 | 아실 조효소a : 콜레스테롤 아실 전이효소(acat)의 억제제로서 신규한 n- 아릴 및 n- 헤테로아릴우레아 유도체(new n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase(acat) |
NZ250916A (en) * | 1993-02-27 | 1995-08-28 | Nihon Nohyaku Co Ltd | N-heteroaryl-n'-phenylureas, their use as acat inhibitors |
IL109568A0 (en) * | 1993-05-19 | 1994-08-26 | Fujisawa Pharmaceutical Co | Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
ES2076865B1 (es) * | 1993-07-05 | 1996-08-01 | Pfizer | Nuevos derivados de n-aril- y n-heteroaril-urea como inhibidores de acil-coenzima a: colesterol acil transferasa (acat). |
NZ264063A (en) * | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
DE4401893A1 (de) * | 1994-01-24 | 1995-07-27 | Bayer Ag | Substituierte Arylharnstoffe |
US6133326A (en) | 1994-08-31 | 2000-10-17 | Pfizer Inc | Compositions and methods for decreasing sebum production |
EP0784612A1 (en) * | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
NO307879B1 (no) * | 1995-09-18 | 2000-06-13 | Sankyo Co | Nye ureaderivater med ACAT-inhiberende aktivitet og farmasøytisk preparat inneholdende disse |
WO1998007718A1 (en) | 1996-08-22 | 1998-02-26 | Warner-Lambert Company | Non-peptide bombesin receptor antagonists |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
EP1473292A1 (en) * | 1997-11-03 | 2004-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
WO1999023091A1 (en) | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
EP1157026A1 (en) | 1999-02-22 | 2001-11-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Polycyclo heterocyclic derivatives as antiinflammatory agents |
KR100709497B1 (ko) | 1999-03-12 | 2007-04-20 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | 소염제로서 유용한 화합물 및 이의 제조방법 |
JP2002539206A (ja) | 1999-03-12 | 2002-11-19 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症剤としての芳香族複素環化合物 |
DE60024830T2 (de) | 1999-07-09 | 2006-06-14 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
MXPA02004594A (es) | 1999-11-16 | 2002-10-23 | Boehringer Ingelheim Pharma | Derivados de urea como agentes anti-inflamatorios. |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
ES2239145T3 (es) | 2000-02-02 | 2005-09-16 | Warner-Lambert Company Llc | Inhibidor doble de la sintesis de ester de colesterilo y de ester de cera avasimibe para el tratamiento de trastornos de la glandula sebacea. |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
CA2445003A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
WO2002096876A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
KR101018318B1 (ko) * | 2001-12-21 | 2011-03-04 | 노보 노르디스크 에이/에스 | Gk 활성제로서의 아미드 유도체 |
ATE529406T1 (de) | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
ATE386030T1 (de) | 2002-02-25 | 2008-03-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen |
GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
WO2004064730A2 (en) * | 2003-01-14 | 2004-08-05 | Cytokinetics, Inc. | Compounds, compositions and methods |
US7015233B2 (en) * | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
US7375126B2 (en) * | 2003-06-12 | 2008-05-20 | Abbott Laboratories | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
CN102516240A (zh) * | 2004-01-06 | 2012-06-27 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
MXPA06014495A (es) * | 2004-06-17 | 2007-03-01 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
EP1904466A1 (en) * | 2005-07-08 | 2008-04-02 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
US7999114B2 (en) * | 2005-07-08 | 2011-08-16 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
CA2615938C (en) | 2005-07-14 | 2014-04-29 | Novo-Nordisk A/S | Urea glucokinase activators |
US7538223B2 (en) * | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
WO2007075377A2 (en) * | 2005-12-15 | 2007-07-05 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
ES2419007T3 (es) | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
EP1959962A2 (en) * | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
JP5178526B2 (ja) * | 2005-12-19 | 2013-04-10 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
JP5015496B2 (ja) | 2006-06-01 | 2012-08-29 | ルネサスエレクトロニクス株式会社 | 固体撮像装置、撮像方法および撮像システム |
US7767705B2 (en) * | 2006-08-25 | 2010-08-03 | Abbott Laboratories | Compounds that inhibit TRPV1 and uses thereof |
EP2450346A1 (en) | 2006-12-20 | 2012-05-09 | Abbott Laboratories | Antagonists of the TRPV1 receptor and uses thereof |
WO2008084043A1 (en) | 2007-01-09 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
WO2008084044A1 (en) | 2007-01-11 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
KR20100090689A (ko) * | 2007-10-19 | 2010-08-16 | 애보트 게엠베하 운트 콤파니 카게 | N―아릴 우레아계 화합물을 함유하는 고체 분산액 생성물 |
WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
JP2011515414A (ja) * | 2008-03-20 | 2011-05-19 | アボット・ラボラトリーズ | Trpv1アンタゴニストである中枢神経系薬剤を作製する方法 |
CN103172543B (zh) * | 2011-12-21 | 2016-02-10 | 中国科学院上海药物研究所 | 一种脲类化合物、制备方法及其用途 |
TWI539385B (zh) | 2015-01-28 | 2016-06-21 | 金佶科技股份有限公司 | 光動能指紋辨識模組 |
MX2020008905A (es) | 2018-06-12 | 2020-12-03 | Vtv Therapeutics Llc | Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. |
CA3220039A1 (en) | 2021-06-14 | 2022-12-22 | Jr. David St. Jean | Urea derivatives which can be used to treat cancer |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3426031A (en) * | 1967-01-19 | 1969-02-04 | Dow Chemical Co | 3,5,6 - trichloro - 4 - (3 - (alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro - 3,5 - xylyl)ureido) picolinic acid and the corresponding amide derivative |
US4623662A (en) * | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
US4751026A (en) * | 1986-03-24 | 1988-06-14 | Warner-Lambert Company | Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase |
US4722927A (en) * | 1986-04-28 | 1988-02-02 | Warner-Lambert Company | Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase |
EP0252524A3 (en) * | 1986-07-11 | 1989-04-19 | Warner-Lambert Company | Aryl- and aralkylamide- derivatives of omega- (substituted-phenyloxy)-alkanoic acids as inhibitors of acyl-coa: cholesterol acyltransferase and pharmaceuticals containing them |
US4743605A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase |
US4716175A (en) * | 1987-02-24 | 1987-12-29 | Warner-Lambert Company | Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase |
IE61716B1 (en) * | 1987-06-02 | 1994-11-30 | Warner Lambert Co | Antihyperlipidemic and antiatherosclerotic urea compounds |
US5015644A (en) * | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
ES2037768T3 (es) * | 1987-07-02 | 1993-07-01 | Warner-Lambert Company | Procedimiento para preparar n-(fenil(2,6-disustituido))-ureas y carbamatos inhibidores de acil-coa: colesterol acil-transferasa. |
US4868210A (en) * | 1988-03-30 | 1989-09-19 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic compounds and compositions |
US5116848A (en) * | 1988-03-30 | 1992-05-26 | Warner-Lambert Company | N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents |
US5155127A (en) * | 1989-02-09 | 1992-10-13 | Warner-Lambert Company | N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents |
US4994465A (en) * | 1989-02-17 | 1991-02-19 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds |
PT93158A (pt) * | 1989-02-17 | 1990-08-31 | Warner Lambert Co | Processo para a preparacao de compostos de ureia trissubstituidos e de composicoes farmaceuticas que os contem |
ZA903906B (en) * | 1989-05-25 | 1992-02-26 | Takeda Chemical Industries Ltd | Benzocycloalkane derivatives and production thereof |
AU632809B2 (en) * | 1989-05-25 | 1993-01-14 | Takeda Chemical Industries Ltd. | Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof |
CA2022346A1 (en) * | 1989-08-04 | 1991-02-05 | Mitsubishi Chemical Corporation | 1-phenylalkyl-3-phenylurea derivatives |
WO1991004027A1 (en) * | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
TW205037B (hr) * | 1989-10-06 | 1993-05-01 | Takeda Pharm Industry Co Ltd | |
JPH05310678A (ja) * | 1990-01-22 | 1993-11-22 | Mitsubishi Kasei Corp | 1−フェニルアルキル−3−フェニル尿素誘導体 |
ATE115558T1 (de) * | 1990-03-12 | 1994-12-15 | Yamanouchi Pharma Co Ltd | Harnstoffderivate, deren herstellung sowie diese enthaltende pharmazeutische zusammensetzungen. |
AU7440691A (en) * | 1990-03-12 | 1991-10-10 | Yamanouchi Pharmaceutical Co., Ltd. | Monourea derivative and its salt |
US5668136A (en) * | 1990-09-25 | 1997-09-16 | Eisai Co., Ltd. | Trisubstituted benzene derivatives, composition and methods of treatment |
FR2674522B1 (fr) * | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
IL101785A0 (en) * | 1991-05-10 | 1992-12-30 | Fujisawa Pharmaceutical Co | Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
KR950701621A (ko) * | 1992-05-28 | 1995-04-28 | 알렌 제이. 스피겔 | 아실 조효소a : 콜레스테롤 아실 전이효소(acat)의 억제제로서 신규한 n- 아릴 및 n- 헤테로아릴우레아 유도체(new n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase(acat) |
-
1993
- 1993-04-20 KR KR1019940704262A patent/KR950701621A/ko not_active Application Discontinuation
- 1993-04-20 EP EP93909519A patent/EP0642498A1/en not_active Withdrawn
- 1993-04-20 SK SK1426-94A patent/SK142694A3/sk unknown
- 1993-04-20 BR BR9306421A patent/BR9306421A/pt not_active Application Discontinuation
- 1993-04-20 AU AU40283/93A patent/AU4028393A/en not_active Abandoned
- 1993-04-20 US US08/343,557 patent/US6001860A/en not_active Expired - Fee Related
- 1993-04-20 WO PCT/US1993/003539 patent/WO1993024458A1/en not_active Application Discontinuation
- 1993-04-20 JP JP6500522A patent/JPH07503737A/ja active Pending
- 1993-04-20 CA CA002134359A patent/CA2134359C/en not_active Expired - Fee Related
- 1993-04-20 RU RU94046149/04A patent/RU94046149A/ru unknown
- 1993-05-20 IL IL105756A patent/IL105756A0/xx unknown
- 1993-05-24 IS IS4023A patent/IS4023A/is unknown
- 1993-05-26 MX MX9303100A patent/MX9303100A/es unknown
- 1993-05-26 HR HR07/890,050A patent/HRP930931A2/hr not_active Application Discontinuation
- 1993-05-26 PL PL93299082A patent/PL299082A1/xx unknown
- 1993-05-27 FI FI932423A patent/FI932423A/fi not_active Application Discontinuation
- 1993-05-27 CN CN93106774A patent/CN1080919A/zh active Pending
- 1993-05-27 YU YU37193A patent/YU37193A/sh unknown
- 1993-05-27 MA MA23195A patent/MA22896A1/fr unknown
- 1993-05-27 HU HU9301552A patent/HUT64303A/hu unknown
- 1993-05-28 UY UY23589A patent/UY23589A1/es unknown
-
1994
- 1994-11-17 BG BG99188A patent/BG99188A/bg unknown
- 1994-11-28 OA OA60588A patent/OA10114A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX9303100A (es) | 1994-06-30 |
JPH07503737A (ja) | 1995-04-20 |
CA2134359A1 (en) | 1993-12-09 |
CN1080919A (zh) | 1994-01-19 |
EP0642498A1 (en) | 1995-03-15 |
IS4023A (is) | 1993-11-29 |
UY23589A1 (es) | 1993-11-15 |
OA10114A (en) | 1996-12-18 |
SK142694A3 (en) | 1995-06-07 |
MA22896A1 (fr) | 1993-12-31 |
IL105756A0 (en) | 1993-09-22 |
FI932423A (fi) | 1993-11-29 |
HU9301552D0 (en) | 1993-09-28 |
PL299082A1 (en) | 1994-04-05 |
BG99188A (bg) | 1995-07-28 |
BR9306421A (pt) | 1998-09-15 |
FI932423A0 (fi) | 1993-05-27 |
RU94046149A (ru) | 1996-11-27 |
YU37193A (sh) | 1997-07-31 |
KR950701621A (ko) | 1995-04-28 |
HUT64303A (en) | 1993-12-28 |
US6001860A (en) | 1999-12-14 |
CA2134359C (en) | 1997-07-01 |
WO1993024458A1 (en) | 1993-12-09 |
AU4028393A (en) | 1993-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP930931A2 (en) | New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat) | |
US5338849A (en) | Azaindoles, preparation processes and medicinal products containing them | |
US5362878A (en) | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | |
US5681959A (en) | Chemical synthesis of azaindoles | |
JP2007523155A (ja) | キナーゼ阻害剤 | |
CA2207784C (en) | Certain pyrrolopyridine derivatives; novel crf1 specific ligands | |
EP0609960A1 (en) | New N-heteroarylamide derivatives as inhibitors of acyl coenzyme A: cholestrol acyl transferase | |
US5874438A (en) | 2,2'-bridged bis-2,4-diaminoquinazolines | |
CZ64799A3 (cs) | Substituované N-[(aminoiminomethyl nebo aminomethyl)fenyl]propylamidy | |
NZ250916A (en) | N-heteroaryl-n'-phenylureas, their use as acat inhibitors | |
AU682768B2 (en) | Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase | |
PL126639B1 (en) | Method for producing 1-acyl-2-cyanoaziridines | |
Wright Jr et al. | Thromboxane synthetase inhibitors and antihypertensive agents. 4. N-[(1H-imidazol-1-yl) alkyl] derivatives of quinazoline-2, 4 (1H, 3H)-diones, quinazolin-4 (3H)-ones, and 1, 2, 3-benzotriazin-4 (3H)-ones | |
KR20150119390A (ko) | 항암제로서의 삼환식 헤테로사이클 | |
SK1062003A3 (en) | Substituted phthalides as anti-convulsive drugs | |
NZ250580A (en) | 3-(hetero)aryloxymorphinan derivatives and their use in the manufacture of medicaments | |
Ozeryanskii et al. | ‘Proton sponge’amides: unusual chemistry and conversion into superbasic 6, 7-bis (dimethylamino) perimidines | |
US4971985A (en) | Pyridylketoxime ether compound and pharmaceutical composition containing it | |
JPH0776215B2 (ja) | 4−アリール−3−(ヘテロアリールウレイド)キノリン誘導体 | |
US4994465A (en) | Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds | |
US6756389B2 (en) | Pharmaceutically active compounds and methods of use | |
CA2453418C (en) | Variolin derivatives and their use as antitumor agents | |
US4840953A (en) | 9-(Substituted thio)-4H-pyrido[1,2,-A]pyrimidin-4-one derivatives | |
Hamon et al. | The search for TCP analogues binding to the low affinity PCP receptor sites in the rat cerebellum | |
US4352807A (en) | Hexahydro-trans-pyridoindole neuroleptic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
OBST | Application withdrawn |